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Abstract 
 
The Influenza virus is a significant global health problem whose worldwide 
circulation constantly triggers new pandemic strains often linked to genetic re-
assortment and new mutations. Virus variability threatens and challenges the health of 
millions of citizens. Vaccination against influenza prior to infection offers the standard 
alternative to antiviral treatment in infected patients. Vaccine production must be 
available in sufficient volume for human and animal vaccination on a large scale.  In this 
study I designed a novel recombinant influenza protein composed of three chimeric 
Hemagglutinin (HA) influenza receptor-binding domains (RBD) expressed in tandem. 
This construct was expressed as a single molecule in Pichia pastoris and characterized 
by gene sequencing, polyacrylamide gel electrophoresis, immuno-detection, and 
carbohydrate composition. The goal of this project is to develop a reagent for use in 
immunological response assays in a mouse model that will provide information 
regarding the potential use of these multisubunit gene-expressing constructs as vaccine 
candidates.  
 
Keywords 
Pichia pastoris, Influenza virus, Hemagglutinin, Antigen, Protein Expression, Gene 
Design, Receptor Binding Domain, Vaccination. 
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 1. INTRODUCTION 
 Influenza virus infection is a global epidemic that each year affects more than 
100 million people worldwide, causing a serious health situation in 3-5 million persons, 
and an estimated 250,000-500,000 deaths (1). Global concern about the development 
of periodic new pathogenic strains, which have the capacity to create new pandemics, 
requires that influenza outbreaks are constantly being monitored by the scientific 
community in centres for surveillance, hospitals and at points of care. The “Spanish Flu’ 
global pandemic started prior to 1920 and killed more than 50 million people over a 50 
year timespan.  The novel “swine influenza” rapidly circulated across the World in 2009 
causing 15,000 death (1). Attempts to prevent further influenza pandemic require an 
improvement in the vaccination methods and in the technology necessary to control 
virus-associated illness. Data from Public Health Agency of Canada for the year 2014-
2015 reveals the seasonal persistence of influenza A and B types, with most cases 
belonging to the influenza strain AH3N1 subtype, followed by Influenza B type 
infections, and then by the AH1N1 pandemic strain (2,3) (Figure 1). Seasonal variation, 
as reported by the World Health Organization (Figure 2 and 3), differs significantly 
depending on the type of virus circulating in the different transmission zones (4). 
Paradoxically, the efficiency by which people can move or connect across the planet 
makes us more prone to the efficient dispersal of these pathogens. 
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Figure 1. Number the number of positive influenza tests and percentage of tests 
positive, by type, subtype, and report week for, Canada, 2014-15 (Public Health 
Agency of Canada). Source:©All Rights Reserved.   Weekly Influenza Reports.   Public 
Health Agency of Canada, 2016.  Adapted and reproduced with permission from the 
Ministery of Health, 2016. 
  
3 
 
1.1. Influenza disease  
1.1.1 Virus composition and structure (Influenza A Type, Influenz B type)  
 
Influenza viruses are negative single-stranded RNA-based viruses [(–)ssRNA 
(family Orthomyxoviridae)] that are classified in five genera, Influenzavirus A, 
Influenzavirus B, Influenzavirus C, Thogovirus, and Isavirus, that differ in 
composition and have differences in protein sequence. Influenza A type is subtyped 
based on the antigenic differences in the Hemagglutinin (HA) and Neuroaminidase 
(NA) proteins. Sixteen HA (HA1-16) subtypes and nine NA (N1-N2) subtypes have 
been described to date. In contrast, no similar description of the antigenic subtypes 
has been found for the Influenza B and C types (5).  
The influenza virus is composed of a lipid membrane envelope derived from the 
host cell. Influenza A and B types share some characteristics, for example, both of 
their genomes are composed of 8 RNA segments that each codes for at least one 
protein. In the case of the influenza A virus, the eighth ssRNA segment encodes for 
12 known proteins, divided into nine structural proteins and three non-structural 
proteins as summarized in Table 1 (1,6,7). 
The influenza A virus exhibits a remarkable pleomorphic structure with shapes 
varying from spherical structures in the range of 80-120 nm in diameter (5), to 
filamentous forms isolated from fresh clinical samples. This phenotypic 
pleomorphism is commonly found in the novel AH1N1 2009 pandemic strain (8,9,10) 
and is promoted mainly by changes in the amino acid sequence of the M1 inner 
envelope protein that contributes to viral pathogenesis (11). 
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Table 1. Genome composition of the influenza virus: the segmented genes 
involved, their translated protein products, and their functions in the life cycle of 
the Influenza A respiratory virus (1,6,7).  
ssRNA segment Protein encoded Function (s) 
Structural proteins 
Segment 1 Polymerase 
Basic Protein 2 
(PB2) 
Temperature-dependent replication 
competence; mRNA synthesis by binding 
host mRNA caps. vRNP complex. 
Segment 2 Polymerase 
Basic Protein 1 
(PB1) 
Component of the RNA polymerase 
involved in RNA replication and 
transcription. vRNP complex. 
Segment 3 Protein 
Associated (PA) 
Component of the RNA polymerase 
involved in RNA replication and 
transcription. Make the vRNP complex. 
Segment 4 Hemagglutinin 
(HA) 
Binding and fusion with the host cell 
(sialic acid linkage specificity); 
antigenicity and tropism. 
Segment 5 Nucleoprotein 
(NP) 
Enclose the viral genome in an helical 
organized fashion (Chenavas et al 2013).  
Segment 6 Neuroaminidase 
(NA) 
Receptor-destroying enzyme. Confers 
resistense to antivirals (oseltamavir). 
Promotes efficient release of virion from 
infected cells. 
Segment 7 Matrix protein 1 
(M1)  
Component of the internal  viral 
envelope. 
Segment 7 Matrix protein 2 
(M2) 
Ion channel. Component of the internal 
viral envelope along with M1. Confers 
resistance to antivirals (adamantanes). 
Segment 8 Nuclear Export 
Protein 2 NS2 
(NEP) 
Localized in virions facilitating nuclear 
export of viral RNP complex. Facilitate 
activity-encreased.  
 
Non-structural proteins  
Segment 2 PB1-F2 Induction of apoptosis; promotion of 
secondary bacterial infection. 
Segment 2 N40 Function not fully understood. 
Segment 8 Non-structural 
protein 1(NS1) 
Host antiviral response antagonist. 
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1.1.2. Hemagglutinin is the major antigenic molecule of influenza 
Hemagglutinin is a Type I integral membrane glycoprotein that is part of the viral lipid 
bilayer surface architecture forming spikes-like structures that binds to host cell 
receptors by interacting with sialic acid moieties (12,13). The hemagglutinin protein is 
encoded by segment four of the viral genome and has a protein size of 60 KDa prior to 
post-translational modification. In the Influenza A virus, biologically active Hemagglutinin 
is a homotrimer with each monomer comprised of two domains: the globular domain 
and the stem domain. Structurally, the globular domain folds into a jelly roll-like motif 
with eight anti-parallel beta sheets forming a pocket known as the receptor-binding site 
that interacts with carbohydrates containing alpha-2-6-linked or alpha-2-3-linked sialic 
acid moieties (7,13,14). It also possesses a vestigial esterase domain that is shared 
with the stem domain and which mainly forms a long alpha coiled-coil structure which 
plays an important role in membrane fusion during virion entry into the plasma 
membrane of the host cell (12). The structure of the stem domain consist of a cleavage 
signal, a hydrophobic peptide domain that is involved in membrane fusion, and a C-
terminal transmembrane domain (12–14). A disulfide bond is formed between cysteine 
residues in the globular and stem domains which stabilizes the molecular conformation 
after the proteolytic cleavage that occurs during hemagglutinin fusion peptide exposure 
and full activity (12). 
 The hemagglutinin molecule is the major antigen involved in generating most of 
the neutralizing antibodies produced in response to infection, with the majority of the 
antigenic sites located within the globular domain (12). Therefore, the globular domain 
of the hemagglutinin molecule is the target for immune protection generated during  
6 
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The basic structure of Influenza Hemagglutinin (AH1N1 2009 pandemic 
virus). After proteolytic cleavage, the HA0 molecule is divided in the HA1 (in blue) 
subunit or globular region which harbors the lectin- or RBD-domain, and the HA2 (in 
green) subunit, or stem region. The structure is based on the H1 subtype of the virus 
A/H1N1 2009 pdm (16) (RCSB Protein Data Bank (PDB) ID: 4DEA) using PyMOL-
Chimera UCSF for visualization .  
  
Receptor  
Binding  
Domain 
 
 
HA1,  
Globular region 
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infection in humans, other mammals and avian species. Consequently, hemagglutinin 
has been been selected as the main target in the development of vaccines, and inhibitor 
molecules (15), and constitutes the target for antigen design and protein expression in 
the present study. 
1.1.3. Mechanisms of influenza infection 
The early events of influenza infection, involve the  binding of the hemagglutinin 
globular domain to cellular receptors via the alpha-2-3-linked and/or alpha-2-6-linked 
sialic acid carbohydrates which promotes entry into  the cell membrane by clathrin-
dependent (17) and independent endocytosis (18). Cellular proteases are responsible 
for hemagglutinin cleavage which exposes the fusion peptide and promotes fusion 
between the viral envelope and the endosomal membrane. Maturation of the endosome 
further activates the virus. The acidification of the endosomal environment has two main 
consequences: i) it activates Matrix Protein 2 ion channels that acidify the inside of the 
virion particle, un-coating the RNP complex from the viral genome; and, ii) it promotes 
the cytoplasmic release of the virion genome originated by the pH-dependent fusion of 
hemagglutinin to the endosomal membrane (1). The genetic information is then 
translocated to the nucleus of the cell where the RNA-dependent RNA polymerase 
replicates a series of RNA molecules to create the negative-sense RNA molecules that 
are necessary templates for packaging co-assembly with the viral proteins. 
Complementary, positive sense RNA segments, are exported to the cytoplasm to be 
translated to create the  viral protein and to be used in the synthesis of the negative 
sense small viral RNA (svRNAs) involved in regulating the switch between the 
transcription and replication processes of the viral messenger RNA in the cytoplasm 
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(1,19). Once translation of the mRNAs has started, the NP and M1 proteins return to the 
nucleus and interact with the negative sense vRNA (1,20). The synthetized proteins 
produced in the nucleus, can be post-translationally processed in the Golgi apparatus, 
and directed towards the plasma membrane (HA, NA, M2) where M1 helps to assemble 
the virus particle (1,21), Release of the membrane-encapsulated virion particle from the 
plasma membrane occurs via facilitation of the Neuraminidase enzymatic activity which 
cleaves the sialic acid moieties (22). 
1.1.4. Virus tropism 
 
The ability of the influenza virus to infect more than one species is known as 
tropism. For example, the H1N1 and H3N2 virus are exclusive in humans, birds and 
pigs (23), because their hemagglutinin surface proteins have the ability to recognize 
different sialic acid molecules on the cells from many species. The viral receptors are 
tissue-specific and are expressed among different types of hosts.  For example, Swine 
virus recognizes a receptor containing alpha-2-3-linked and alpha-2-6-linked sialic 
acids, both presented on swine trachea, which promotes the binding of the HA molecule 
to the swine and human upper respiratory tract-rich alpha-2-6 linked sialic acid 
receptors and lower respiratory-rich alpha-2-3-linked sialic acid receptors (1,24). The 
Avian virus infects birds preferentially using alpha-2-3-linked sialic acid receptors 
present in their guts and respiratory systems but can also bind to swine alpha 2-3-linked 
sialic acid, and human 2-3-linked sialic acid receptors (23,25). Receptor switching can 
occur by mutagenesis, as in the case of the avian H3 subtype, where a single change in 
two residues confers an affinity for human 2-6-linked sialic acid receptors (26). Thus, a 
major shift in the Hemagglutinin and Neuraminidase segments among distantly related 
9 
 
viruses, can generate significant opportunities for the newly arranged virus 
combinations to infect humans and spread faster on the surface of host cells. For 
example, structural studies on the Receptor Binding domains RBDs of HA have 
demonstrated that amino acid substitution within this region is responsible for receptor 
specificity and tissue tropism. For the H2 and H3 subtypes, the amino acid mutations 
Q226L and G228S in the RBD confer binding preference to switch from avian to human 
receptors (27). In another study, using ferret differentiated primary cells, the human 
influenza virus was able to infect ciliated epithelial cells whereas the Highly Pathogenic 
Avian Influenza Virus, H5N1, was able to replicate efficiently in non-conciliated epithelial 
cells where α2,3-linked sialic acid receptor are highly abundant (28).  
1.1.5. Virus reassortment and antigenic drift as a major source of antigenic variation  
 
Virus re-assortment occurs when two or more Influenza viruses of the same type are 
able to co-infect a single host cell and exchange their segmented genomes (5). This 
major genome exchange contributes to the generation of pandemic virus reassortants 
like the recent Influenza A H1N1 2009 pandemic outbreak (29).  H1N1 2009 was 
comprised of a triple re-assortant between Avian Swine and Human genomes, that 
coexisted in the naturally occurring swine influenza A virus strains, which increased the 
efficiency of virus replication in human lungs cells and enhanced aeroseol 
transmissibility (30).  
Antigenic drift in influenza viruses is the result of genetic modification in the influenza 
virus genome, that result from point mutations that accumulate mainly due to error –
prone replication of the viral genome viral RNA-dependent polymerase. These 
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mutations can become fixed in the viral genome and can then be selected for their 
effect on virulence by selection primarily of the Hemagglutinin and Neuraminidase 
genes which promote viral spread. The result of this selection can be creation of 
virulence- and immunologically-distinct viruses that can efficiently spread in the 
population. 
 
1.2. FLU vaccine technologis: Overview 
 
Influenza vaccines represent the best current method to prevent pathogenesis 
resulting from influenza virus infection. Conventional and approved methods for vaccine 
production are based on the production of attenuated virus particles following virus 
inoculation, culture and harvest using chicken eggs (31). Each year, new vaccine 
formulations are engineered and millions of single dose vaccines are created for human 
and animal immunization programs (32). The yearly vaccine formulations are based on 
the predictions of multiple surveillance programs  which predict which virus serotypes 
will be in circulation and cause disease (33). Scientists around the world work hard and 
invest huge amounts of time and resources to create vaccines that correspond to the 
most likely combinations of virus strains and re-assorted viral forms that are present in 
the world each year. The drawbacks of this approach are that different viruses 
serotypes can emerge or unperceived pandemic strains can circumvent the 
implemented detection strategies (31) or the ability control them (34). When unpredicted 
influenza subtypes emerge they can create a significant health problem which cannot 
be met by the vaccines created by the conventional egg-dependent virus production 
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methodologies which require a significant amount of time.  Although this method 
represents a stable and reliable vaccine technology, it takes a significant amount of time 
to produce a new vaccine formulation.  Current alternative technologies may be 
developed to better compete  in such hypothetical but plausible pandemics events 
(31,34–36). 
1.2.1. Current vaccine technologies  
1.2.1.1. Propagation of Influenza Virus in Embryonated Chicken Eggs 
 
The production of new virus for influenza vaccines candidates is based on the 
propagation of multiple virus antigens in embryonated chicken eggs and requires the 
combination or reassortment of the identified genes from the most likely influenza virus 
strains.  To create the vaccine, the genes of the first, target flu strain, are expressed in 
an egg with the genes of a second flu strain that grows well in eggs but is harmless to 
humans (i.e. a virus that does not replicate at human body temperature). Initially, both 
flu strains are injected into a fertilized chicken egg and both genomes are replicated. 
During their replication, the influenza genes segments mix and reassemble to create 
new viral offspring combinations. Since each genome contains 8 different gene 
segments, this reassortment makes it possible to have as many as 256 different genes 
combinations in the viral offspring. As a consequence, a labor intensive screening 
process is required to identify the desired features from both strains, for example, the 
expression of surface antigens corresponding to the new pandemic Hemagglutinin and 
Neuroaminidase proteins integrated into the genome of the egg-adapted and 
replication-defective (to humans) second virus (37).  
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The conventional and approved method of virus antigen production for vaccine 
composition may be some complicated when the target strains infect the eggs with 
lower efficiency making it difficult to create the desired levels of final antigen product 
(31).  There is also a high risk of cross contamination of the vaccine with material 
isolated from the egg during vaccine manufacture (38). In addition, there are more 
complex facilities required for vaccine manufacture using this method. These various 
complications are driving the search for a new method to produce appropriate influenza 
antigens that can be adopted for the production of vaccine. 
1.2.1.2. Influenza DNA-based vaccines 
 
The formulation of DNA vaccines is based on using purified DNA that encodes the 
appropriate viral proteins.   The viral DNA is present in plasmid vectors,  which can be 
electroporated into host cells to exploit the host cellular machinery to translate the 
specific antigens and express them in the transformed animal tissues (39,40). Viral 
DNA-based vaccines are able to stimulate humoral, cell-mediated responses. For 
example, vaccination with a plasmid that codes for a viral antigen in combination with a 
plasmid encoding a neutralizing monoclonal antibody for the same antigen, is able to 
induce a  synergistic effect and a broader immune response, compared to separate 
administration, representing a more robust and flexible vaccine platform (41–44).  
1.2.1.3. Influenza Synthetic Peptide Vaccines 
 
 Influenza vaccines have also been creating using synthetic peptides. This 
approach allows the use of chemically synthetized peptides that correspond to portions 
of the Influenza proteins that are well known to elicit immune protection via innate or 
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humoral responses. This methodology has made it possible to create many formulations 
targeting different epitopes of the virus, with peptide cocktails based on conserved or 
variable regions and with the ability to generate  immune cross-protection among 
various types or subtypes of virus in the same formulation (45–47). However, since 
smaller peptide antigens do not stimulate strong immune responses these formulations 
also have to include adjuvants to stimulate the immune response which have to be 
evaluated to produce effective vaccine  candidates (48) .   
1.2.1.4. Universal Vaccines 
 
The creation of Universal vaccines requires the use of antigens that correspond to 
highly conserved regions of the virus and which code for proteins critical for the function 
of the pathogen’s infection process.  For example, the main targets of universal 
influenza vaccines include epitopes that are critical for the conformational changes 
necessary for the persistence and success of infection (49).  In general, peptide 
sequences that have been conserved during the evolution of the pathogen and that play 
a critical function in the mechanism of infection are the most successful candidates. 
Evolution of the virus sequence is also important in terms of immune system recognition 
and neutralization since protection of critical sites of the molecules is required to ensure 
survival of the virus. Examples where viral evolution has resulting in burying those 
sequences within a larger macromolecule are very well known. In HIV, conserved 
sequences in the gp120 molecule which correspond to the CD4-binding site (CD4bs) 
and coreceptor-binding site (CoRbs) are only exposed after conformational changes 
occur in gp120 during infection.  This means that the immune system is unable to 
normally make antibodies which block gp120-mediated infection (50). The presence of 
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antibodies can be used for the identification of such epitopes, since epitope mapping 
with neutralizing polyclonal or monoclonal antibodies can identify crucial regions that 
might make functionally important vaccine targets. Therefore, the composition of a 
universal vaccine can be based on using short or larger peptides with linear 
conformational structure, peptides that correspond to conserved or consensus critical 
regions, or a set of engineered peptides that present a stabilized conserved antigen that 
might be functionally important (49). 
1.2.1.5. Recombinant subunit vaccines. using yeast Pichia pastoris as a platform for 
vaccine production for novel influenza antigens. 
 
  The methylotrophic yeast Pichia pastoris has been of great interest and widely 
used for the production of vaccines since the technology arose in the middle of the 
1980’s (51). Its versatility relies on many factors:  
a) Pichias pastoris is an eukaryotic microorganism that is very easy to culture and 
which requires no-complex media formulations for its growth and maintenance. 
The Pinchia pastoris optimal growth condition are very well established with an 
optimal temperature of 28-30oC that permits the expression of temperature-stable 
proteins and has the advantage that its growth kinetics may not be significantly 
altered if the optimum temperature for recombinant protein expression has to be 
lowered to the range of 20-24oC. Pichia pastoris can also generate a large 
biomass even in the absence of protein induction, which makes it suitable for 
fermentative bioprocessing.  
b) The expression of the heterologous genes can be placed under the control of 
very strong DNA promoters. The Alcohol Oxidase 1 (AOX1) promoter has  a 
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DNA size of 960 base pairs, and drives the expression of polypeptides using 
methanol as the sole inducer carbon source (52).  The Glyceraldehyde-3-
Phosphate promoter, or its alternate mutated form, is 477 DNA base pairs in 
length and can be used to enhance protein expression (53,54). Furthermore, 
expressing a combination of two different recombinant protein-promoter 
constructs inserted in the same genome of a Pichia pastoris clone is used as a 
biotechnological strategy to increase protein expression synergistically compared 
to when they are used separately (personal experience). 
c) The genome of Pichia pastoris can be modified with standard molecular biology 
techniques. The exogenous genes cloned in a Pinchia pastoris expression 
plasmid, can be presented as a linear or circular vector inserted into the yeast 
genome using chemical, electrical, physical, or the combination of all the 
aforementioned transfection methods. For example, the pPicZalpha plasmids can 
be successfully integrated into the Pinchia pastoris genome by homologous 
recombination at the terminal sites of the digested AOX1 promoter, thus 
facilitating the integration of multiple DNA cassettes during a single 
transformation procedure. The selection process employs an antibiotic resistance 
marker, like the Zeocin resistant ble gene or the blasticidin S-resistance (bsr) 
gene. As a rule, the amount of soluble protein expressedby a single transformed 
Pichia clone can be increased by using higher levels of selecting antibiotics to 
isolate antibiotic hyper-resistance (up to 2000 µg/mL) clones, which is an indirect 
indicator of clones where multiple cassettes containing the gene of interest have 
been integrated. 
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d) Recombinant protein expression and posttranslational modification in Pichia 
pastoris is robust where other expression systems have failed. Expression of 
therapeutic proteins, antigens, monoclonal antibodies, and peptides in Pichia 
pastoris are abundant in the literature  ranging from milligram to grams per liter 
(55,56,57). The possibility of expressing the recombinant protein at significant 
levels with large industrial volumes in bioreactors, must be considered an 
important step when the production of antigens for human or animal vaccination 
programs is being proposed. The influenza hemagglutinin subunits have been 
successfully expressed in Pichia pastoris cells at high levels and in a 
conformation capable of eliciting production of neutralising antibodies in animals 
(56). On the other hand Pichia pastoris possesses an eukaryotic posttranslational 
modification system that is useful when the proteins require a certain 
glycosylation pattern for expression of the full activity of human-intended 
therapeutic proteins (58) . The normal forms of N-linked or O-linked glycosilation 
motif patterns are easily recognized in this yeast system. Pichia pastoris can 
introduce hyper-glycosylated carbohydrate side chains (59,60) that may affect 
protein functionality, folding, or protein-protein interactions (61). In addition, 
Pichia pastoris strains can be bioengineered to generate humanized N-
glycosylation patterns (59),(62). Substitution of residues within the glycosylation 
motifs by DNA mutagenesis has also been shown to be a method to generate 
protein heterogeneity without affecting the biological function that is commonly 
associated with hyper-glycosylation (61,63). Expression of recombinant proteins 
in prokaryotic systems results in un-glycosylated proteins that can have an 
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impact on antibody responses in animal models, which can affect success 
(63,64) or cause low efficacy (65) of antibody binding  in response to high virus 
challenges.  This deficiency in the effectiveness of prokaryote-derived proteins is 
often associated with incorrect conformational folding and lack of post-
translational modification that may affect the formation of the neutralising 
epitopes (64), (65). The intention of the present study is focused more on the 
advantages of the eukaryotic yeast expression system for a robust yield of novel 
influenza antigens to assist in the production of influenza globular head domains 
for heterosubtypic immunity or to be integrated in approaches to induce stem-
reactive antibodies (49,63) 
 
1.3. Protein engineering and antigen design 
A perfect vaccine should comprise many characteristics in its design: 
a) Gene-based protein vaccines should stimulate the immune system. The 
larger the protein molecule, the better the immune response (66). In this way the 
use of adjuvants is abate: not meaning that they are no longer needed but 
instead, that their addition increases the chance that less antigen in the final 
formulation can still stimulate a strong immune response, thus resulting in more 
doses of vaccines being produced (67). 
b) The expressed protein molecules should resemble the normal 3-
dimensional structure, folding and post-translational modification of the 
antigen protein. There is some evidence that post-translational modifications, 
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like glycosylation modification, may negatively affect the immune response 
although this concept has been challenged. For instance, the enzymatic de-
glycosylation of Hamagglutinin proteins expressed in cell cultures, are able to 
induce a better neutralizing serum protection than untreated proteins in 
vaccinated organisms (65). Therefore, changing the expression platform from a 
eukaryotic to a prokaryotic system results in an antigen that lacks glycan 
moieties that can elicit high neutralizing antibodies titers (68). In addition, 
bioengineering of cysteine residues in the hemagluttinin stem-based domain to 
create peptides that showed conformational constraints to mimic the proper 
antigenic exposition and promote stabilization by disulphide bridging enhanced 
its effectiveness (69,70). 
c) The antigen must be produced at high levels with the protein expression 
system used and must be easy to purify. Some antigens express better by 
changing the expression system used, changing from prokaryotic to eukaryotic or 
vice versa may overcome such situations. Strategies like adding a soluble 
domain and a protease cleavage site next to the C- or N- terminal portion of the 
gene of interest can facilitate the recovery of the protein from the soluble phase 
followed by its release from the unwanted domain. Even though protein 
precipitation like the situation which occurs in inclusion bodies in prokaryotic 
systems permits the recovery of large amounts of antigen, the refolding process 
is not always successful at restoring immunogenicity. It is also likely that the 
current use of bioinformatics tools for codon optimization of the gene, based on 
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the relative abundance of transfer RNA and secondary mRNA structure, can be 
an important optimizing parameter for heterologous expression.   
 
1.4. HYPOTHESIS AND AIMS 
The main objective of this study is to to obtain expression of chimeric Receptor 
Binding domains in Pichia pastoris without resulting in insoluble proteins as previously 
reported in prokaryotic systems. 
To generate a platform for protein expression in Pichia pastoris that can be used 
to produce high levels of recombinant influenza virus proteins that are composed of at 
least of three Receptor Binding Domains.   
The receptor binding domains represents antigenic determinants in different 
Influenza types and subtypes, in this regards, a single expressed antigen can be used 
as a vaccine against hetero-subtyped potential candidate viruses. 
Evaluate the recovery of native designed antigens and tagged designed antigens 
that help to simplify the purification steps for future scale-up conditions. 
Characterize the antigens expressed in Pichia pastoris by its biochemical 
methods (immunodetection, glycan-content, N-teminal sequencing, DNA sequencing, 
Mass-Spec analsysis) that helps us to asses and confirm the identity of the antigens 
expressed. 
 Based on expression and characterization results, apply the use of bioinformatics 
that help us to improve the antigens design. 
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2.0 METHODS 
2.1. Influenza RBD expression in Pichia pastoris 
2.1.1 Gene design for avian and human RBD trimers 
2.1.1.1. Gene sequences and synthesis. 
 
Influenza full HA sequences of avian origin were obtained from the biological 
manufacturer company, Investigacion Aplicada S.A. (IASA). These sequences 
represent influenza virus isolates from Mexican chicken farms, which have been 
identified according to the strain of origin. The sequences of the DNA were aligned 
using the Basic Local Aligment Search Tool (BLAST) from the National Center for 
Biotechnology Information (NCBI) to show areas of homology. Protein sequences 
corresponding to the HA molecules of human origin where retrieved from the NCBI 
database based on the 2013-2014 influenza vaccine composition as approved for use 
by the World Health Organization (71).  
The antigen design was based on previous studies, which have used the 
Receptor Binding Domain from Influenza AH1N1 California 2009 pandemic, named 
RBS(28-265), as the basis for a candidate vaccine (64,68). This approach uses these lectin 
globular domains from different virus-specific HA1 subunits as the antigenic molecules 
for the creation of a potential multivalent vaccine. These antigens lack the fusion 
peptide sequence and other amino acid residues related to the stalk, and HA2 
subdomain. The selected sequences were modelled individually using the Phyre2 
website server to calculate the predicted globular structure (72).  
21 
 
The gene construct designed for this vaccine was composed of three RBD’s 
expressed in tandem (the RBD trimer) with two flexible linker sequences that code for 
(serine-glycine-glycine-glycine-glycine)2 (10 a.a. length) to facilitate an intermolecular 
spacing between each of the monomers. The Avian RBD trimer gene version V3.4 is 
composed of the three avian RBD: (5’-3’ DNA sense): an Avian H5-like Hemagglutinin 
domain, followed by another Avian H5-like hemagglutinin domain, and an Avian H7-like 
hemmagglutinin virus domain.  
Based on the Avian RBD trimer V3.4, three additional versions were designed: 
V3.5, V3.6 and V3.7.  These constructs included the addition of an HIV-Tat basic 
domain cell-penetrating peptide, an immune-stimulant 5-mer peptide, or a combination 
of both (immune-stimulant 5-mer peptide and HIV-Tat basic domain cell-penetrating 
peptide), respectively, engineered on the 3’ end of the coding region.  
The Human RBD trimer version V3.3 is composed of the following RBDs (listed 
in the 5’-3’ DNA sense): the Human A type, H1 hemmagglutinin domain from the 
AH1N1/California/09/2009 pandemic strain; the Human A type, H3 hemmaglutinin 
domain from AH3N2 A/Texas/50/2012 virus; and, the Human B type, B hemagglutinin 
domain from the B/Brisbane/33/2008 virus.  
The sequences of the artificial gene RBD trimer versions were code-optimized 
and synthetized for the Pichia pastoris expression system using the services of 
Genescript Inc (Piscataway, NJ). The gene construct versions were originally designed 
to contain an XhoI (5’ CTCGAG 3’) restriction site at the 5’ end of the gene and an XbaI 
(5’ TCTAGA 3’) restriction site followed by a Stop codon (TAA) at the 3’ end of the gene 
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in all the versions. The two restriction sites allow for unidirectional cloning in the Pichia 
pastoris extracellular expression plasmid pPicZalphaA.  
2.1.1.2. Custom Cloning 
 
The different versions of the genes (V3.3, V3.4, V3.5, V3.6, and V3.7) were 
synthethized containing a stop codon at the C-terminus of the artificial RBD trimers and 
were custom cloned in the extracellular expression plasmid pPicZalphaA (Figure 3) 
using the two restriction sites XhoI and XbaI. The first restriction site (XhoI) is in frame 
with the sequences encoding the endopeptidase cleaveage site, Kex2, thus facilitating 
the complete removal of the alpha factor peptide and leaving the native N-terminal 
portion of the RB trimer without any additional modification (Figure 4).  
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Figure 3 . The extracellular pPicZ-Alpha-A and Intracellular pPicZ-B vectors used 
for the expression of Avian and Human HA-RBD synthetic and codon-optimized 
versions in the Pichia pastoris expression system.  Two restriction sites, XhoI and 
XbaI were used to clone the HA RBD multimeric genes. The extracellular vector 
possesses the alpha factor secretion signal for protein export. 
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Figure 4 . General custom cloning strategy for expression of extracellular Avian 
and Human HA-RBD multimeric genes in the plasmid pPicZalpha-A. In this 
particular case, Avian HA-RBD V3.4 was synthetized (GeneScript, Inc.) containing a 
premature stop codon after the C-terminal sequence of the multimeric RBD gene. Alpha 
factor sequences facilitate export to the secretory pathway and removal by the Kex2 
endopeptidase. The intention of this first design strategy was to produce and to purify 
recombinant RBDs in their native sequence state. 
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2.2. Modifications to gene design 
2.2.1. Removal of premature stop codon in the Avian and Human HA-RBD versions to 
restore 6-Myc and 6-His tag  
 
As part of a second strategy, the modification of the codon optimized synthetic 
Avian and Human HA-RBD versions was performed. A PCR amplification, using specific 
primers, removed the stop codon located after the C-terminal portion of the HA-RBDs.  
This allowed the creation of an open reading frame that included the c-Myc and 6-His 
tag sequences for purification and detection purposes that were present in the original 
plasmid design (Figure 5). At the same time, the avian and human HA-RBD versions 
were inserted into the pPicZ-B vector to explore the effects of intracellular expression of 
the various RBD proteins in Pichia pastoris. 
The PpicZ-B plasmid lacks the in-frame reading of the alpha-factor signal peptide 
which is required to secrete the recombinant protein. The cloned Avian and Human 
RBD genes (V3.3, V3.4, V3.6, V3.7) in the pPicZ-alphaA plasmids were used as the 
template in a PCR reaction using an antisense primer that altered the premature stop 
codon to facilitate the in-frame translation of the c-myc and 6-His tags. Briefly, a specific 
primer corresponding to the 5’ DNA region was used to add an XhoI restriction site 
sequence, a yeast consensus Kozak’s sequence and a methionine start codon 
sequence to the 5’ sequence of each of the avian RBD gene constructs in order to 
facilitate the correct ligation, translation initiation and intracellular expression of the RBD 
trimer proteins.  The new constructs were named: HA-RBD mutV3.3, HA-RBD 
mutV3.4, HA-RBD mutV3.6, and HA-RBD mutV3.7.  
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2.2.2. PCR mutagenesis 
 
To clone into the pPicZalpha-A plasmid, the Avian RBD gene constructs were 
isolated using PCR performed.  The PCR used the forward primer 3ALL-F and the 
reverse primer 3.4RMUT for amplification of version V3.4; the forward primer 3ALL-F and 
the reverse primer 3.6-Rmut were used to amplify version 3.6; the forward primer 3ALL-
F and the reverse primer 3.7Rmut were used for version V3.7. Additionally, RBD’s from 
human origin V3.3 were amplified using the forward primer 33-FWD and the reverse 
primer 33-R and subsequently cloned in the extracellular expressing vector pPicZalpha-
A.  
For cloning of the Avian RBD into the intracellular expression vector pPicZ-B, the 
forward primer INTRA-F and the reverse primer 3.4Rmut were used for PCR 
amplification of version V3.4. The forward primer INTRA-F and the reverse primer 3.6-
Rmut  were used for the amplification of version V3.6 The forward primer INTRA-F and 
the reverse primer 3.7Rmut were used to amplify version V3.7. The human RBD version 
mutV3.3 was PCR amplified using the primers F-INTRA33 and 33-R and 200 ng of 
Pichia genomic DNA from clone D7 which had been transformed with the inserted 
pPicZalpha-A HA Human RBD V3.3 construct (premature Stop codon-No 6His tagged). 
Primers are shown in Table 2. 
The PCR reactions consisted a total volume of 50 µl containing 5 ng of either  
pPicZalphaA plasmid vector containing one of the unmodified versions of the Avian 
RBD contructs V.3.4, V3.6, V3.7; forward primer (0.5 µΜ final concentration), reverse 
primer (0.5 µΜ final concentration), 1 µl of High Fidelity Phusion Polymerase (1U total) 
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(ThermoFisher), 1 µl of dNTPs (10 mM each), 10 µl of Buffer HF (1x final concentration) 
and H2O. Cycling parameters consisted of an initial denaturation step  (98oC for 30 sec); 
followed by 30 amplification cycles (each cycle consisted of a denaturation step at 98oC 
for 10 sec, a primer annealing-amplification step at 72oC for 1 min 10 sec; and a final 
extension at 72oC for 10 min); and a final incubation step at 4oC applied to all samples 
until they were removed. 
All reverse primers were designed to avoid amplification of the stop codon 
located next the 3’ site of the Avian RBD template version but kept the XbaI restriction 
site for re-cloning into the pPicZalpha-A and pPicZB expression vectors (Figure 2). Two 
forward primers were designed to amplify the sense DNA strand: for all avian RBD 
versions, 3ALL-F 5’ GAGGAGGAGCTCTCGAGAAGAGAAGTGTTAAGGGAG 3’ was 
used; and for the human RBD version the forward primer 33-Fwd 5’ 
GAGGAGGAGCTCTCGAGAAAAGAGGTGTCGCTCCATTGC 3’ and the reverse 
primer 33-R 5’ GAGGAGGAGCTTCTAGACCTTTGATGACTTTACTTCTACC 3’ was 
used in the PCR amplification for cloning in the extracellular vector pPicZalpha-A.  
2.2.3. Avian and Human HA-RBD re-cloning in pPicZalpha and pPicZ-B 
 
The PCR of each version of the RBD amplified a ds DNA fragment of 
approximately 2.1 Kb.  These bands were excised and recovered after electrophroresis 
on 1.2 % agarose gels in TAE 1X, pH 8.0 (40mM Tris, 20mM acetic acid, and 1mM 
EDTA) using the Qiaquick Gel extraction kit (Qiagen Inc) following the manufacturer 
recommendation. The isolated fragments were quantitated by spectroscopy at 260/280 
nm and 500 ng of purified PCR products were double-digested at 37oC for 4 h with both 
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the XhoI (30 Units total) and XbaI (30 Units total) restriction enzymes in 1X Cutsmart 
Buffer in 50 µl total reaction volume.  After incubation, the samples were heat 
inactivated at 70oC for 20 min, and subjected to electrophoresis on a 1.2% Agarose gel 
in 1X TAE buffer along with the DNA standard 1kb DNA ladder (Invitrogen). Samples 
were visualized under a UV trans-illuminator and the DNA fragments that correspond to 
the RBD’s (2.1 Kb long) were recovered from the agarose gel and stored in 1.5 ml 
microcentrifuge tubes. The gel slices were extracted using the gel recovery kit (Qiagen) 
following the manufactured instructions and the recovered DNA was quantified using a 
Nanodrop 2000c spectrophotometer evaluating the purity at 260/280 nm. 
The DNA vectors pPicZalpha and pPicZ-B were double-digested in 50 µl total 
volume reaction using 500 ng of each plasmid and the restriction enzymes XhoI (10 
units total) and Xba (10 units total) in 1X Cutsmart Buffer and incubated to 37oC for 4 h. 
After incubation, the samples were subjected to electrophoresis on a 1.2% agarose gel 
in 1X TAE buffer along with the DNA standard 1kb DNA ladder (Invitrogen). Samples 
were visualized under a UV transilluminator and the DNA fragments that correspond to 
the pPiczAlpha-A (3.6 Kbases long) or pPicZ-B (3.1 kbases long) plasmids were 
collected separately by excising the gel slices, which were stored in 1.5 mL 
microcentrifuge tubes. The gel slices were extracted using the gel recovery kit (Qiagen) 
following the manufactured instructions and the recovered DNA was quantitated using a 
Nanodrop 2000c spectrophotometer at 260/280 nm. 
For DNA ligation, a 3:1 insert to vector molar ratio was used.  The reaction was 
performed using  87 ng of DNA corresponding to each RBD gene version (insert), and 
50 ng each of pPicZalpha-A or pPicZ-B digested DNA (the inserts were cloned 
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separately into both plasmid vectors) with 1 µl of T4 ligase enzyme (0.5 Units, 
Fermentas, Fisher Scientific) and 1X T4 ligase buffer (Fermentas,).  The mixture was 
combined gently using a pipet tip and incubated at 23oC for 1 h followed by incubation 
at 4oC for 4 h. The ligation reaction was stopped by incubation at 70oC for 20 min to 
inactivate the enzyme and then the ligation reactions were stored at -20oC or used 
immediately for DNA transformation. 
The plasmids created by ligating the RBD genes into the pPicZalpha-A or pPicZ-
B vector backbones were transformed into E.coli using a heat shock protocol. 50 µl of 
E. coli TOP10 chemical competent cells (in 60 mM calcium chloride, 15% (w/v) glycerol, 
10 mM PIPES, pH 7.0, solution) were incubated with 2 µl of ligation reaction in an ice-
bath for 30 min, then the cells were heat shocked at 42oC for 45 s, and immediately 
returned to the ice bath for 2 min. The cells were recovered by incubation in pre-
warmed (37oC) LB-Low-Salt, pH 7.5 medium (1% Tryptone, 0.5% NaCl, 0.5% yeast 
extract) for 1 h. 100 µl of the culture was then spread on LB-agar plates containing the 
Zeocin (25 µg s/ml) selective agent and incubated at 37oC for 12 h to allow clonal 
growth. Five to ten positive E. coli clones were picked individually and grown in 10 mL 
of LB-low-salt pH 7.5 liquid media containing Zeocin (25 µg/mL) for plasmid selection. 
The cultures were grown for 12-14 h at 37oC in a rotator set at 250 rpm and then the 
plasmids expressed in the individual clones were purified using the PureYield Plasmid 
Miniprep system (Promega, Cat. A2393) according to manufacturer’s instructions. The 
plasmid concentrations and purity were quantitated using the NanoDrop 2000c. 
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The insertion of the RBD genes into the plasmid pPicZalphaA or pPicZB were 
confirmed by restriction analysis using 500 ng of purified plasmid and the XhoI (5 units) 
and XbaI (5 units) restriction enzymes in Cutsmart 1X buffer (1X , NEB) in a volume of 
20 µl. The reactions were heated at 70oC for 20 min, subjected to electrophoreseis on a 
1.2% agarose gel in 1X TEA electrophoresis buffer  (40 mM Tris, pH 8.0,  20 mM 
acetate , and 1 mM EDTA), and the fragment size evaluated by comparison to the DNA 
size standard, 1KbPlus DNA ladder (Invitrogen).  
2.2.4. Sanger sequencing confirmation of positive clones. 
 
Six specific sequencing primers, that target the internal sequence of the Avian 
RBD version, were designed based on the initial sequence of the avian RBD 
monomers, taking care to start the primer sequences with a cytosine (C) or a guanine 
(G) base (one primer started with a T).  The sequencing primers were all approximately 
20 bases in length and were shown to be unable to self dimerize and form “primer-
dimers”. In this way, the sequencing primers used were: FWD520: 
5’TCAACTCCAACAATTGCCAC3’; RV524: 5’GTGGCAATTGTTGGAGTTGA3’; 
FWD715: 5’CTTATTTTGAAGGATTGTTCTG3’; Fwd955: 5’GGTGTTAGTTCTG-
CTTGTCC3’, FWD1399: 5’CCTACCGATCTTGGTCAATG3’; RV1418: 5’CATTGACC-
AAGATCGGTAGG3’. Two plasmid-specific sequencing primers, the 5´ AOX1: 
5’GACTGGTTCCAATTGACAAGC3’ and 3’AOX1: 5’GCAAATGGCATTCTGACATCC3’ 
targeting the 5’ and 3’ AOX1 Pichia’s promoter region were also used. Using these 
primers, it was possible to determine the sequences of the avian RBD genes in both the 
sense and antisense DNA directions to identity the fidelity of the amplification across the 
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whole ligated sequence. No sequencing primers were designed and synthesized for the 
human RBD cloned versions (Figure 6, Table 3). 
Positive clones with the inserted RBD gene were sequenced using capillary-
based fluorescent sequencing on a ABI 3730XL sequencer using a commercial service 
provider. Individual samples were prepared for sequencing using 250 ng of plasmid 
containing the RBD gene and 5 pmoles of the appropriate sequencing primer in a total 
volume of 7.7 µl, the samples were loaded on a 96 well PCR plate, sealed and sent for 
analysis to the Center for Applied Genomics at the Hospital for Sick Children in Toronto, 
Canada. The retrieved sequence files from the core facility were analysed using either 
Sequencher, CLC Workbench, or SnapGene software. The sequences were compared 
to the sequenced RBD genes originally synthetized by GeneScript, to confirm the 
removal of the pre-stop codon, correct addition of restriction sites, and lack of nucleotide 
sequence modifications (insertions, deletion, substitution in nucleotides bases). 
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Table 2. Polymerase Chain Reaction (PCR) amplification primers used for 
modification of the Avian and Human HA-RBD sequences.  The numbers in the 
primer names denote the Version amplified, with the exception of 3ALL-F and INTRA-F, 
which were used to amplifiy all the extracellular and intracellular Avian versions, 
respectively. For each primer 11 base pairs  was added at the  5’ end of the coding 
sequence (GAGGAGGAGGT) to promote optimal enzymatic digestion of the XhoI 
(CTCGAG) or XbaI (TCTAGA) restriction sites (in italics). In the case of intracellular 
expression a consensus Kozak’s  sequence (in bold & italic) was inserted for translation 
initiation, next to a methionine (ATG) start codon (lower capitals). DNA sequences 
specific for the avian or human HA-RBD versions (in bold). 
Primer name Primer Sequence (5’ to 3’) Orientation Expression Vector 
3ALL-F 5’GAGGAGGAGCTCTCGAGAAGAGAAGTGTTAAG
GGAG 3’ 
Forward  pPicZalpha-A 
3.4RMUT 5’GAGGAGGAGGTTCTAGAGACTGGATTCCGATA
GATTCTCC3’ 
Reverse pPicZalpha-A & pPicZ-B 
3.6-Rmut 5’GAGGAGGAGGTTCTAGACACTCACACCACTTT
GAC3’ 
Reverse pPicZalpha-A & pPicZ-B 
3.7Rmut 5’GAGGAGGAGGTTCTAGACTTCTTCTCTGTCTTC
TCTTC 3’ 
Reverse pPicZalpha-A & pPicZ-B 
3.3-FWD 5’GAGGAGGAGCTCTCGAGAAAAGAGGTGTCGCT
CCATTGC 3’ 
Forward pPicZalpha-A & pPicZ-B 
3.3-R 5’GAGGAGGAGCTTCTAGACCTTTGATGACTTTAC
TTCTACC 3’ 
Reverse pPicZalpha-A & pPicZ-B 
INTRA-F 5’GAGGAGGAGGTCTCGAGCGAAACGatgGAGAA
GAGAAGTGTTAAGGGAG-3’ 
Forward pPicZ-B 
F-INTRA3.3  Forward pPicZ-B 
 
 
 
  
33 
 
 
 
 
 
Figure 5. PCR mutagenesis modifications to enhance Extracellular and 
Intracellular expression of the original gene design. In A, a version-specific primer 
used to remove the premature stop codon originally designed for this study (in this case 
Avian HA RBD v3.4). The designed primer reconstitutes the open-reading frame to 
include the c-myc and 6-histidines tag sequences for protein purification and detection. 
This strategy was applied for the extracellular and intracellular re-cloning of the genes. 
In B, to increase the level of intracellular expression, it was necessary to design a 
primer that inserted a XhoI restriction site and Kozak sequence to the 5’ end of the 
Avian or Human HA-RBD mutated versions. 
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Figure 6. Schematic localization of the sequencing primers. The location of the 
primers used to confirm the correct amplification and cloning of the different types of 
avian HA RBD genes within the Avian HA RBDs gene located within the pPicZalpha-A 
or pPicZ-B vectors. A total of 8 primers were used to cover the 2.1 Kb bp length RBD 
sequence in both DNA strand orientations.  
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Table 3. List of primers used for sequencing the Avian RBD versions. The number 
that appears in each primer corresponds to the nucleotide position within the aligned 
chimeric avian RBD versions. 
 
Primer 
name 
Primer Sequence (5’ to 3’) Orientation Expression Vector 
FWD520 TCAACTCCAACAATTGCCAC Forward Avian Intracellular and 
Extracellular 
RV524 GTGGCAATTGTTGGAGTTGA Reverse Avian Intracellular and 
Extracellular 
Fwd955 GGTGTTAGTTCTGCTTGTCC Forward Avian Intracellular and 
Extracellular 
FWD 1399   CCTACCGATCTTGGTCAATG Forward Avian Intracellular and 
Extracellular 
RV1418        CATTGACCAAGATCGGTAGG Reverse Avian Intracellular and 
Extracellular 
FWD715    CTTATTTTGAAGGATTGTTCTG Forward Avian Intracellular and 
Extracellular 
5´ AOX1 GACTGGTTCCAATTGACAAGC Forward Avian Intracellular and 
Extracellular 
3´ AOX1 GCAAATGGCATTCTGACATCC Reverse Avian Intracellular and 
Extracellular 
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2.3. Pichia pastoris transformation and antibiotic marker selection  
2.3.1. Pichia pastoris X-33 strain transformation 
 
Competent Pichia pastoris strain X-33 cells were prepared for electroporation 
using a highly efficiently transformation method (73). Briefly, 5 ml of liquid YPD media 
culture grown from a single colony were used to inoculate 1 L YPD liquid media (2% 
peptone, 1% yeast extract, 2% glucose). The cell concentration was monitored until the 
optical density (OD) of the culture reached 0.6. A total of 1x10^8 cells were harvested 
by centrifugation and treated in 8 ml of electrochemical competent solution (100 mM 
LiAc, 10 mM DTT, 0.6 M Sorbitol, 10 mM Tris-HCl, pH 7.5).  The suspension was 
centrifuged at 1500x g for 4 min, and sequentially washed in 1 M Sorbitol three times. 
The cells were resuspendend to a total volume of 80 µl in electrochemical competent 
solution and used immediately for electrotransformation. A total of 1 µg of pPicZalphaA-
RBD plasmid, which had been linearized by treatment with the SacI restriction enzyme, 
was incubated on ice in an electro-cuvette containing 80 µL of electrochemical 
competent Pinchia pastoris X-33 cells. The electro-transformation parameters consisted 
of a single pulse of 1.5 kV, 200 Ω, 25 µF, using a BioRad Gene Pulser system, followed 
immediately by incubation in ice-cold 1 M Sorbitol solution for 1 h. Following incubation, 
20 - 200 µL of the recovered cells were plated on YPDS-agar plates (2% peptone, 1% 
yeast extract,2%  glucose, 1.2 M sorbitol) containing different concentrations of the 
selective antibiotic Zeocin at 200 µg/mL, 500 µg/mL, 1000 µg/mL and 1500 µg/mL.     
2.3.2. Antibiotic selection 
 
The transfected Pichia pastoris colonies that grew on solid YPDS-Agar media 
plates containing zeocin concentrations ranging from 200-1500 µg/mL were selected 
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(high levels of antibiotic were used in order to select zeocin hyperresistant P. pastoris 
colonies). Between 10-20 resistant Pichia pastoris colonies were selected 3-4 days after 
plating on selective media, and transferred by “toothpick” replating to selective YPD 
solid media and then transferred to 96-well tissue culture plates for selection in liquid 
culture to reconfirm hyper-resistance to 1500 µL/mL zeocin antibiotic. The clones grown 
in 96-wells plates were reselected over three rounds of growth: each clone in the 96-
well plate was diluted 1/10th after 24 h of incubation at 260 rpm into a new 96-well plate 
(Zeocin 200 µg/mL) for each round. After the third selection 5 µl of each clone was 
transferred to three different 96-well plates with different zeocin concentrations ranging 
from 500 µg/mL, 1000 µg/mL, and 1500 µg/mL.    
2.2.3. Short-term and long-term storage of Pichia pastoris transformants 
 
Hyper-resistant selected colonies were plated individually on YPD solid media for 
short term storage. For long-term storage the clones were cultured in 10 ml YPD liquid 
media cells harvested by centrifugation at 1500 rpm per 5 min, re-suspended in 1 ml 
YPD supplemented with 20% glycerol ( final concentration), and stored at -80oC. 
 
2.4. Protein expression analysis 
2.4.1. Pichia pastoris expression growth conditions and media 
 
Zeocin-selected clones were cultured in 200 ml BMGY (1% Bacto Extract, 2% 
yeast extract, 1% glycerol, 0.005% Biotine, and 2.17% yeast nitrogen base) liquid media 
until they reached an O.D. between 2 - 6. The cells were harvested by centrifugation 
and grown in BMMY liquid media containing 1% methanol, to induce recombinant 
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protein expression, to a final O.D. = 1. The culture was incubated for 48 h and then the 
cells were harvested by centrifugation at 3500 x g for 30 min. The proteins in the 
supernatant were subjected to analysis by electrophoresis on polyacrylamide gels 
containing SDS (SDS-PAGE) and purified using Metal ion Affinity Chromatography 
(IMAC), gel slice isolation, size exclusion chromatography or anion Exchange 
Chromatography (AEX) depending of the analysis performed.     
2.4.2. Clarification and Ultrafiltration of media supernatant from induced Pichia pastoris 
cultures 
 
Prior to IMAC, the 1 L culture supernatant from the induced Pichia pastoris was 
microfiltered using a 0.2 µm membrane (PALL), was and then ultrafiltered using the 
QuixStand BenchTop System equipment and a Xampler Filtration Cartridge with a 
molecular cutoff of 10 KDa.  The supernatant was concentrated to 1/10th of the original 
volume and then diafiltrated/buffer exchanged with PBS, pH7.4 to allow a further 
decrease in its volume to ~1/20th to facilitate downstream purification. 
2.4.3. Anion-Exchange chromatography for the non-6His tagged HA RBD (premature-
Stop) proteins. 
 
An anion exchange DEAE (Di-Eethyl-AminoEthyl) resin was used in the first 
attempt to isolate the full-length, native RBD recombinant proteins. An isolation protocol 
described for hemagglutinin molecules was used where the supernatants prepared from 
the cultures induced in 1% methanol for 48 h were concentrated to 1/10th (as described 
in 2.8.2) and loaded on a 10 ml DEAE-Sepharose column by gravity flow, washed with 2 
volumes of phosphate Buffer, pH 7.4 and eluted using a linear gradient of 0 - 1 M NaCl 
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in phosphate buffer, pH 7.4.  The eluted fractions were collected and analyzed by SDS-
PAGE, mass-spectroscopy, and immunoblot analysis using polyclonal antibodies In the 
case of Avian influenza, Ferret (H7N2) antisera to Influenza A virus 
A/Turkey/Virginia/202 (H7N2)-PR8-IBCDC-5 (IRR FR-1088), Ferret antisera (H5N1) to 
Influenza A virus A/Chicken/Yunna/1251/2003 was used.  In the case of Human 
Influenza: ferret antisera (H1N1) to influenza A virus A/California/07/2009 (H1N1) 
pdm09 (IRR FR-359), WHO supplemental antiserum Influenza A (H3N2)v Reference 
Ferret Antiserum (IRR FR-1000), ferret antiserum (B) to influenza B virus 
B/Texas/06/2011 (Yamagata Lineage) was used. 
2.4.4. Size-Exclusion Chromatography for the DEAE-purified protein fractions 
 
After DEAE-chromatography, the eluted fractions were examined for 
appropriately sized proteins using Mass Spectrometry.  Fractions containing putative 
protein bands where further separated on an AKTA system for protein purification using 
a DEAE column.  The fractions were loaded onto the column at a flow speed of 1 
mL/min, the columns washed with 2 column volumes of phosphate buffer, pH 7.4 at 1 
mL/min, and then eluted over a linear gradient of 0 - 1 M NaCl in phosphate buffer, pH 
7.4. The fractions corresponding to the protein peaks were monitored using UV 
absorbance and were then collected and pooled for Mass Spectroscopic analysis and 
Immunodetection with polyclonal antibodies. 
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2.4.5. Tandem Mass-Spectrometry of DEAE- and Size-Exclusion purified non-6-HIS 
tagged HA-RBD peptides 
 
For the tandem Mass-Spec analysis, protein bands in the range of 72-120 KDa in 
size were excised directly from the SDS-PAGE gels using a sterile scalpel in a biosafety 
cabinet in order to avoid an external source of protein contamination for the analysis. 
The gel slice containing the band of interest was stored in 1% acetic acid prepared 
using ultrapure water (Sigma). Proteomics analysis was performed at the OHRI 
Proteomics Core Facility (Ottawa, Canada). 
2.4.6. Collaborative Methodologies 
 
As stated by the Core Facility guidelines, proteins were digested in-gel using 
trypsin (Promega) according to the method of Shevchenko (74).  The resulting peptide 
extracts were concentrated using a vacufuge (Eppendorf), purified and desalted using a 
ZipTip (Millipore), and resuspended in 1% formic acid (Fisher).  Peptides were analyzed 
by LC-MS/MS (liquid chromatography – tandem mass spectrometry) on a system 
comprised of an UltiMate 3000 RSLC nano-HPLC, LTQ Orbitrap XL hybrid mass 
spectrometer and nanospray ionization source (Thermo Scientific).  The system was 
controlled by Xcalibur software, version 2.0.7 (Thermo Scientific). 
Peptides were loaded by autosampler onto a trap column (C18 CapTrap; 
Michrom, USA) in 3% acetonitrile, 0.1% formic acid at a flow rate of 15 µl/min for 5 min.   
Peptides were eluted over 60 minute on a gradient of 3% - 45% acetonitrile at a flow 
rate of 300 nl/min through a 10-cm long column with integrated emitter tip (Picofrit 
PF360-75-15-N-5 from New Objective packed with Zorbax SB-C18, 5 µm from Agilent), 
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and nanosprayed into the mass spectrometer.  The nanoflow HPLC solvents contained 
0.1% formic acid and 5% DMSO (75). MS scans were acquired in FTMS mode at a 
resolution setting of 60,000.  MS2 scans were acquired in ion trap CID mode using data-
dependent acquisition of the top 5 ions from each MS scan. 
MASCOT software version 2.5 (Matrix Science) was used to infer peptide and 
protein identities from the mass spectra data.  The observed MS/MS spectra were 
matched against sequences from SwissProt version 2013_05, a database of common 
contaminants, and database of customer-supplied sequences.  Mass tolerance 
parameters were set to MS ±10 ppm and MS/MS ±0.6 Da.  Enzyme specificity was set 
to ‘Trypsin’ with <2 miscuts.  Oxidation of methionine, protein N-terminal acetylation, 
pyrocarbamidomethlyation of N-terminal cysteine, and conversion of glutamine to 
pyroglutamate were allowed as variable modifications. Carbamidomethylation of 
cysteine was set as a fixed modification. 
2.4.7. Immobilized Metal Affinity Chromatography (IMAC) for His-Tagged RBD proteins 
 
For IMAC purification, the culture supernatant from methanol-induced Pichia 
pastoris, zeocin-hyperrresistant clones was filtered through 0.2 µm filters (Stericup, 
Nalgene),  concentrated using the Quixstand ultrafiltration device and filtered using a 
10,000 molecular weight cut off filter (General Electric), and then buffer exchanged for 
PBS, pH 7.4.  The sample was then mixed with 1 ml of Ni-NTA agarose buffer-
equilibrated resin in a 50 ml centrifuge tube and mixed for 1.5 hours at room 
temperature and 10 rpm.  
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The Ni-NTA resin was centrifuged at 1500 x r.p.m. for 5 minutes to settle the 
beads and the resin slurry transferred into a 10 ml chromatographic column. The 
sample contained in the agarose beads was washed with 7 bead-volumes of Washing 
Buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) in order to remove 
protein impurities and weakly interacting (histidines-containing proteins) and unwanted 
proteins. The washed beads were immediately eluted with 3 ml of Elution Buffer (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) and 0.5 ml fractions were 
collected in 1.5 ml centrifuge tubes. Samples of each fraction were analyzed for the 
presence of the His-tagged protein following electrophoresis on 10% PAGE containing 
SDS 10% gels and immunoblot analysis using an anti-Histidine mouse monoclonal 
antibody (Roche Ltd). After confirming the presence of the appropriately sized reactive 
proteins(s), the positive fractions were pooled, concentrated and buffer exchanged with 
PBS, pH 7.5, using a mini ultrafiltration device (10,000 MWCO, Millex-Millipore) 
following the manufacture’s instructions.  Protein concentration of the purified Avian or 
Human RBDs, were determined either by a BCA protein assay kit (Pierce, Cat 
No.23225) or by UV-spectrophotometry reading at 280 nm using a NanoDrop 2000s. 
2.4.8. Sodium Dodecyl-Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein Analysis. 
 
Protein samples were analysed on 10% polyacrylamide gels containing SDS 
(SDS-PAGE), and subjected to electrophoresis at 120 Volts for 1.5-2 h or until full 
separation of the protein size standard (Blueye Protein Ladder, Genedirex) was present.  
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2.4.9. Immunodetection by immunoblot analysis 
 
The first strategy for immunodetection following protein purification of the HA 
RBD that did not contain a 6-His tag, employed the use of a mix of primary ferret-
polyclonal antibodies raised against the Avian Influenza virus AH5N1 and AH7N3 or 
ferret-polyclonal antibodies raised against human influenza virus A/H1N1 and B 
influenza, obtained from the CDC-Influenza Research Repository (address).  A goat 
anti-ferret-HRP was used as the secondary detection antibody. The mutated versions 
HA-RBDmut-V3.3, HA-RBDmut-V3.4 and HA-RBDmut-V3.6, were probed using only an 
anti-6His-HRP mouse monoclonal antibody (Roche diagnostics, Catalogue 
No.11965085001). Briefly, HA-RBD purified by IMAC were boiled for 5 minutes in SDS 
Loading Buffer (0.25 % bromophenol blue; 50 mM dithiothreitol; 20% glycerol; 4% 
sodium dodecyl sulfate; 0.125 M Tris-Cl, pH 6.8). The denatured RBDs samples were 
loaded on a 5% stacking gel/ 7%-running SDS-PAGE gel to facilitate protein separation 
as above. The gels were transferred to PVDF membranes (Biorad) that were previously 
activated by soaking in absolute methanol. Ice-cold Transfer Buffer/SDS (25 mM Tris-
Cl, 192 mM glycine, 20% v/v methanol, 5% SDS) was used to facilitate the movement of 
high molecular size polypeptides out of the gel. The current applied for the transfer was 
determined empirically, with the best results obtained using 25 V for 18 min using a 
Semi-Dry transfer cell (Biorad). A prestained protein standard (Blueye, Genedirex) 
helped to visually assess the optimal transfer. The PVDF immobilized RBDs samples 
were blocked by incubation in 1X PBS/0.5%Tween20/5%skim milk (PBST/M), pH 7.4, 
and washed with PBST three times for 5 minutes each. The blots were then probed with 
anti-6 His mouse monoclonal antibody-coupled to horseradish peroxidase (titre of 
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1:500) in PBST/1% skim milk, and incubated for 2 h with slight agitation at room 
temperature. After incubation, the blots were washed three times with PBST for 5 
minutes each. To detect the bound antibodies, the blots were incubated in 10 ml of 1-
Step™ Ultra TMB-Blotting Solution (Cat No.37574, ThermoFisher) following the 
manufacturer instructions to cover the membrane area to fully develope the enzymatic 
reaction. The evolved chromogenic reaction was detected using a digital camera. 
2.4.10. Deglycosylation Assays 
 
For the identification of the RBD glycosylation patterns in the recovered His-
Tagged HA-RBD mutV3.4, HA RBD mutV3.6, and HA RBD mutV3.7 proteins, 1-20 µg 
of sample protein were combined with 1 μl of 10X glycoprotein denaturing buffer to a 
total volume of 10 μl (with water)total reaction volume.  The protein samples were 
denatured by heating at 100 oC for 10 min. To the denatured samples, 10 µl was added 
containing, 2 µl 10X Glycobuffer, 2 µl endoglycosidase EndoHf  (2000 units total, 
NEBiolabs), and H2O (if necessary) to 10 µl, both solutions were mixed gently and 
incubated at 37 oC for 1 h. The de-glycosylation protein pattern was analysed using a 
10%SDS-PAGE gel, transferred to a PVDF (Biorad) membrane for western blot 
detection using anti-hexahistidine-HRP mouse monoclonal antibody (Roche). Avian or 
Human RBDs protein concentrations were determined either by a BCA protein assay kit 
(Pierce, Cat No.23225) or by the UV-spectrophotometry reading at 260 nm using the 
NanoDrop equipment. 
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2.4.11. Hemmaglutination assays in Guinea Pig Red Blood Cells 
Serial dilutions composed of 50 µl of purified RBD proteins in PBS pH 7.5 ,  were 
incubated with 50 µl of Guinea pig red blood cells (RBC) 0.5 % in PBS pH 7.4, for one 
h. The amount of hemagglutination was recorded and compared to positive controls 
consisting of Control antigen (H1) pdm09-A/California/07/2009-NYMC X-179A 
(Catalogue No. FR 1184, IRC) and a positive control consisting of the trivalent Fluviral 
vaccine version 2013-2014 (GlaxoSmith&Kline). The negative control consisted of PBS, 
pH7.5, only. The scores were based on the guidelines and lab procedures suggested by 
the National Veterinary Services Laboratory, USA (76). 
 
2.5 Bioinformatics tools   
2.5.1. Protein homology/analogY Recognition Engine version2.0 (Phyre2) as a tool for 
protein folding prediction. 
 
The linear sequence for each monomer protein contained in the avian and in the 
human RBDs versions were analysed individually using the Phyre2 (72) server under 
“normal” mode modelling, and for the multimeric gene design uder “intensive” mode. 
Protein DataBank (*.pdb) files were generated to predict and analyze protein structure 
based on sequence homology with PSI-Blast database. The purpose of this 3-D 
modelled protein analysis was merely exploratory, but helped to visualize the predicted 
glycosylated sites in the HA RBD sequences and other post-translated modifications 
observed in experimental results. 
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2.5.2.   glycosylation modelling of proteins using Gly-Pro.  
 
Based on the difference between the experimentally observed N-glycosylated 
and N-deglycosylated form of the human and avian RBDs, the software GlyPro 
(Glycosciences) was used in order to create in silico  models of potential N-
glycosylation sites based on the presence of the sequence motif, N-X-S/T/C (X not 
proline). The putative protein glycosylation sites were modeled on the human and avian 
modelled RBD PDB files created with Phyre2 software. The predicted sites and 
carbohydrate superimposition were reflected over the surface of the 3D protein 
structure. 
2.5.3. The use of ProP V1.0 as a tool for protease signal sequence prediction 
 
In order to explain certain experimental results suggesting the presence of an 
internal cleavage site during processing within the Human HA RBD version, the 
predictor software ProP V1.0 (77) was employed.  Protease cleavage (PC) scores 
above the default predictor threshold values were only taken into account to suggest 
internal endopeptidase cleavage sites within the Avian and Human HA RBD versions. 
Using the same software, a series of hypothetical single residues modifications were 
performed manually and retrieved for software analysis to evaluate the best 
mutagenesis substitution that was able to abolish the cleavage signal predictor score to 
suggest  mutagenesis modifications of the multimeric RBD gene.  
  
47 
 
3.0 RESULTS 
3.1. Antigen design 
3.1.1. Antigen selection of human HA RBD Subunits for the HA-RBD multimeric 
versions. 
 
Three HA RBD subtypes comprising the 2013-2014 vaccine composition (1) 
were selected from full Hemagglutinins (HA0) sequences directly retrieved from 
GeneBank (Figure 7) and analysed using Clustal W/UCSD Chimera. Published Human 
globular RBD1 (GenBank: ACQ99608.1) from A/California/7/2009 (H1N1)pdm09-like 
(GenBank: YP_009118626.1), was used as a backbone sequence for the polypeptide 
selection of the RBD2 (A/Texas/50/2012(H3N2) (GenBank: AIE52525.1) ( (Figure 9) 
and RBD3 (B/Brisbane/33/2008) (GenBank: ACN29387.1) (Figure 11) subunits. As a 
consensus, the RBD subunits avoided a basic patch region found in the HA1 domain 
and the fusion peptide-transmembrane helix sequences that form part of the 
Hemagglutin HA2 domain, as previously reported for RBD1 (2,3) (Table 4). The 
sequences subunits selected were analyzed individually in Phyre2 server. All 
sequences predicted the lectin globular structural domain for RBD1, RBD2 and RBD3 
and their modelled structures superimposed correctly to extant HA’s X-Ray diffraction 
data for A/California/7/2009 (H1N1) pdm09-like (PDB 4M4Y) (Figure 8), to 
A/Victoria/361/2011 (H3N2) (PDB 4WE9) (Figure 10) and (B/Brisbane/33/2008) 
(Influenza B) (PBD 4FQK) (Figure 12), respectively.  
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Antigen selection for Human HA-RBD Subunit 1  
Hemagglutinin Influenza A virus (A/California/07/2009(H1N1) 
ORIGIN       
        1 mkailvvlly tfatanadtl cigyhannst dtvdtvlekn vtvthsvnll edkhngklck 
       61 lrgvaplhlg kcniagwilg npeceslsta sswsyivetp ssdngtcypg dfidyeelre 
      121 qlssvssfer feifpktssw pnhdsnkgvt aacphagaks fyknliwlvk kgnsypklsk 
      181 syindkgkev lvlwgihhps tsadqqslyq nadayvfvgs srysktfkpe iairpkvrdr 
      241 egrmnyywtl vepgdkitfe atgnlvvpry afamernags giiisdtpvh dcnttcqtpk 
      301 gaintslpfq nihpitigkc pkyvkstklr latglrnips iqsrglfgai agfieggwtg 
      361 mvdgwygyhh qneqgsgyaa dlkstqnaid eitnkvnsvi ekmntqftav gkefnhlekr 
      421 ienlnkkvdd gfldiwtyna ellvllener tldyhdsnvk nlyekvrsql knnakeigng 
      481 cfefyhkcdn tcmesvkngt ydypkyseea klnreeidgv klestriyqi laiystvass 
      541 lvlvvslgai sfwmcsngsl qcrici 
// 
 
 
 
 
Figure 7. Diagram alignment showing the HA-RBD1 residues selected from the 
Influenza Hemagglutinin A/California/7/2009 (H1N1) pdm09-like virus. Virus 
selection was based on the recommendation by WHO for the 2013-2014 trivalent 
influenza vaccine composition (1).  The RBD1 region (in bold letters and as Human 
RBD1 in diagram) is part of HA1 domain but lacks its charged patch region and 
additionally excludes the fusion peptide and transmembrane domain and all the 
residues of the HA2 stem region (4). 
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Modelling and Structure comparison for Human HA-RBD Subunit1 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Structural model of the Human HA RBD subunit 1. The PDB file of the 
globular head comprising the human HA RBD Subunit 1(green) was generated by the 
Phyre2 server (5) and superimposed over the determined crystal structure map of the 
Hemagglutinin HA1 (in cyan) for the virus A/California/07/2009 (H1N1) pandemic virus 
(PDB file 4M4Y) for comparison and illustration of the region selected for antigen 
expression in the present study (black box). The arrow indicates the receptor binding 
site for the HA1 molecule. The graphs were generated using Chimera UCSF software, 
and the crystal structure PDB file retrieved from the RCSB Protein Data Bank website.   
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Antigen selection for Human HA-RBD Subunit 2 
Influenza A virus (A/Texas/50/2012(H3N2)) 
ORIGIN       
        1 mktiialsyi lclvfaqklp gndnstatlc lghhavpngt ivktitndri evtnatelvq 
       61 nssigeicds phqildgenc tlidallgdp qcdgfqnkkw dlfverskay sncypydvpd 
      121 yaslrslvas sgtlefnnes fnwngvtqng tssacirrsn nsffsrlnwl thlnfkypal 
      181 nvtmpnneqf dklyiwgvhh pgtdkdqifl yaqpsgritv stkrsqqavi pnigsrprir 
      241 nipsrisiyw tivkpgdill instgnliap rgyfkirsgk ssimrsdapi gkcksecitp 
      301 ngsipndkpf qnvnrityga cpryvkqstl klatgmrnvp ekqtrgifga iagfiengwe 
      361 gmvdgwygfr hqnsegrgqa adlkstqaai dqingklnrl igktnekfhq iekefseveg 
      421 riqdlekyve dtkidlwsyn aellvalenq htidltdsem nklfektkkq lrenaedmgn 
      481 gcfkiyhkcd nacigsirng tydhdvyrde alnnrfqikg velksgykdw ilwisfaisc 
      541 fllcvallgf imwacqkgni rcnici 
// 
 
Figure 9. Sequence alignment showing the HA-RBDs residues selected from the 
Influenza Hemagglutinin of Influenza A virus (A/Texas/50/2012(H3N2)). Virus 
selection was based on the recommendation by WHO for the 2013-2014 trivalent 
influenza vaccine composition (1).  The RBD2 region (in bold letters and as Human 
RBD2 in diagram) is part of the HA1 globular region and excludes the fusion peptide 
and transmembrane domain and all the residues of the HA2 stem region (6). 
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Modelling and Structure comparison for Human HA-RBD Subunit 2 
 
 
 
 
 
 
 
 
 
 
Figure 10. Structural model of the Human HA RBD subunit 2. The PDB file of the 
globular head comprising the human HA RBD Subunit 2 (red) was generated by the 
Phyre2 server (5) and superimposed over the determined crystal structure map of the 
Hemagglutinin HA3 (in cyan) of the virus A/Victoria/361/2011 (PDB file 4WE9) for 
comparison and illustration of the region selected for antigen expression in the present 
study (black box). The graphs were generated using Chimera UCSF software, and the 
crystal structure PDB file was retrieved from the RCSB Protein Data Bank website.   
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Antigen selection for Human HA-RBD Subunit 3 
Influenza B virus (B/Brisbane/33/2008) 
ORIGIN       
        1 mkaiivilmv vtsnadrict gitssnsphv vktatqgevn vtgviplttt ptkshfanlk 
       61 gtetrgklcp kclnctdldv algrpkctgk ipsarvsilh evrpvtsgcf pimhdrtkir 
      121 qlpnllrgye hirlsthnvi naenapggpy kigtsgscpn itngngffat mawavpkndk 
      181 nktatnplti evpyictege dqitvwgfhs dsetqmakly gdskpqkfts sangvtthyv 
      241 sqiggfpnqt edgglpqsgr ivvdymvqks gktgtityqr gillpqkvwc asgrskvikg 
      301 slpligeadc lhekygglnk skpyytgeha kaigncpiwv ktplklangt kyrppakllk 
      361 ergffgaiag fleggwegmi agwhgytshg ahgvavaadl kstqeainki tknlnslsel 
      421 evknlqrlsg amdelhneil eldekvddlr adtissqiel avllsnegii nsedehllal 
      481 erklkkmlgp saveigngcf etkhkcnqtc ldriaagtfd agefslptfd slnitaasln 
      541 ddgldnhtil lyystaassl avtlmiaifv vymvsrdnvs csicl 
// 
 
Figure 11. Sequence alignment showing the HA-RBD selected from the Influenza 
Hemagglutinin of Influenza B virus (B/Brisbane/33/2008). Virus selection was based 
on the recommendation by WHO for the 2013-2014 trivalent influenza vaccine 
composition (1).  RBD region (in bold letters and as Human RBD3 in diagram) is part of 
the HA2 globular region and excludes the fusion peptide and transmembrane domain 
and all the residues of the HA2 stem region (7). 
  
53 
 
 
Modelling and Structure comparison for Human HA-RBD Subunit 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Structural model of the Human Influenza B, HA-RBD subunit 3. The 
PDB file of the globular head comprising the human HA-RBD Subunit 3 (orange) was 
generated by the Phyre2 server (5) and superimposed over the determined crystal 
structure map of the Influenza B Hemagglutinin (in cyan) of the virus 
B/Brisbane/60/2008  (PDB file 4FQK) for comparison and illustration of the region 
selected for antigen expression in the present study (black box)(8). The graphs were 
generated using Chimera UCSF software, and the crystal structure PDB file was 
retrieved from the RCSB Protein Data Bank website.   
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Table 4. Protein Sequence alignment for the Human HA’s RBD Subunits used to 
construct the Human multimeric gene versions. Using the previously reported  
RBD1 (A/California/07/2009(H1N1) sequence (2,3) as a template, RBD2 
(A/Texas/50/2012(H3N2), RBD3 (B/Brisbane/33/2008), were aligned for comparison to 
IV A/California/07/2009(H1N1) Hemagglutinin used as a template to determine the 
border sequences of the lectin domain and was based on the conserved residues share 
among all the sequences used as a backbone scaffold guidance, their predicted 
globular folding generated by Phyre2 server presented in Figures 8,10,12. (*), asterisk 
indicated fully conserved residue; (:), semicolon indicates conservation among groups 
of residues with strongly similar properties; (.), period indicates residues conservation 
among weakly similar properties; (highlighted in grey), sequence corresponding to the 
fusion peptide present in HA2 domain; (residues in closed boxes), represent a charged 
patch region in the HA1 domain formed when HA1-HA2 folds natively, it was excluded 
from the final sequence. The alignment was generated using ClustalW program from 
the Chimera UCSF software. 
 
 
 
  
  
CLUSTAL W ALN saved from UCSF Chimera/MultAlignViewer 
 
HA_[A/California/07/2009(H1N1]      MKAILVV---LLY------TFATANADTLCIGYHANNSTDTVDTVLEKNV 41 
HA_[A/Texas/50/2012(H3N2]           MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDRI 50 
HA_[B/Brisbane/33/2008]             MKAIIVILM-----------VVTSNADRICTGITSSNSPHVVKTATQGEV 39 
                                    **:*:.:                 .:  :* *  :  .   *.*  : .: 
 
HA_[A/California/07/2009(H1N1]      TVTHSVNLLEDKHNGKLCKLRG-----VAPLHLGKCNIAGWILGNPECES 86 
HA_[A/Texas/50/2012(H3N2]           EVTNATELVQNSSIGEICDSPH------QILDGENCTLIDALLGDPQCDG 94 
HA_[B/Brisbane/33/2008]             NVTGVIPLTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTG 89 
                                     **    *      ..:..            .  :*.  .  ** *:* . 
 
HA_[A/California/07/2009(H1N1]      LSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIF-- 134 
HA_[A/Texas/50/2012(H3N2]           FQN-KKWDLFVER-SKAYSNCYPYDVPDYASLRSLVASSGTL---EFN-- 137 
HA_[B/Brisbane/33/2008]             KIPSARVSILHEV-RPVTSGCFPIMH-DRTKIRQLPNLLRGYEHIRLSTH 137 
                                           . : *      . *:*    *  .:*.           .:    
 
HA_[A/California/07/2009(H1N1]      --PKTSSWPNHDSNKGVTAACPHAG-AKSFYKNLIWLVKKGNSYPK---- 177 
HA_[A/Texas/50/2012(H3N2]           --NESFNWNG-VTQNGTSSACIRRS-NNSFFSRLNWLTHLNFKYPA---- 179 
HA_[B/Brisbane/33/2008]             NVINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTATNP 187 
                                       :: .  .   : *.:.:* .    :.*:  : * .  . .        
 
HA_[A/California/07/2009(H1N1]      --LSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGS-SRYS 224 
HA_[A/Texas/50/2012(H3N2]           --LNVTMPNNEQFDKLYIWGVHHPVTDKDQIFLYAQPSGRITVST-KRSQ 226 
HA_[B/Brisbane/33/2008]             LTIEVPYICTEGEDQITVWGFHSDSETQM-AKLYGDSKPQKFTSSANGVT 236 
                                      :. .    :  : : :**.*          ** :..    ..: .    
 
HA_[A/California/07/2009(H1N1]      KKFKPEIAIRPKVR-----DQEGRMNYYWTLVEPGDKITFEATGNLVVPR 269 
HA_[A/Texas/50/2012(H3N2]           QAVIPNIGFRPRIR-----NIPSRISIYWTIVKPGDILLINSTGNLIAPR 271 
HA_[B/Brisbane/33/2008]             THYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQ 286 
                                        .:*.  *.          .*:   : : :.*.   :    .:: *: 
 
HA_[A/California/07/2009(H1N1]      YAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPF-QNIHPITIG 318 
HA_[A/Texas/50/2012(H3N2]           GYFKIR-SGKSSIMRSDAPIGKCKSECITPNGSIPNDKPF-QNVNRITYG 319 
HA_[B/Brisbane/33/2008]             KVWCA--SGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIG 334 
                                      :    .. * :: .. *:           *.: .. *:  . :  : * 
 
HA_[A/California/07/2009(H1N1]      KCPKYVKSTKLRLATGLRNIPS---IQSRGLFGAIAGFIEGGWTGMVDGW 365 
HA_[A/Texas/50/2012(H3N2]           ACPRYVKQSTLKLATGMRNVPE---KQTRGIFGAIAGFIENGWEGMVDGW 366 
HA_[B/Brisbane/33/2008]             NCPIWVKT-PLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGW 383 
                                     ** :**   *:**.* :  *     : **:*******:*.** **: ** 
 
HA_[A/California/07/2009(H1N1]      YGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFN 415 
HA_[A/Texas/50/2012(H3N2]           YGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQIEKEFS 416 
HA_[B/Brisbane/33/2008]             HGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGAMD 433 
                                    :*:  :. .* . ******** **::*. ::* :      ::  :   :. 
 
HA_[A/California/07/2009(H1N1]      HLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEK 465 
HA_[A/Texas/50/2012(H3N2]           EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEK 466 
HA_[B/Brisbane/33/2008]             ELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLLALERK 483 
                                    .:. .* :*:: *:*   *  : : ** * *.*:  ::  *..:  * .* 
 
HA_[A/California/07/2009(H1N1]      VRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNRE 515 
HA_[A/Texas/50/2012(H3N2]           TKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDEALNNRF 516 
HA_[B/Brisbane/33/2008]             LKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPTFDS-L 532 
                                     :. *  .* ::*****:  ***:::*:  :  **:*   :   :  .   
 
HA_[A/California/07/2009(H1N1]      EIDGVKLE--STRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCR 563 
HA_[A/Texas/50/2012(H3N2]           QIKGVELK--SGYKDWILWIS-FAISCFLLCVALLGFIMWACQKGNIRCN 563 
HA_[B/Brisbane/33/2008]             NITAASLNDDGLDNHTILLYYSTAASSLAVTLMIAIFVVYMVSRDNVSCS 582 
                                    :* ...*:  .     **     . *.: : : :  : .:  ....: *  
 
HA_[A/California/07/2009(H1N1]      ICI 566 
HA_[A/Texas/50/2012(H3N2]           ICI 566 
HA_[B/Brisbane/33/2008]             ICL 585 
                                    **: 
 
 
 
 
56 
 
3.1.2. Antigen selection of Avian HA-RBD subunits for the HA-RBD multimeric versions 
 
Three Avian Hemagglutinin polypeptide sequences, identified from RT-PCR 
sequencing of the HA1 domain from Avian virus were circulating among Chicken Farms 
from México, were provided by the vaccine company Investigación Aplicada S.A. The 
residues of three Avian HA RBD subtypes were trimmed using as a template the 
published Human globular RBD1 (GenBank: ACQ99608.1) from A/California/7/2009 
(H1N1) pdm09-like (GenBank: YP_009118626.1 (Figure 7) and analysed using Clustal 
W/UCSD Chimera. All NCBI Blast results for the RBD sequences confirmed its Avian 
origin, best- scored sequences identifies both RBD1 (Table 4) and RBD2 (Table 6) as 
high homologue to A/chicken/Hidalgo/1336-06/2006(H5N2) (GenBank: AIN25320.1); 
and best-scored sequence identifies RBD3 (Table 8) as (A/Turkey/Ontario/18/2000(H7-
like) (GenBank: AF497552_1). As a consensus, the parameters for RBD subunits 
selection was based on the closest first and last conserved residues the Avian HA1 
sequences shared with the backbone sequence of Human globular RBD1 peptide (2,3) 
(Table 11) used as scaffold. The selected sequences subunits were analyzed 
individually in Phyre2 server. All sequences predicted the lectin globular structural 
domain for RBD1 (Figure 13), RBD2 (Figure 15) and RBD3 (Figure 17). The modelled 
structures superimposed to extant HA’s X-Ray diffraction data in 
A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 5E2Y) (Figure 13-14, Table 5), in 
A/Victoria/361/2011 (H3N2) (PDB 5E2Y)(Figure 15-16, Table 7) and in A/Anhui/1/2013 
(PDB file 4R8W) (H7-like)  (Figure 17-18, Table 9), respectively.  
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Table 5.  Antigen selection for Avian HA-RBD Subunit 1 (H5-like) Sequence 
BLAST for Avian HA-RBD Subunit 1. The HA RBD Subunit 1 sequence was derived 
from a field virus isolation from chicken farms located in Mexico. The sequences 
provided by IASA Company, were used in Blast searches of the NCBI database to 
compare and identify the origin of the Hemagglutinin RBD gene product used in this 
study. The HA-RBD subunit 1 has a high protein homology to the H5-like hemaglutinin 
protein. The best score was obtained for the Influenza A virus (A/chicken/Hidalgo/1336-
06/2006(H5N2) virus isolate present in the NCBI database. 
Hemaglutinin [Influenza A virus (A/chicken/Hidalgo/1336-06/2006(H5N2)) 
Sequence ID: gi|682021806|gb|AIN25320.1|Length: 564Number of Matches: 1 
Score Expect Method Identities Positives Gaps 
441 bits(1134) 1e-151 
Compositional  
matrix adjust. 
209/224(93%) 215/224(95%) 2/224(0%) 
Query  1    SVKG--GFILKDCSVAGWLLGNPMCDEFLTAPEWSYIVEKDNPSNDLCYPGNFDNYEELK  58 
            S+KG    ILKDCSVAGWLLGNPMCDEFL+ PEWSYIVEKDNPSNDLCYPGNFDNYEELK 
Sbjct  59   SLKGIKPLILKDCSVAGWLLGNPMCDEFLSVPEWSYIVEKDNPSNDLCYPGNFDNYEELK  118 
 
Query  59   HLMSSTNHMERIQIFPRNSWTNHNASAGVSSACPFNGGSSFFRNVVWLIKKNDVYRTLKR  118 
            HLMSSTNH+ERIQIFPRNSW++HNAS+GVSSACPFNG SSFFRNVVWLIKKNDVYRTLKR 
Sbjct  119  HLMSSTNHLERIQIFPRNSWSSHNASSGVSSACPFNGRSSFFRNVVWLIKKNDVYRTLKR  178 
 
Query  119  NYTNTNVEDLLIIWGVHHPNDATEQTKLYQNLNTYVSVGTSTLNQRSTPTIATRPQVNGQ  178 
            NYTNTNVEDLLIIWGVHHPNDATEQTKLYQNLNTYVSVGTSTLNQRS PTIATRPQVNGQ 
Sbjct  179  NYTNTNVEDLLIIWGVHHPNDATEQTKLYQNLNTYVSVGTSTLNQRSIPTIATRPQVNGQ  238 
 
Query  179  RGRMEFFWTILKSNDSIFFESTGNFIAPEYAYKIVKKGKSTVMK  222 
            RGRMEFFWTILKSNDSIFFESTGNFIAPEYAYKIVKKG S VMK 
Sbjct  239  RGRMEFFWTILKSNDSIFFESTGNFIAPEYAYKIVKKGNSAVMK  282 
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Modelling and Structure comparison for Avian HA-RBD Subunit 1 
 
Figure 13. Structural model of the Avian HA RBD subunit 1. The PDB file of globular 
head comprising the Avian HA-RBD subunit 1 (in olive green) was generated by the 
Phyre2 server (5) and superimposed over the determined crystal structure map of the 
Hemagglutinin HA5 (in cyan) of the virus A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 
5E2Y) for comparison and illustration of the region selected for antigen expression in 
the present study (black box). The arrow indicates the N- acetyl-D-glucosamine 
molecule, interacting with one of the receptor binding sites on the HA5 molecule. The 
graphs were generated using Chimera UCSF software, and the crystal structure PDB 
file was retrieved from the RCSB Protein Data Bank website.   
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Figure 14. Structural model of the Avian HA RBD subunit 1. The PDB file of the 
molecule generated for the Avian HA RBD Subunit 1 (in olive) was superimposed over 
the crystal structure determined map of the Hemagglutinin HA5 (in cyan) of the virus 
A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 5E2Y) for comparison and illustration of 
the region selected for antigen expression in the present study (9). In A, the Avian 
RBD1 was superimposed on the whole HA monomeric molecule; B, the Avian RBD1 
superimposed over one monomer of the hemotrimeric HA5 form; C, Upper view of C. 
Arrows indicated the N-Acetyl-D-glucosamine molecule, interacting with the receptor 
binding site of HA5 molecule. The PDB structure file of the Avian HA RBD subunit 1 
was generated using the Phyre2 server, analysis and superposition of graphs generated 
using Chimera UCSF software. The crystal structure PDB file was retrieved from the 
RCSB Protein Data Bank website.   
A B C 
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Table 6. Protein Sequence alignment of the Avian HA RBD Subunit 1 compared to the X-Ray diffraction data for 
HA1 domain of A/duck/Egypt/10185SS/2010 (H5N1) virus. (*) asterisk indicated fully conserved residue; (:), semicolon, 
conservation among groups of residues with strongly similar propiertes; (.), period indicates conservation residues 
conservation among weakly similar propierties.   The aligment was generated using ClustalW program from the Chimera 
UCSF software.   
CLUSTAL W ALN saved from UCSF Chimera/MultAlignViewer 
 
5e2y,_chain_A/7-339                ADPGDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCNLDG 50 
Avian_RBD1_complete.pdb/5-224      .................................................. 
                                                                                      
 
5e2y,_chain_A/7-339                VKPLILRDCSVAGWLLGNPMCDEFLNVPEWSYIVEKINPANDLCYPGNFN 100 
Avian_RBD1_complete.pdb/5-224      KGGFILKDCSVAGWLLGNPMCDEFLTAPEWSYIVEKDNPSNDLCYPGNFD 50 
                                      :**:******************..********* **:*********: 
 
5e2y,_chain_A/7-339                DYEELKHLLSRINHFEKIQITPKNSWSDHEAS.GVSSACPYQGRSSFFRN 149 
Avian_RBD1_complete.pdb/5-224      NYEELKHLMSSTNHMERIQIFPRNSWTNHNASAGVSSACPFNGGSSFFRN 100 
                                   :*******:*  **:*:*** *:***::*:** *******::* ****** 
 
5e2y,_chain_A/7-339                VVWLTKKDNAYPTIKRSYNNTNQEDLLVLWGIHHPNDATEQTRLYQNPTT 199 
Avian_RBD1_complete.pdb/5-224      VVWLIKKNDVYRTLKRNYTNTNVEDLLIIWGVHHPNDATEQTKLYQNLNT 150 
                                   **** **::.* *:**.*.*** ****::**:**********:**** .* 
 
5e2y,_chain_A/7-339                YISVGTSTLNQKLVPKIATRSKVKGLSGRMEFFWTILKSNDAINFESNGN 249 
Avian_RBD1_complete.pdb/5-224      YVSVGTSTLNQRSTPTIATRPQVNGQRGRMEFFWTILKSNDSIFFESTGN 200 
                                   *:*********: .*.****.:*:*  **************:* ***.** 
 
5e2y,_chain_A/7-339                FIAPENAYKIVKKGDSTIMKSELEYGDCNTKCQTPIGAINSSMPFHNIHP 299 
Avian_RBD1_complete.pdb/5-224      FIAPEYAYKIVKKGKSTVMK.............................. 220 
                                   ***** ********.**:**                               
 
5e2y,_chain_A/7-339                LTIGECPKYVKSNRLVLATGLRNSPQGERRRKKR 333 
Avian_RBD1_complete.pdb/5-224      .................................. 
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Table 7. The HA-RBD Subunit 2 Sequence was derived from a field virus isolation 
from chicken farms located in Mexico. The sequences provided by IASA company 
were used in Blast searches of the NCBI database to compare and identify the origin of 
the Hemagglutinin RBD gene product used in this study. The HA RBD subunit 2 has a 
high protein homology to the H5-like hemaglutinin protein. The best score was obtained 
for the Influenza A virus -A/chicken/Hidalgo/1336-06/2006(H5N2)- isolate present in the 
database. 
 
Hemaglutinin [Influenza A virus (A/chicken/Hidalgo/1336-06/2006(H5N2))] 
Sequence ID: gi|682021806|gb|AIN25320.1|Length: 564 Number of Matches: 1 
Score Expect Method Identities Positives Gaps 
437 bits(1123) 5e-150 
Compositional  
matrix adjust. 
205/218(94%) 212/218(97%) 0/218(0%) 
Query  1    PLILKDCSVAGWLLGNPMCDEFLNVQEWSYIVEKDNPSNDLCYPGNFDNYEELKHLMSST  60 
            PLILKDCSVAGWLLGNPMCDEFL+V EWSYIVEKDNPSNDLCYPGNFDNYEELKHLMSST 
Sbjct  65   PLILKDCSVAGWLLGNPMCDEFLSVPEWSYIVEKDNPSNDLCYPGNFDNYEELKHLMSST  124 
 
Query  61   NHLERIQIFPRNSWPNHDSSSGVSSACPFNGESSFFRNVVWLIKKNDVYRTLKRNYTNTN  120 
            NHLERIQIFPRNSW +H++SSGVSSACPFNG SSFFRNVVWLIKKNDVYRTLKRNYTNTN 
Sbjct  125  NHLERIQIFPRNSWSSHNASSGVSSACPFNGRSSFFRNVVWLIKKNDVYRTLKRNYTNTN  184 
 
Query  121  VEDLLIIWGVHHPNDATVQTKLYQNLNTYVSVGTSTLNQRSIPTIATRPQVNGQRGRVEF  180 
            VEDLLIIWGVHHPNDAT QTKLYQNLNTYVSVGTSTLNQRSIPTIATRPQVNGQRGR+EF 
Sbjct  185  VEDLLIIWGVHHPNDATEQTKLYQNLNTYVSVGTSTLNQRSIPTIATRPQVNGQRGRMEF  244 
 
Query  181  FWTILESNDSIFFESTGNFIAPEYAYKVTKKGKSAVMK  218 
            FWTIL+SNDSIFFESTGNFIAPEYAYK+ KKG SAVMK 
Sbjct  245  FWTILKSNDSIFFESTGNFIAPEYAYKIVKKGNSAVMK  282 
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Modelling and Structure comparison for Avian HA-RBD Subunit 2 
 
Figure 15. Structural model of the Avian HA-RBD subunit 2. The PDB file of the 
globular head  comprising the Avian HA-RBD subunit 2 (in blue) and generated by the 
Phyre2 server (5), was superimposed over the determined crystal structure map of the 
Hemagglutinin HA5 (in cyan) of the virus A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 
5E2Y) for comparison and illustration of the region selected for antigen expression in 
the present study (black box) (9). Arrow indicates the N-acetyl-D-glucosamine molecule, 
interacting with one of the receptor binding sites on the HA5 molecule. The graphs were 
generated using Chimera UCSF software, crystal structure PDB file retrieved from the 
RCSB Protein Data Bank website.   
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Figure 16. Structural model of the Avian HA RBD subunit 2. The generated PDB file 
of the Avian HA RBD Subunit 2 molecule (in blue) was superimposed over the crystal 
structure-determined map of the Hemagglutinin HA5 (in cyan) of the virus 
A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 5E2Y) for comparison and illustration of 
the region selected for antigen expression in the present study. In A, Avian RBD2 
superimposed on whole HA H5 monomeric molecule; B, Avian RBD2 superimposed 
over one monomer of the hemotrimeric HA H5 form; C, Upper view of C. Arrows 
indicated the NAG (N- acetyl-D-glucosamine) molecule, interacting with the receptor 
binding site of HA H5 molecule. PDB of the Avian HA RBD subunit 2 was generated by 
Phyre2 server, analysis and superposition graphs was generated using Chimera UCSF 
software, crystal structure PDB file was retrieved from the RCSB Protein Data Bank 
website.   
A B C 
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Table 8. Protein Sequence alignment of the Avian HA-RBD Subunit 2 compared to the X-Ray diffraction HA1 
domain of A/duck/Egypt/10185SS/2010 (H5N1) (PDB 5e2y) virus. (*) asterisk indicated fully conserved residue; (:), 
semicolon, conservation among groups of residues with strongly similar propiertes; (.), period indicates conservation 
residues conservation among weakly similar propierties.  The aligment was generated using ClustalW program from the 
Chimera UCSF software. 
 
 
 
CLUSTAL W ALN saved from UCSF Chimera/MultAlignViewer 
 
5e2y,_chain_A/7-339                ADPGDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCNLDG 50 
Avian_RBD2_complete.pdb/1-218      .................................................. 
                                                                                      
 
5e2y,_chain_A/7-339                VKPLILRDCSVAGWLLGNPMCDEFLNVPEWSYIVEKINPANDLCYPGNFN 100 
Avian_RBD2_complete.pdb/1-218      ..PLILKDCSVAGWLLGNPMCDEFLNVQEWSYIVEKDNPSNDLCYPGNFD 48 
                                     ****:******************** ******** **:*********: 
 
5e2y,_chain_A/7-339                DYEELKHLLSRINHFEKIQITPKNSWSDHEAS.GVSSACPYQGRSSFFRN 149 
Avian_RBD2_complete.pdb/1-218      NYEELKHLMSSTNHLERIQIFPRNSWPNHDSSSGVSSACPFNGESSFFRN 98 
                                   :*******:*  **:*:*** *:***.:*::* *******::*.****** 
 
5e2y,_chain_A/7-339                VVWLTKKDNAYPTIKRSYNNTNQEDLLVLWGIHHPNDATEQTRLYQNPTT 199 
Avian_RBD2_complete.pdb/1-218      VVWLIKKNDVYRTLKRNYTNTNVEDLLIIWGVHHPNDATVQTKLYQNLNT 148 
                                   **** **::.* *:**.*.*** ****::**:******* **:**** .* 
 
5e2y,_chain_A/7-339                YISVGTSTLNQKLVPKIATRSKVKGLSGRMEFFWTILKSNDAINFESNGN 249 
Avian_RBD2_complete.pdb/1-218      YVSVGTSTLNQRSIPTIATRPQVNGQRGRVEFFWTILESNDSIFFESTGN 198 
                                   *:*********: :*.****.:*:*  **:*******:***:* ***.** 
 
5e2y,_chain_A/7-339                FIAPENAYKIVKKGDSTIMKSELEYGDCNTKCQTPIGAINSSMPFHNIHP 299 
Avian_RBD2_complete.pdb/1-218      FIAPEYAYKVTKKGKSAVMK.............................. 218 
                                   ***** ***:.***.*::**                               
 
5e2y,_chain_A/7-339                LTIGECPKYVKSNRLVLATGLRNSPQGERRRKKR 333 
Avian_RBD2_complete.pdb/1-218      ..................................      
 
.                                        
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Table 9. The Avian HA-RBD Subunit 3 Sequence was derived from field virus 
isolates obtained from chicken farms located in Mexico. The sequences provided 
by IASA company were used in Blast searches of the NCBI database to compare and 
identify the origin of the Hemagglutinin RBD gene product used in this study (Query 1). 
HA-RBD subunit 3 has a high protein homology to H7-like hemaglutinin protein (Sbjct) 
in the present case, the best score was obtained for the Influenza A virus 
(A/Turkey/Ontario/18/2000(H7) virus isolate.  
Hemagglutinin, partial [Influenza A virus (A/Turkey/Ontario/18/2000(H7))] 
Sequence ID: gi|20335019|gb|AAM19229.1|AF497552_1Length: 337Number of Matches: 1 
Score Expect Method Identities Positives Gaps 
424 bits(1091) 2e-148 
Compositional 
matrix adjust. 
202/213(95%) 206/213(96%) 0/213(0%) 
Query  1    PTDLGQCGLLGTLIGPPQCDQFLKFDADLIIERREGTDVCYPGKFTNEESLRQILRRSGG  60 
            PTDLGQCGLLGTLIGPPQCDQFL+FDADLIIERREGTDVCYPGKFTNEESLRQILR SGG 
Sbjct  53   PTDLGQCGLLGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFTNEESLRQILRGSGG  112 
 
Query  61   IDKESMGFTYSGIRTNGTTSACRRSNPSFYAEMKWLLSNSDNATFPQMTKSYRNPRNKPA  120 
            IDKESMGFTYSGIRTNG TSACRRS  SFYAEMKWLLSNSDNA FPQMTKSYRNPRNKPA 
Sbjct  113  IDKESMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA  172 
 
Query  121  LITWGVHHSGSATEQTKLYGSGDKLITVGSSKYLQSFTPSPGARPQVNGQSGRIDFHWLL  180 
            LI WGVHHSGSATEQTKLYGSG+KLITVGSSKY QSFTPSPGARPQVNGQSGRIDFHWLL 
Sbjct  173  LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLL  232 
 
Query  181  LDPNDTVTFTFNGAFIAPDRASFFRGESIGIQS  213 
            LDPNDTVTFTFNGAFIAPDRASFFRGES+G+QS 
Sbjct  233  LDPNDTVTFTFNGAFIAPDRASFFRGESLGVQS  265 
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Modelling and Structure comparison for Avian HA-RBD Subunit 3 
 
Figure 17. Structural model of the Avian HA-RBD subunit 3. The PDB file of 
globular head  comprising the Avian HA-RBD Subunit 3 (in green) and generated by the 
Phyre2 server  (5), superimposed over the determined crystal structure map of the 
Hemagglutinin H7 (in cyan, ) of the virus A/Anhui/1/2013 (PDB file 4R8W) (10) for 
comparison and illustration of the region selected for antigen expression in the present 
study (black box). Arrow indicates the NAG (N-acetyl-D-glucosamine) molecule, 
interacting with one receptor binding site of HA5 molecule. The graphs were generated 
using Chimera UCSF software, crystal structure PDB file retrieved from the RCSB 
Protein Data Bank website.   
  
67 
 
 
 
Figure 18. Structural model of the Avian HA-RBD subunit 3. The generated PDB file 
of the molecule Avian HA-RBD Subunit 3 (in blue) superimposed over the crystal 
structure determined map of the Hemagglutinin H7 (in cyan) of the virus A/Anhui/1/2013 
(PDB file 4R8W) (10) for comparison and illustration of the region selected for antigen 
expression in the present study. In A, Avian RBD2 superimposed on whole HA H5 
monomeric molecule; B, Avian RBD2 superimposed over one monomer of the 
hemotrimeric HA H5 form; C, Upper view of C. Arrows indicates the NAG (N- acetyl-D-
glucosamine) molecule, interacting with the receptor binding site of HA H5 molecule. 
PDB of the Avian HA RBD subunit 2 was generated by Phyre2 server  (5) , analysis and 
superposition graphs was generated using Chimera UCSF software, crystal structure 
PDB file was retrieved from the RCSB Protein Data Bank website.   
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Table 10. Protein Sequence alignment of the Avian HA-RBD Subunit 3 compared 
to the X-Ray diffraction HA1 domain of H7 Hemagglutinin of A/Anhui/1/2013 virus. 
(*) asterisk indicated fully conserved residue; (:), semicolon, conservation among 
groups of residues with strongly similar propiertes; (.), period indicates conservation 
residues conservation among weakly similar properties.   The alignment was generated 
using ClustalW program from the Chimera UCSF software. 
 
CLUSTAL W ALN saved from UCSF Chimera/MultAlignViewer 
 
4R8W,_chain_A/1-321                DKICLGHHAVSNGTKVNTLTERGVEVVNATETVERTNIPRICSKGKRTVD 50 
Avian_RBD3_complete.pdb/1-213      ...............................................PTD 3 
                                                                                  ..* 
 
4R8W,_chain_A/1-321                LGQCGLLGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQ 100 
Avian_RBD3_complete.pdb/1-213      LGQCGLLGTLIGPPQCDQFLKFDADLIIERREGTDVCYPGKFTNEESLRQ 53 
                                   *********: *********:*.**********:********.***:*** 
 
4R8W,_chain_A/1-321                ILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNTDNA 150 
Avian_RBD3_complete.pdb/1-213      ILRRSGGIDKESMGFTYSGIRTNGTTSACRRSNPSFYAEMKWLLSNSDNA 103 
                                   ***.*******:************:*******..************:*** 
 
4R8W,_chain_A/1-321                AFPQMTKSYKNTRKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNY 200 
Avian_RBD3_complete.pdb/1-213      TFPQMTKSYRNPRNKPALITWGVHHSGSATEQTKLYGSGDKLITVGSSKY 153 
                                   :********:*.*:.****.**:*** *::*********:**:*****:* 
 
4R8W,_chain_A/1-321                QQSFVPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASF 250 
Avian_RBD3_complete.pdb/1-213      LQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASF 203 
                                   ***.*********** *********:*:*******:************* 
 
4R8W,_chain_A/1-321                LRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYV 300 
Avian_RBD3_complete.pdb/1-213      FRGESIGIQS........................................ 213 
                                   :**:*:**** 
 
4R8W,_chain_A/1-321                KQRSLLLATGMKNVPEIPKGR 321 
Avian_RBD3_complete.pdb/1-213      ..................... 
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Table 11. Protein Sequence alignment of the Avian HA-RBD Subunits used to 
construct the Avian multimeric gene versions.  The RBD1, RBD2, RBD3 were 
aligned for comparison to IV A/California/07/2009(H1N1), which was used as a template 
to determine the border sequences that determine the lectin domain and was based on 
the conserved residues (in blue) shared among all the sequences as the backbone 
scaffold; their predicted globular folding were in Figures 13-17. (*) asterisk indicated 
fully conserved residue; (:), semicolon, conservation among groups of residues with 
strongly similar properties; (.), period indicates conservation residues conservation 
among weakly similar properties; (highlighted in grey) sequence corresponding to the 
fusion peptide present in HA2 domain. The alignment was generated using ClustalW 
program from the Chimera UCSF software. 
CLUSTAL W ALN saved from UCSF Chimera/MultAlignViewer 
 
A/California/07/2009(H1N1)      MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLL 50 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
 
A/California/07/2009(H1N1)      EDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETP 100 
Avian_RBD1_(H5-like)            --------------GGFILKDCSVAGWLLGNPMCDEFLTAPEWSYIVEKD 37 
Avian_RBD2_(H5-like)            --------------SPLILKDCSVAGWLLGNPMCDEFLNVQEWSYIVEKD 36 
Avian_RBD3_(H7-like)            --------------SPTDLGQCGLLGTLIGPPQCDQFLKFDA-DLIIER- 34 
                                              .   * .*.: * ::* * *:.: .    . *:*   
 
A/California/07/2009(H1N1)      SSDNGTCYPGDFIDYEELREQLSSVSSFERFEI-FPKTSSWPNHDSNKGV 149 
Avian_RBD1_(H5-like)            NPSNDLCYPGNFDNYEELKHLMSSTNHMERIQI-FPR-NSWTNHNASAGV 85 
Avian_RBD2_(H5-like)            NPSNDLCYPGNFDNYEELKHLMSSTNHLERIQI-FPR-NSWPNHDSSSGV 84 
Avian_RBD3_(H7-like)            REGTDVCYPGKFTNEESLRQILRRSGGIDKESMGFTYSGIRTN-----GT 79 
                                  ... ****.* : *.*:. :   . ::: .: *.  .  .*     *. 
 
A/California/07/2009(H1N1)      TAACPHAGAKSFYKNLIWLVKKGN--SYPKLSKSYINDKGKEVLVLWGIH 197 
Avian_RBD1_(H5-like)            SSACPFNGGSSFFRNVVWLIKKND--VYRTLKRNYTNTNVEDLLIIWGVH 133 
Avian_RBD2_(H5-like)            SSACPFNGESSFFRNVVWLIKKND--VYRTLKRNYTNTNVEDLLIIWGVH 132 
Avian_RBD3_(H7-like)            TSAC-RRSNPSFYAEMKWLLSNSDNATFPQMTKSYRNPRNKPALITWGVH 128 
                                ::**   .  **: :: **:.:.:   :  :.:.* * . :  *: **:* 
 
A/California/07/2009(H1N1)      HPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYY 247 
Avian_RBD1_(H5-like)            HPNDATEQTKLYQNLNTYVSVGTSTLNQRSTPTIATRPQVNGQRGRMEFF 183 
Avian_RBD2_(H5-like)            HPNDATVQTKLYQNLNTYVSVGTSTLNQRSIPTIATRPQVNGQRGRVEFF 182 
Avian_RBD3_(H7-like)            HSGSATEQTKLYGSGDKLITVGSSKYLQSFTPSPGARPQVNGQSGRIDFH 178 
                                *.. :: * .** . :  : **:*   :   *  . **:*..* **:::. 
 
A/California/07/2009(H1N1)      WTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQ 297 
Avian_RBD1_(H5-like)            WTILKSNDSIFFESTGNFIAPEYAYKIVKKGKSTVMKS------------ 220 
Avian_RBD2_(H5-like)            WTILESNDSIFFESTGNFIAPEYAYKVTKKGKSAVMKS------------ 219 
Avian_RBD3_(H7-like)            WLLLDPNDTVTFTFNGAFIAPDRASFF--RGESIGIQS------------ 214 
                                * ::...*.: *  .* ::.*  *  .  .. *  : *              
 
A/California/07/2009(H1N1)      TPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLF 347 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
 
A/California/07/2009(H1N1)      GAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVN 397 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
 
A/California/07/2009(H1N1)      SVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLE 447 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
70 
 
 
A/California/07/2009(H1N1)      NERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVK 497 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
 
A/California/07/2009(H1N1)      NGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSL 547 
Avian_RBD1_(H5-like)            -------------------------------------------------- 
Avian_RBD2_(H5-like)            -------------------------------------------------- 
Avian_RBD3_(H7-like)            -------------------------------------------------- 
                                                                                   
 
 
A/California/07/2009(H1N1)      GAISFWMCSNGSLQCRICI 566 
Avian_RBD1_(H5-like)            ------------------- 
Avian_RBD2_(H5-like)            ------------------- 
Avian_RBD3_(H7-like)            ------------------- 
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3.1.3.  HIV-TAT cell penetrating peptide sequence  
 
 The correct synthesis of the nucleotide sequence coding for the Tat-cell 
penetrating peptide RKKRRQRRR was confirmed in the sequencing results of the Avian 
HA-RBD V3.7 version (Table 12) retrieved by GeneScript Inc. 
3.1.4. 5-mer Immuno-stimulatory peptide sequence  
 
The correct synthesis of the nucleotide sequence coding for the 5-mer immune-
stimulatory peptide KWCEC was confirmed in the sequencing results of the Avian HA-
RBD V3.6 (Table 11) and Avian HA-RBD V3.7 (Table 12) versions retrieved by 
GeneScript Inc.  
  
3.2. Avian RBD designs, synthetic gene sequences 
 
The codon optimized DNA sequence of the HA RBD CV3.4 was cloned into the 
yeast Pinchia pastoris strain X-33. 
Sequencing results confirmed the correct codon-optimized gene synthesis and 
their specific features  for the Avian HA-RBD V3.4 multimeric gene, 2026 nucleotide 
base pairs (Table 10, Table 14); for Avian HA-RBD V3.6 multimeric gene, 2055 
nucleotide base pairs (Table 11, Table 14); for Avian HA-RBD V3.7 multimeric gene, 
2088 nucleotide base pairs (Table 12, Table 14); and finally for the Human HA-RBD 
V3.3 multimeric gene, 2145 nucleotide base pairs (Table 13, Table 14). All gene 
versions were custom cloned in the extracellular vector pPicZalphaA flanked at the 5’ 
site by the restriction sequence XhoI and at the 3’ by the restriction site XbaI for all 
versions.  
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Table 12. The Avian HA-RBD V3.4 sequence  was  synthetized and codon 
optimized for Pichia pastoris expression using the OptiGene software available 
from  GeneScript Inc. Features of the synthetized sequence include:  an XhoI, 5’ 
restriction site; an XbaI, 3’ restriction site; a pSTOP, premature stop codon; an RBD1, 
Receptor binding domain derived from H5; an RBD2, the Receptor binding domain 
derived from H5 an; RBD3, and the Receptor binding domain DNA sequence derived 
from H7 hemagglutinin. Sequence analysis and its theoretical translation to protein were 
performed using the software DNAMAN V9.0 (Lynnon). The list of features was 
obtained through SnapGene software (SnapGene). 
Translation of HA RBD V(3.4)(1-2046) 
Universal code H 
Total amino acid number: 680, MW=75697 
Max ORF starts at AA pos 1(may be DNA pos 1) for 679 AA(2037 bases), 
MW=75610 
                  10        20        30        40        50        60 
1         CTCGAGAAGAGAAGTGTTAAGGGAGGTTTTATTTTGAAAGACTGTTCTGTCGCTGGTTGG 
1          L  E  K  R  S  V  K  G  G  F  I  L  K  D  C  S  V  A  G  W  
 
                  70        80        90       100       110       120 
61        TTGCTTGGAAATCCTATGTGTGATGAGTTTTTGACTGCTCCAGAATGGTCCTACATTGTT 
21         L  L  G  N  P  M  C  D  E  F  L  T  A  P  E  W  S  Y  I  V   
 
                 130       140       150       160       170       180 
121       GAGAAGGATAACCCATCAAATGACTTGTGTTACCCTGGTAACTTCGATAACTACGAAGAG 
41         E  K  D  N  P  S  N  D  L  C  Y  P  G  N  F  D  N  Y  E  E   
 
                 190       200       210       220       230       240 
181       CTTAAGCATTTGATGTCTTCCACCAACCACATGGAAAGAATTCAAATCTTCCCAAGAAAT 
61         L  K  H  L  M  S  S  T  N  H  M  E  R  I  Q  I  F  P  R  N   
 
                 250       260       270       280       290       300 
241       TCCTGGACTAACCATAATGCTTCAGCCGGTGTTTCAAGTGCTTGCCCTTTTAACGGTGGA 
81         S  W  T  N  H  N  A  S  A  G  V  S  S  A  C  P  F  N  G  G   
 
                 310       320       330       340       350       360 
301       TCTTCCTTTTTCAGAAATGTTGTCTGGCTTATTAAGAAAAACGATGTTTACAGAACTTTG 
101        S  S  F  F  R  N  V  V  W  L  I  K  K  N  D  V  Y  R  T  L   
 
                 370       380       390       400       410       420 
361       AAGAGAAACTACACCAACACTAATGTTGAGGATTTGCTTATTATCTGGGGTGTCCATCAC 
121        K  R  N  Y  T  N  T  N  V  E  D  L  L  I  I  W  G  V  H  H   
 
                 430       440       450       460       470       480 
421       CCAAATGACGCTACTGAACAAACAAAGCTTTACCAGAACTTGAACACATACGTTAGTGTC 
141        P  N  D  A  T  E  Q  T  K  L  Y  Q  N  L  N  T  Y  V  S  V   
 
                 490       500       510       520       530       540 
481       GGTACATCTACCTTGAACCAAAGATCAACTCCAACAATTGCCACTAGACCTCAAGTTAAT 
161        G  T  S  T  L  N  Q  R  S  T  P  T  I  A  T  R  P  Q  V  N   
 
                 550       560       570       580       590       600 
541       GGTCAGAGAGGAAGAATGGAATTTTTCTGGACTATCTTGAAGTCCAACGATTCAATCTTT 
181        G  Q  R  G  R  M  E  F  F  W  T  I  L  K  S  N  D  S  I  F   
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                 610       620       630       640       650       660 
601       TTCGAGTCCACTGGTAATTTTATTGCCCCTGAATACGCATACAAGATCGTTAAGAAAGGA 
201        F  E  S  T  G  N  F  I  A  P  E  Y  A  Y  K  I  V  K  K  G   
 
                 670       680       690       700       710       720 
661       AAGTCCACTGTCATGAAATCTGGTGGAGGTGGAAGTGGTGGAGGTGGATCTCCACTTATT 
221        K  S  T  V  M  K  S  G  G  G  G  S  G  G  G  G  S  P  L  I   
 
                 730       740       750       760       770       780 
721       TTGAAGGATTGTTCTGTTGCTGGATGGTTGCTTGGTAATCCTATGTGCGACGAATTCTTG 
241        L  K  D  C  S  V  A  G  W  L  L  G  N  P  M  C  D  E  F  L   
 
                 790       800       810       820       830       840 
781       AACGTTCAAGAGTGGTCTTACATCGTCGAAAAGGATAACCCATCCAACGACTTGTGCTAT 
261        N  V  Q  E  W  S  Y  I  V  E  K  D  N  P  S  N  D  L  C  Y   
 
                 850       860       870       880       890       900 
841       CCAGGAAATTTTGACAATTATGAGGAGCTTAAACATTTGATGTCAAGTACTAACCACTTG 
281        P  G  N  F  D  N  Y  E  E  L  K  H  L  M  S  S  T  N  H  L   
 
                 910       920       930       940       950       960 
901       GAGAGAATTCAGATCTTCCCAAGAAACTCTTGGCCTAATCACGATTCTTCCTCAGGTGTT 
301        E  R  I  Q  I  F  P  R  N  S  W  P  N  H  D  S  S  S  G  V   
 
                 970       980       990      1000      1010      1020 
961       AGTTCTGCTTGTCCTTTTAACGGAGAATCCTCATTTTTCAGAAACGTTGTCTGGTTGATT 
321        S  S  A  C  P  F  N  G  E  S  S  F  F  R  N  V  V  W  L  I   
 
                1030      1040      1050      1060      1070      1080 
1021      AAGAAAAATGACGTCTATAGAACCCTTAAGAGAAACTATACCAACACTAATGTCGAAGAT 
341        K  K  N  D  V  Y  R  T  L  K  R  N  Y  T  N  T  N  V  E  D   
 
                1090      1100      1110      1120      1130      1140 
1081      TTGTTGATCATCTGGGGTGTTCATCACCCTAATGACGCAACCGTCCAAACTAAATTGTAC 
361        L  L  I  I  W  G  V  H  H  P  N  D  A  T  V  Q  T  K  L  Y   
 
                1150      1160      1170      1180      1190      1200 
1141      CAGAACTTGAACACTTACGTTTCCGTCGGTACATCAACCTTGAACCAAAGATCTATTCCA 
381        Q  N  L  N  T  Y  V  S  V  G  T  S  T  L  N  Q  R  S  I  P   
 
                1210      1220      1230      1240      1250      1260 
1201      ACAATCGCTACCAGACCACAGGTCAACGGTCAGAGAGGAAGAGTCGAGTTTTTCTGGACC 
401        T  I  A  T  R  P  Q  V  N  G  Q  R  G  R  V  E  F  F  W  T   
 
                1270      1280      1290      1300      1310      1320 
1261      ATTTTGGAAAGTAACGATTCTATCTTTTTCGAGTCTACTGGTAACTTCATTGCTCCAGAA 
421        I  L  E  S  N  D  S  I  F  F  E  S  T  G  N  F  I  A  P  E   
 
                1330      1340      1350      1360      1370      1380 
1321      TACGCCTATAAGGTTACAAAGAAAGGAAAGTCCGCTGTCATGAAGTCTGGAGGTGGAGGT 
441        Y  A  Y  K  V  T  K  K  G  K  S  A  V  M  K  S  G  G  G  G   
 
                1390      1400      1410      1420      1430      1440 
1381      TCTGGAGGAGGTGGATCTCCTACCGATCTTGGTCAATGTGGATTGCTTGGTACTTTGATT 
461        S  G  G  G  G  S  P  T  D  L  G  Q  C  G  L  L  G  T  L  I   
                1450      1460      1470      1480      1490      1500 
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1441      GGTCCACCTCAATGCGACCAGTTTCTTAAATTCGATGCCGACTTGATTATCGAAAGAAGA 
481        G  P  P  Q  C  D  Q  F  L  K  F  D  A  D  L  I  I  E  R  R   
 
                1510      1520      1530      1540      1550      1560 
1501      GAGGGTACTGATGTTTGTTACCCTGGAAAGTTCACAAACGAAGAGAGTCTTAGACAGATT 
501        E  G  T  D  V  C  Y  P  G  K  F  T  N  E  E  S  L  R  Q  I   
 
                1570      1580      1590      1600      1610      1620 
1561      TTGAGAAGATCTGGTGGAATCGACAAAGAGTCCATGGGTTTTACTTACTCAGGTATTAGA 
521        L  R  R  S  G  G  I  D  K  E  S  M  G  F  T  Y  S  G  I  R   
 
                1630      1640      1650      1660      1670      1680 
1621      ACCAACGGAACTACATCTGCATGCAGAAGATCCAATCCATCATTTTATGCTGAAATGAAG 
541        T  N  G  T  T  S  A  C  R  R  S  N  P  S  F  Y  A  E  M  K   
 
                1690      1700      1710      1720      1730      1740 
1681      TGGTTGCTTTCCAACTCAGATAATGCTACCTTCCCTCAAATGACTAAGTCATATAGAAAC 
561        W  L  L  S  N  S  D  N  A  T  F  P  Q  M  T  K  S  Y  R  N   
 
                1750      1760      1770      1780      1790      1800 
1741      CCAAGAAACAAGCCTGCCTTGATTACTTGGGGTGTTCATCACAGTGGATCTGCAACTGAG 
581        P  R  N  K  P  A  L  I  T  W  G  V  H  H  S  G  S  A  T  E   
 
                1810      1820      1830      1840      1850      1860 
1801      CAAACAAAGCTTTACGGTTCTGGAGACAAGTTGATCACAGTTGGTAGTTCTAAGTATTTG 
601        Q  T  K  L  Y  G  S  G  D  K  L  I  T  V  G  S  S  K  Y  L   
 
                1870      1880      1890      1900      1910      1920 
1861      CAGAGTTTTACCCCATCTCCTGGAGCCAGACCTCAAGTCAATGGACAGTCCGGTAGAATT 
621        Q  S  F  T  P  S  P  G  A  R  P  Q  V  N  G  Q  S  G  R  I   
 
                1930      1940      1950      1960      1970      1980 
1921      GATTTCCATTGGTTGCTTTTGGATCCAAACGACACTGTTACTTTTACTTTTAACGGTGCT 
641        D  F  H  W  L  L  L  D  P  N  D  T  V  T  F  T  F  N  G  A   
 
                1990      2000      2010      2020      2030      2040 
1981      TTTATTGCTCCTGACAGAGCATCTTTCTTTAGAGGAGAATCTATCGGAATCCAGTCATAA 
661        F  I  A  P  D  R  A  S  F  F  R  G  E  S  I  G  I  Q  S  *   
 
           
2041      TCTAGA 
681        S  R                                                         
 
XhoI Site                  1..6       6    == Restriction Site   
Kex2 Endopeptidase Signal  7..12      6    => misc_structure 
AVIAN HA RBD V3.6          13..2052   2040 => CDS            
HA RBD Subunit1 (H5) V3.4  13..678    666  => CDS            
HA RBD Ser1/Gly4 Linker    679..711   33   => CDS            
HA RBD Subunit2 (H5) V3.4  712..1365  654  => CDS            
HA RBD Ser1/Gly4 Linker    1366..1398 33   => CDS            
HA RBD Subunit 3 (H7) V3.4 1399..2037 639  => CDS            
pSTOP                  2038..2052 15   => CDS            
XbaI site                   2041..2046 3    == Restriction Site   
Table 13. DNA sequencing results for the Avian HA-RBD V3.6 version that was 
synthesized and codon optimized for Pichia pastoris expression (OptiGene 
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software by GeneScript Inc) in the vector pPicZalphaA. The presence of the XhoI, 5’ 
restriction site facilitates cloning next to the Kex2 cleavage signal for N-terminal native 
expression. The XbaI, 3’ restriction site; pSTOP, premature stop codon, RBD1, 
Receptor binding domain derived from H5; RBD2, Receptor binding domain derived 
from H5; RBD3, Receptor binding domain DNA sequence derived from H7; Pep5aa, an 
immune-stimulant penta peptide.  
 
Translation of HA RBD V(3.6)(1-2061) 
Universal code 
Total amino acid number: 685, MW=76346 
Max ORF starts at AA pos 1(may be DNA pos 1) for 684 AA(2052 
bases),MW=76259 
           10        20        30        40        50        60 
1         CTCGAGAAGAGAAGTGTTAAGGGAGGTTTTATTTTGAAAGACTGTTCTGTCGCTGGTTGG 
1          L  E  K  R  S  V  K  G  G  F  I  L  K  D  C  S  V  A  G  W  
 
                  70        80        90       100       110       120 
61        TTGCTTGGAAATCCTATGTGTGATGAGTTTTTGACTGCTCCAGAATGGTCCTACATTGTT 
21         L  L  G  N  P  M  C  D  E  F  L  T  A  P  E  W  S  Y  I  V   
 
                 130       140       150       160       170       180 
121       GAGAAGGATAACCCATCAAATGACTTGTGTTACCCTGGTAACTTCGATAACTACGAAGAG 
41         E  K  D  N  P  S  N  D  L  C  Y  P  G  N  F  D  N  Y  E  E   
 
                 190       200       210       220       230       240 
181       CTTAAGCATTTGATGTCTTCCACCAACCACATGGAAAGAATTCAAATCTTCCCAAGAAAT 
61         L  K  H  L  M  S  S  T  N  H  M  E  R  I  Q  I  F  P  R  N   
 
                 250       260       270       280       290       300 
241       TCCTGGACTAACCATAATGCTTCAGCCGGTGTTTCAAGTGCTTGCCCTTTTAACGGTGGA 
81         S  W  T  N  H  N  A  S  A  G  V  S  S  A  C  P  F  N  G  G   
 
                 310       320       330       340       350       360 
301       TCTTCCTTTTTCAGAAATGTTGTCTGGCTTATTAAGAAAAACGATGTTTACAGAACTTTG 
101        S  S  F  F  R  N  V  V  W  L  I  K  K  N  D  V  Y  R  T  L   
 
                 370       380       390       400       410       420 
361       AAGAGAAACTACACCAACACTAATGTTGAGGATTTGCTTATTATCTGGGGTGTCCATCAC 
121        K  R  N  Y  T  N  T  N  V  E  D  L  L  I  I  W  G  V  H  H   
 
                 430       440       450       460       470       480 
421       CCAAATGACGCTACTGAACAAACAAAGCTTTACCAGAACTTGAACACATACGTTAGTGTC 
141        P  N  D  A  T  E  Q  T  K  L  Y  Q  N  L  N  T  Y  V  S  V   
 
                 490       500       510       520       530       540 
481       GGTACATCTACCTTGAACCAAAGATCAACTCCAACAATTGCCACTAGACCTCAAGTTAAT 
161        G  T  S  T  L  N  Q  R  S  T  P  T  I  A  T  R  P  Q  V  N   
 
                 550       560       570       580       590       600 
541       GGTCAGAGAGGAAGAATGGAATTTTTCTGGACTATCTTGAAGTCCAACGATTCAATCTTT 
181        G  Q  R  G  R  M  E  F  F  W  T  I  L  K  S  N  D  S  I  F   
 
                 610       620       630       640       650       660 
601       TTCGAGTCCACTGGTAATTTTATTGCCCCTGAATACGCATACAAGATCGTTAAGAAAGGA 
201        F  E  S  T  G  N  F  I  A  P  E  Y  A  Y  K  I  V  K  K  G   
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                 670       680       690       700       710       720 
661       AAGTCCACTGTCATGAAATCTGGTGGAGGTGGAAGTGGTGGAGGTGGATCTCCACTTATT 
221        K  S  T  V  M  K  S  G  G  G  G  S  G  G  G  G  S  P  L  I   
 
                 730       740       750       760       770       780 
721       TTGAAGGATTGTTCTGTTGCTGGATGGTTGCTTGGTAATCCTATGTGCGACGAATTCTTG 
241        L  K  D  C  S  V  A  G  W  L  L  G  N  P  M  C  D  E  F  L   
 
                 790       800       810       820       830       840 
781       AACGTTCAAGAGTGGTCTTACATCGTCGAAAAGGATAACCCATCCAACGACTTGTGCTAT 
261        N  V  Q  E  W  S  Y  I  V  E  K  D  N  P  S  N  D  L  C  Y   
 
                 850       860       870       880       890       900 
841       CCAGGAAATTTTGACAATTATGAGGAGCTTAAACATTTGATGTCAAGTACTAACCACTTG 
281        P  G  N  F  D  N  Y  E  E  L  K  H  L  M  S  S  T  N  H  L   
 
                 910       920       930       940       950       960 
901       GAGAGAATTCAGATCTTCCCAAGAAACTCTTGGCCTAATCACGATTCTTCCTCAGGTGTT 
301        E  R  I  Q  I  F  P  R  N  S  W  P  N  H  D  S  S  S  G  V   
 
                 970       980       990      1000      1010      1020 
961       AGTTCTGCTTGTCCTTTTAACGGAGAATCCTCATTTTTCAGAAACGTTGTCTGGTTGATT 
321        S  S  A  C  P  F  N  G  E  S  S  F  F  R  N  V  V  W  L  I   
 
                1030      1040      1050      1060      1070      1080 
1021      AAGAAAAATGACGTCTATAGAACCCTTAAGAGAAACTATACCAACACTAATGTCGAAGAT 
341        K  K  N  D  V  Y  R  T  L  K  R  N  Y  T  N  T  N  V  E  D   
 
                1090      1100      1110      1120      1130      1140 
1081      TTGTTGATCATCTGGGGTGTTCATCACCCTAATGACGCAACCGTCCAAACTAAATTGTAC 
361        L  L  I  I  W  G  V  H  H  P  N  D  A  T  V  Q  T  K  L  Y   
 
                1150      1160      1170      1180      1190      1200 
1141      CAGAACTTGAACACTTACGTTTCCGTCGGTACATCAACCTTGAACCAAAGATCTATTCCA 
381        Q  N  L  N  T  Y  V  S  V  G  T  S  T  L  N  Q  R  S  I  P   
 
                1210      1220      1230      1240      1250      1260 
1201      ACAATCGCTACCAGACCACAGGTCAACGGTCAGAGAGGAAGAGTCGAGTTTTTCTGGACC 
401        T  I  A  T  R  P  Q  V  N  G  Q  R  G  R  V  E  F  F  W  T   
 
                1270      1280      1290      1300      1310      1320 
1261      ATTTTGGAAAGTAACGATTCTATCTTTTTCGAGTCTACTGGTAACTTCATTGCTCCAGAA 
421        I  L  E  S  N  D  S  I  F  F  E  S  T  G  N  F  I  A  P  E   
 
                1330      1340      1350      1360      1370      1380 
1321      TACGCCTATAAGGTTACAAAGAAAGGAAAGTCCGCTGTCATGAAGTCTGGAGGTGGAGGT 
441        Y  A  Y  K  V  T  K  K  G  K  S  A  V  M  K  S  G  G  G  G   
 
                1390      1400      1410      1420      1430      1440 
1381      TCTGGAGGAGGTGGATCTCCTACCGATCTTGGTCAATGTGGATTGCTTGGTACTTTGATT 
461        S  G  G  G  G  S  P  T  D  L  G  Q  C  G  L  L  G  T  L  I   
 
                1450      1460      1470      1480      1490      1500 
1441      GGTCCACCTCAATGCGACCAGTTTCTTAAATTCGATGCCGACTTGATTATCGAAAGAAGA 
481        G  P  P  Q  C  D  Q  F  L  K  F  D  A  D  L  I  I  E  R  R   
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                1510      1520      1530      1540      1550      1560 
1501      GAGGGTACTGATGTTTGTTACCCTGGAAAGTTCACAAACGAAGAGAGTCTTAGACAGATT 
501        E  G  T  D  V  C  Y  P  G  K  F  T  N  E  E  S  L  R  Q  I   
 
                1570      1580      1590      1600      1610      1620 
1561      TTGAGAAGATCTGGTGGAATCGACAAAGAGTCCATGGGTTTTACTTACTCAGGTATTAGA 
521        L  R  R  S  G  G  I  D  K  E  S  M  G  F  T  Y  S  G  I  R   
 
                1630      1640      1650      1660      1670      1680 
1621      ACCAACGGAACTACATCTGCATGCAGAAGATCCAATCCATCATTTTATGCTGAAATGAAG 
541        T  N  G  T  T  S  A  C  R  R  S  N  P  S  F  Y  A  E  M  K   
 
                1690      1700      1710      1720      1730      1740 
1681      TGGTTGCTTTCCAACTCAGATAATGCTACCTTCCCTCAAATGACTAAGTCATATAGAAAC 
561        W  L  L  S  N  S  D  N  A  T  F  P  Q  M  T  K  S  Y  R  N   
 
                1750      1760      1770      1780      1790      1800 
1741      CCAAGAAACAAGCCTGCCTTGATTACTTGGGGTGTTCATCACAGTGGATCTGCAACTGAG 
581        P  R  N  K  P  A  L  I  T  W  G  V  H  H  S  G  S  A  T  E   
 
                1810      1820      1830      1840      1850      1860 
1801      CAAACAAAGCTTTACGGTTCTGGAGACAAGTTGATCACAGTTGGTAGTTCTAAGTATTTG 
601        Q  T  K  L  Y  G  S  G  D  K  L  I  T  V  G  S  S  K  Y  L   
 
                1870      1880      1890      1900      1910      1920 
1861      CAGAGTTTTACCCCATCTCCTGGAGCCAGACCTCAAGTCAATGGACAGTCCGGTAGAATT 
621        Q  S  F  T  P  S  P  G  A  R  P  Q  V  N  G  Q  S  G  R  I   
 
                1930      1940      1950      1960      1970      1980 
1921      GATTTCCATTGGTTGCTTTTGGATCCAAACGACACTGTTACTTTTACTTTTAACGGTGCT 
641        D  F  H  W  L  L  L  D  P  N  D  T  V  T  F  T  F  N  G  A   
 
                1990      2000      2010      2020      2030      2040 
1981      TTTATTGCTCCTGACAGAGCATCTTTCTTTAGAGGAGAATCTATCGGAATCCAGTCAAAG 
661        F  I  A  P  D  R  A  S  F  F  R  G  E  S  I  G  I  Q  S  K   
 
                2050      2060 
2041      TGGTGTGAGTGCTAATCTAGA 
681        W  C  E  C  *  S  R       
  
     
XhoI Site                  1..6       6    == misc_feature   
Kex2 Endopeptidase Signal  7..12      6    => misc_structure 
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AVIAN HA RBD V3.6          13..2052   2040 => CDS            
HA RBD Subunit1 (H5) V3.4  13..678    666  => CDS            
HA RBD Ser1/Gly4 Linker    679..711   33   => CDS            
HA RBD Subunit2 (H5) V3.4  712..1365  654  => CDS            
HA RBD Ser1/Gly4 Linker    1366..1398 33   => CDS            
HA RBD Subunit 3 (H7) V3.4 1399..2037 639  => CDS            
5-Mer Immuno Peptide       2038..2052 15   => CDS            
pSTOP                       2053..2055 3    == misc_feature   
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Table 14. DNA sequencing results for the Avian HA-RBD V3.7 version that was 
synthethized and codon optimized for Pichia pastoris expression (OptiGene 
software by GeneScript Inc) in the vector pPicZalphaA. (In Red) The XhoI, 5’ and 
XbaI, 3’ restriction sited were added to facilitate cloning.  The pSTOP, premature stop 
codon, C-myc, detection epitope tag; 6His, Protein Recovery Tag; STOP, vector stop 
codon; RBD1, Receptor binding domain derived from H5; RBD2, Receptor binding 
domain derived from H5; RBD3, Receptor binding domain DNA sequence derived from 
H7; (In olive green) Pep5aa, immune-stimulant penta peptide; and Tat- pep , HIV-cell 
penetrating peptide are indicated.  
 
Translation of HA RBD V(3.7)(1-2088) 
Universal code 
Total amino acid number: 694, MW=77666 
Max ORF starts at AA pos 1(may be DNA pos 1) for 693 AA(2079 
bases),MW=77579 
           10        20        30        40        50        60 
1         CTCGAGAAGAGAAGTGTTAAGGGAGGTTTTATTTTGAAAGACTGTTCTGTCGCTGGTTGG 
1          L  E  K  R  S  V  K  G  G  F  I  L  K  D  C  S  V  A  G  W  
 
                  70        80        90       100       110       120 
61        TTGCTTGGAAATCCTATGTGTGATGAGTTTTTGACTGCTCCAGAATGGTCCTACATTGTT 
21         L  L  G  N  P  M  C  D  E  F  L  T  A  P  E  W  S  Y  I  V   
 
                 130       140       150       160       170       180 
121       GAGAAGGATAACCCATCAAATGACTTGTGTTACCCTGGTAACTTCGATAACTACGAAGAG 
41         E  K  D  N  P  S  N  D  L  C  Y  P  G  N  F  D  N  Y  E  E   
 
                 190       200       210       220       230       240 
181       CTTAAGCATTTGATGTCTTCCACCAACCACATGGAAAGAATTCAAATCTTCCCAAGAAAT 
61         L  K  H  L  M  S  S  T  N  H  M  E  R  I  Q  I  F  P  R  N   
 
                 250       260       270       280       290       300 
241       TCCTGGACTAACCATAATGCTTCAGCCGGTGTTTCAAGTGCTTGCCCTTTTAACGGTGGA 
81         S  W  T  N  H  N  A  S  A  G  V  S  S  A  C  P  F  N  G  G   
 
                 310       320       330       340       350       360 
301       TCTTCCTTTTTCAGAAATGTTGTCTGGCTTATTAAGAAAAACGATGTTTACAGAACTTTG 
101        S  S  F  F  R  N  V  V  W  L  I  K  K  N  D  V  Y  R  T  L   
 
                 370       380       390       400       410       420 
361       AAGAGAAACTACACCAACACTAATGTTGAGGATTTGCTTATTATCTGGGGTGTCCATCAC 
121        K  R  N  Y  T  N  T  N  V  E  D  L  L  I  I  W  G  V  H  H   
 
                 430       440       450       460       470       480 
421       CCAAATGACGCTACTGAACAAACAAAGCTTTACCAGAACTTGAACACATACGTTAGTGTC 
141        P  N  D  A  T  E  Q  T  K  L  Y  Q  N  L  N  T  Y  V  S  V   
 
                 490       500       510       520       530       540 
481       GGTACATCTACCTTGAACCAAAGATCAACTCCAACAATTGCCACTAGACCTCAAGTTAAT 
161        G  T  S  T  L  N  Q  R  S  T  P  T  I  A  T  R  P  Q  V  N   
 
                 550       560       570       580       590       600 
541       GGTCAGAGAGGAAGAATGGAATTTTTCTGGACTATCTTGAAGTCCAACGATTCAATCTTT 
181        G  Q  R  G  R  M  E  F  F  W  T  I  L  K  S  N  D  S  I  F   
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                 610       620       630       640       650       660 
601       TTCGAGTCCACTGGTAATTTTATTGCCCCTGAATACGCATACAAGATCGTTAAGAAAGGA 
201        F  E  S  T  G  N  F  I  A  P  E  Y  A  Y  K  I  V  K  K  G   
 
                 670       680       690       700       710       720 
661       AAGTCCACTGTCATGAAATCTGGTGGAGGTGGAAGTGGTGGAGGTGGATCTCCACTTATT 
221        K  S  T  V  M  K  S  G  G  G  G  S  G  G  G  G  S  P  L  I   
 
                 730       740       750       760       770       780 
721       TTGAAGGATTGTTCTGTTGCTGGATGGTTGCTTGGTAATCCTATGTGCGACGAATTCTTG 
241        L  K  D  C  S  V  A  G  W  L  L  G  N  P  M  C  D  E  F  L   
 
                 790       800       810       820       830       840 
781       AACGTTCAAGAGTGGTCTTACATCGTCGAAAAGGATAACCCATCCAACGACTTGTGCTAT 
261        N  V  Q  E  W  S  Y  I  V  E  K  D  N  P  S  N  D  L  C  Y   
 
                 850       860       870       880       890       900 
841       CCAGGAAATTTTGACAATTATGAGGAGCTTAAACATTTGATGTCAAGTACTAACCACTTG 
281        P  G  N  F  D  N  Y  E  E  L  K  H  L  M  S  S  T  N  H  L   
 
                 910       920       930       940       950       960 
901       GAGAGAATTCAGATCTTCCCAAGAAACTCTTGGCCTAATCACGATTCTTCCTCAGGTGTT 
301        E  R  I  Q  I  F  P  R  N  S  W  P  N  H  D  S  S  S  G  V   
 
                 970       980       990      1000      1010      1020 
961       AGTTCTGCTTGTCCTTTTAACGGAGAATCCTCATTTTTCAGAAACGTTGTCTGGTTGATT 
321        S  S  A  C  P  F  N  G  E  S  S  F  F  R  N  V  V  W  L  I   
 
                1030      1040      1050      1060      1070      1080 
1021      AAGAAAAATGACGTCTATAGAACCCTTAAGAGAAACTATACCAACACTAATGTCGAAGAT 
341        K  K  N  D  V  Y  R  T  L  K  R  N  Y  T  N  T  N  V  E  D   
 
                1090      1100      1110      1120      1130      1140 
1081      TTGTTGATCATCTGGGGTGTTCATCACCCTAATGACGCAACCGTCCAAACTAAATTGTAC 
361        L  L  I  I  W  G  V  H  H  P  N  D  A  T  V  Q  T  K  L  Y   
 
                1150      1160      1170      1180      1190      1200 
1141      CAGAACTTGAACACTTACGTTTCCGTCGGTACATCAACCTTGAACCAAAGATCTATTCCA 
381        Q  N  L  N  T  Y  V  S  V  G  T  S  T  L  N  Q  R  S  I  P   
 
                1210      1220      1230      1240      1250      1260 
1201      ACAATCGCTACCAGACCACAGGTCAACGGTCAGAGAGGAAGAGTCGAGTTTTTCTGGACC 
401        T  I  A  T  R  P  Q  V  N  G  Q  R  G  R  V  E  F  F  W  T   
 
                1270      1280      1290      1300      1310      1320 
1261      ATTTTGGAAAGTAACGATTCTATCTTTTTCGAGTCTACTGGTAACTTCATTGCTCCAGAA 
421        I  L  E  S  N  D  S  I  F  F  E  S  T  G  N  F  I  A  P  E   
 
                1330      1340      1350      1360      1370      1380 
1321      TACGCCTATAAGGTTACAAAGAAAGGAAAGTCCGCTGTCATGAAGTCTGGAGGTGGAGGT 
441        Y  A  Y  K  V  T  K  K  G  K  S  A  V  M  K  S  G  G  G  G   
 
                1390      1400      1410      1420      1430      1440 
1381      TCTGGAGGAGGTGGATCTCCTACCGATCTTGGTCAATGTGGATTGCTTGGTACTTTGATT 
461        S  G  G  G  G  S  P  T  D  L  G  Q  C  G  L  L  G  T  L  I   
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                1450      1460      1470      1480      1490      1500 
1441      GGTCCACCTCAATGCGACCAGTTTCTTAAATTCGATGCCGACTTGATTATCGAAAGAAGA 
481        G  P  P  Q  C  D  Q  F  L  K  F  D  A  D  L  I  I  E  R  R   
 
                1510      1520      1530      1540      1550      1560 
1501      GAGGGTACTGATGTTTGTTACCCTGGAAAGTTCACAAACGAAGAGAGTCTTAGACAGATT 
501        E  G  T  D  V  C  Y  P  G  K  F  T  N  E  E  S  L  R  Q  I   
 
                1570      1580      1590      1600      1610      1620 
1561      TTGAGAAGATCTGGTGGAATCGACAAAGAGTCCATGGGTTTTACTTACTCAGGTATTAGA 
521        L  R  R  S  G  G  I  D  K  E  S  M  G  F  T  Y  S  G  I  R   
 
                1630      1640      1650      1660      1670      1680 
1621      ACCAACGGAACTACATCTGCATGCAGAAGATCCAATCCATCATTTTATGCTGAAATGAAG 
541        T  N  G  T  T  S  A  C  R  R  S  N  P  S  F  Y  A  E  M  K   
 
                1690      1700      1710      1720      1730      1740 
1681      TGGTTGCTTTCCAACTCAGATAATGCTACCTTCCCTCAAATGACTAAGTCATATAGAAAC 
561        W  L  L  S  N  S  D  N  A  T  F  P  Q  M  T  K  S  Y  R  N   
 
                1750      1760      1770      1780      1790      1800 
1741      CCAAGAAACAAGCCTGCCTTGATTACTTGGGGTGTTCATCACAGTGGATCTGCAACTGAG 
581        P  R  N  K  P  A  L  I  T  W  G  V  H  H  S  G  S  A  T  E   
 
                1810      1820      1830      1840      1850      1860 
1801      CAAACAAAGCTTTACGGTTCTGGAGACAAGTTGATCACAGTTGGTAGTTCTAAGTATTTG 
601        Q  T  K  L  Y  G  S  G  D  K  L  I  T  V  G  S  S  K  Y  L   
 
                1870      1880      1890      1900      1910      1920 
1861      CAGAGTTTTACCCCATCTCCTGGAGCCAGACCTCAAGTCAATGGACAGTCCGGTAGAATT 
621        Q  S  F  T  P  S  P  G  A  R  P  Q  V  N  G  Q  S  G  R  I   
 
                1930      1940      1950      1960      1970      1980 
1921      GATTTCCATTGGTTGCTTTTGGATCCAAACGACACTGTTACTTTTACTTTTAACGGTGCT 
641        D  F  H  W  L  L  L  D  P  N  D  T  V  T  F  T  F  N  G  A   
 
                1990      2000      2010      2020      2030      2040 
1981      TTTATTGCTCCTGACAGAGCATCTTTCTTTAGAGGAGAATCTATCGGAATCCAGTCAAAG 
661        F  I  A  P  D  R  A  S  F  F  R  G  E  S  I  G  I  Q  S  K   
 
                2050      2060      2070      2080 
2041      TGGTGTGAGTGCAGAAAGAAGAGAAGACAGAGAAGAAGATAATCTAGA 
681        W  C  E  C  R  K  K  R  R  Q  R  R  R  *  S  R               
 
XhoI Site                  1..6       6    == misc_feature   
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Kex2 Endopeptidase Signal  7..12      6    => misc_structure 
AVIAN HA RBD V3.6          13..2052   2040 => CDS            
HA RBD Subunit1 (H5) V3.4  13..678    666  => CDS            
HA RBD Ser1/Gly4 Linker    679..711   33   => CDS            
HA RBD Subunit2 (H5) V3.4  712..1365  654  => CDS            
HA RBD Ser1/Gly4 Linker    1366..1398 33   => CDS            
HA RBD Subunit 3 (H7) V3.4 1399..2037 639  => CDS            
5-Mer Immuno Peptide        2038..2052 15   => CDS 
Tat-Peptide             2053..2079     27      =>     CDS 
pSTOP                       2080..2082 3    == misc_feature   
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Table 15. Human HA-RBD V3.3 sequence that was codon optimized for Pichia 
pastoris expression using the software OptiGene by the company GeneScript Inc.  
(In Red) XhoI, 5’ and XbaI, 3’ restriction sited were added to facilitate cloning; a 
cleavage site KR for correct endopeptidase processing and native N-Terminal 
purification; pSTOP, premature stop codon (TAA, in light green) for C-terminal Native 
purification; RBD1, Receptor binding domain derived from H1 subtype; RBD2, Receptor 
binding domain derived from H3 subtype; RBD3, Receptor binding domain DNA 
sequence derived from Influenza B. 
 
Translation of HUMAN HA RBD V(3.3(1-2145) 
Universal code 
Total amino acid number: 713, MW=78171 
Max ORF starts at AA pos 1(may be DNA pos 1) for 712 AA(2136 bases),  
MW=78084 
                  10        20        30        40        50        60 
1         CTCGAGAAAAGAGGTGTCGCTCCATTGCATTTGGGAAAGTGTAATATCGCCGGTTGGATC 
1          L  E  K  R  G  V  A  P  L  H  L  G  K  C  N  I  A  G  W  I  
 
                  70        80        90       100       110       120 
61        CTTGGTAATCCTGAGTGTGAGTCATTGTCTACTGCTTCTTCCTGGAGTTACATTGTTGAA 
21         L  G  N  P  E  C  E  S  L  S  T  A  S  S  W  S  Y  I  V  E   
 
                 130       140       150       160       170       180 
121       ACACCTTCTGATAACGGTACCTGTTACCCAGGAGATTTCATCGACTATGAAGAGCTTAGA 
41         T  P  S  D  N  G  T  C  Y  P  G  D  F  I  D  Y  E  E  L  R   
 
                 190       200       210       220       230       240 
181       GAGCAATTGTCAAGTGTTTCTTCCTTTGAAAGATTCGAGATTTTTCCAAAGACATCAAGT 
61         E  Q  L  S  S  V  S  S  F  E  R  F  E  I  F  P  K  T  S  S   
 
                 250       260       270       280       290       300 
241       TGGCCTAATCATGACTCTAACAAAGGAGTTACCGCTGCCTGTCCTCACGCAGGTGCTAAG 
81         W  P  N  H  D  S  N  K  G  V  T  A  A  C  P  H  A  G  A  K   
 
                 310       320       330       340       350       360 
301       TCTTTCTACAAGAACTTGATCTGGCTTGTCAAGAAAGGAAATTCCTACCCAAAGTTGTCT 
101        S  F  Y  K  N  L  I  W  L  V  K  K  G  N  S  Y  P  K  L  S   
 
                 370       380       390       400       410       420 
361       AAGTCCTACATCAACGATAAGGGAAAAGAAGTTTTGGTCCTTTGGGGTATCCATCACCCA 
121        K  S  Y  I  N  D  K  G  K  E  V  L  V  L  W  G  I  H  H  P   
 
                 430       440       450       460       470       480 
421       TCAACTAGTGCTGATCAACAGTCATTGTACCAGAATGCCGACGCATATGTTTTCGTCGGT 
141        S  T  S  A  D  Q  Q  S  L  Y  Q  N  A  D  A  Y  V  F  V  G   
 
                 490       500       510       520       530       540 
481       TCTTCCAGATATTCTAAGAAGTTTAAGCCAGAAATCGCTATTAGACCTAAAGTTAGAGAT 
161        S  S  R  Y  S  K  K  F  K  P  E  I  A  I  R  P  K  V  R  D   
 
                 550       560       570       580       590       600 
541       CAAGAGGGTAGAATGAACTACTATTGGACTCTTGTCGAACCTGGAGACAAGATTACTTTC 
181        Q  E  G  R  M  N  Y  Y  W  T  L  V  E  P  G  D  K  I  T  F   
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                 610       620       630       640       650       660 
601       GAGGCAACTGGTAACTTGGTTGTCCCAAGATACGCTTTTGCCATGGAAAGAAATGCTGGT 
201        E  A  T  G  N  L  V  V  P  R  Y  A  F  A  M  E  R  N  A  G   
 
                 670       680       690       700       710       720 
661       AGTGGAATTATCATTTCTGATGGTGGAGGTGGATCCGGTGGAGGTGGATCAGGAGAAATC 
221        S  G  I  I  I  S  D  G  G  G  G  S  G  G  G  G  S  G  E  I   
 
                 730       740       750       760       770       780 
721       TGCGATTCTCCTCATCAAATTCTTGACGGAGAGAATTGTACTTTGATTGATGCTTTGCTT 
241        C  D  S  P  H  Q  I  L  D  G  E  N  C  T  L  I  D  A  L  L   
 
                 790       800       810       820       830       840 
781       GGAGATCCACAATGCGACGGATTCCAGAACAAGAAATGGGACTTGTTTGTTGAGAGATCC 
261        G  D  P  Q  C  D  G  F  Q  N  K  K  W  D  L  F  V  E  R  S   
 
                 850       860       870       880       890       900 
841       AAGGCCTACTCAAATTGTTACCCATATGATGTTCCTGACTATGCATCATTGAGAAGTCTT 
281        K  A  Y  S  N  C  Y  P  Y  D  V  P  D  Y  A  S  L  R  S  L   
 
                 910       920       930       940       950       960 
901       GTCGCTTCAAGTGGTACATTGGAATTCAACAACGAGTCTTTTAATTGGACCGGTGTTACT 
301        V  A  S  S  G  T  L  E  F  N  N  E  S  F  N  W  T  G  V  T   
 
                 970       980       990      1000      1010      1020 
961       CAGAACGGAACCTCTTCCGCATGTATCAGAAGATCTAACAACTCCTTTTTCTCAAGATTG 
321        Q  N  G  T  S  S  A  C  I  R  R  S  N  N  S  F  F  S  R  L   
 
                1030      1040      1050      1060      1070      1080 
1021      AATTGGCTTCACAGATTGAACTTCAAATACCCTGCCCTTAACGTTACAATGCCAAACAAC 
341        N  W  L  H  R  L  N  F  K  Y  P  A  L  N  V  T  M  P  N  N   
 
                1090      1100      1110      1120      1130      1140 
1081      GAACAATTCGATAAGTTGTACATTTGGGGTGTCCATCACCCTGGAACTGACAAAGAGCAA 
361        E  Q  F  D  K  L  Y  I  W  G  V  H  H  P  G  T  D  K  E  Q   
 
                1150      1160      1170      1180      1190      1200 
1141      ATTTTCTTGTACGCTCAGTCAAGTGGAAGAATCACAGTTAGTACCAAGAGATCTCAACAG 
381        I  F  L  Y  A  Q  S  S  G  R  I  T  V  S  T  K  R  S  Q  Q   
 
                1210      1220      1230      1240      1250      1260 
1201      GCCGTCATCCCAAACATTGGTTCCAGACCTAGAATCAGAAACATCCCAAGTAGAATCTCT 
401        A  V  I  P  N  I  G  S  R  P  R  I  R  N  I  P  S  R  I  S   
 
                1270      1280      1290      1300      1310      1320 
1261      ATCTACTGGACTATTGTTAAGCCTGGAGATATCTTGCTTATTAATTCCACTGGTAACTTG 
421        I  Y  W  T  I  V  K  P  G  D  I  L  L  I  N  S  T  G  N  L   
 
                1330      1340      1350      1360      1370      1380 
1321      ATCGCCCCAAGAGGATACTTTAAGATCAGATCCGGTAAATCTTCCATTATGAGATCAGAT 
441        I  A  P  R  G  Y  F  K  I  R  S  G  K  S  S  I  M  R  S  D   
 
                1390      1400      1410      1420      1430      1440 
1381      GCACCTATCGGTGGAGGTGGAAGTGGTGGAGGTGGATCTGGTACAAGAACCAGAGGAAAG 
461        A  P  I  G  G  G  G  S  G  G  G  G  S  G  T  R  T  R  G  K   
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                1450      1460      1470      1480      1490      1500 
1441      CTTTGTCCAGACTGCTTGAATTGTACTGATCTTGACGTTGCTTTGGGTAGACCTATGTGT 
481        L  C  P  D  C  L  N  C  T  D  L  D  V  A  L  G  R  P  M  C   
 
                1510      1520      1530      1540      1550      1560 
1501      GTCGGAACTACACCATCCGCAAAGGCTTCAATTTTGCATGAAGTTAGACCTGTCACCTCT 
501        V  G  T  T  P  S  A  K  A  S  I  L  H  E  V  R  P  V  T  S   
 
                1570      1580      1590      1600      1610      1620 
1561      GGATGCTTCCCAATTATGCACGATAGAACTAAAATCAGACAGCTTCCAAATTTGCTTAGA 
521        G  C  F  P  I  M  H  D  R  T  K  I  R  Q  L  P  N  L  L  R   
 
                1630      1640      1650      1660      1670      1680 
1621      GGTTACGAAAACATCAGATTGTCTACTCAAAATGTTATCGACGCTGAGAAGGCCCCAGGT 
541        G  Y  E  N  I  R  L  S  T  Q  N  V  I  D  A  E  K  A  P  G   
 
                1690      1700      1710      1720      1730      1740 
1681      GGACCTTACAGATTGGGTACCTCTGGATCCTGTCCTAACGCCACTTCTAAAATTGGTTTC 
561        G  P  Y  R  L  G  T  S  G  S  C  P  N  A  T  S  K  I  G  F   
 
                1750      1760      1770      1780      1790      1800 
1741      TTTGCAACAATGGCCTGGGCAGTTCCAAAGGATAACTACAAAAATGCTACCAACCCTTTG 
581        F  A  T  M  A  W  A  V  P  K  D  N  Y  K  N  A  T  N  P  L   
 
                1810      1820      1830      1840      1850      1860 
1801      ACTGTTGAAGTCCCATATATTTGCACTGAAGGAGAGGATCAAATCACAGTTTGGGGTTTT 
601        T  V  E  V  P  Y  I  C  T  E  G  E  D  Q  I  T  V  W  G  F   
 
                1870      1880      1890      1900      1910      1920 
1861      CATTCTGACAATAAGACCCAAATGAAATCCTTGTATGGAGATTCAAACCCTCAGAAATTC 
621        H  S  D  N  K  T  Q  M  K  S  L  Y  G  D  S  N  P  Q  K  F   
 
                1930      1940      1950      1960      1970      1980 
1921      ACTTCAAGTGCTAATGGAGTTACCACTCACTACGTCTCCCAAATTGGAGATTTTCCTGAC 
641        T  S  S  A  N  G  V  T  T  H  Y  V  S  Q  I  G  D  F  P  D   
 
                1990      2000      2010      2020      2030      2040 
1981      CAGACTGAGGATGGTGGATTGCCACAATCAGGAAGAATTGTTGTCGACTACATGATGCAG 
661        Q  T  E  D  G  G  L  P  Q  S  G  R  I  V  V  D  Y  M  M  Q   
 
                2050      2060      2070      2080      2090      2100 
2041      AAGCCAGGTAAAACTGGAACAATCGTTTATCAAAGAGGTGTCTTGTTGCCTCAAAAAGTC 
681        K  P  G  K  T  G  T  I  V  Y  Q  R  G  V  L  L  P  Q  K  V   
 
                2110      2120      2130      2140 
2101      TGGTGTGCATCAGGTAGAAGTAAAGTCATCAAAGGATAATCTAGA 
701        W  C  A  S  G  R  S  K  V  I  K  G  *                    
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Table 16. RBD subunits and peptide composition for the HA-RBD genes versions used in the study. Versions 
V3.3, V3.4, V3.6, and V3.7 were synthetized and custom cloned in the pPicZalpha plasmid by GeneScript Corp.; whereas 
versions mutV3.3, mut V3.4, mutV3.6 and mutV3.7 were sequence modified by PCR and recloned in the plasmids 
pPicZalpha-A and pPicZ-B.  
Avian 
Version 
Subunit 1 Subunit 2 Subunit 3  5-Mer 
peptide 
TAT-
peptide 
Premature 
Stop Codon 
(Native C-
Terminal)  
c-Myc 
Tag 
6-His 
Tag 
Extra- 
cellular  
pPicZα-A 
Intra- 
Cellular 
pPicZ-B 
V3.4 + + + - - + - - + - 
V3.6 + + + + - + - - + - 
V3.7 + + + + + + - - + - 
mutV3.4 + + + - - - + + + + 
mutV3.6 + + + + - - + + + + 
mutV3.7 + + + + + - + + + + 
Human 
Version 
Subunit 1 Subunit 2 Subunit 3  5-Mer 
peptide 
TAT-
peptide 
Premature 
Stop Codon 
(Native C-
Terminal)  
c-Myc 
Tag 
6-His 
Tag 
Extra- 
cellular  
pPicZα-A 
Intra- 
Cellular 
pPicZ-B 
V3.3 + + + - - + - - + - 
mutV3.3 + + + - - - + + + + 
 
87 
 
3.3. Zeocin selection to obtain hyper-resistant Pichia pastoris clones carrying any of 
the HA-RBD gene versions. 
 
A typical Pichia pastoris X-33 electro-transformation resulted in a highly efficient 
growth and recovery of hundreds of zeocine resistance colonies (Figure 19 A). 
Depending of the HA-RBD expression cassette being transformed, two to four Zeocine 
hyper-resistant clones at 1500 µL/mL antibiotic selection where recovered and stored, 
as observed and described (Figure 19 B). Thus, for a broader search of expressing 
clones, the panel of hyper-resistant  cells at 1000 µL/mL where used for the expression 
analysis with the expectative to have better chances to induce higher expression level in 
individual clones than randomly picked ones (Figure 19 C). 
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Figure 19.  Antibiotic selection of the Pichia pastoris Zeocin resistant clones.  A, 
Pichia pastoris X-33 cells were transformed with the HA RBD Version 3.4 cloned in the 
pPicZalpha-A plasmid and selected in YPDS-agar plates, containing 200 g/l of 
Zeocin. B, Isolated clones were selected using a tooth-pick and transferred individually 
to 96-well culture plates for further antibiotic hyperresistance selection.  The cultures 
were replica plated in 96-well plates with different antibiotic concentrations, and those 
clones able to growth at the highest antibiotic concentration (dotted arrows) were 
selected for protein expression analysis. C, the expected results of applying this 
strategy is that cells hyper-resistant to zeocin will be carrying more gene copies in their 
genomes that will be translated into higher protein expression levels.   
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3.4. MASS-spectroscopy results from a protein band isolated from the avian 
HA RBD V3.4 – pPicZalpha-A Clone 1.1 identifies peptides derived from 
the Avian HA-RBD V3.4 protein sequence. 
 
 Pichia pastoris extracellular integrated Avian HA-RBD V3.4 1.1 was observed to 
express a putative band under a methanol-induced 10 fold concentrated culture 
supernatant that migrates on a 12%SDS-PAGE gel between a molecular size of 100 
KDa  and 75 KDa  (72 kDa expected). These bands (Figure 20) were recovered by 
DEAE anion exchange chromatography and further analyzed by Tandem Mass-
Spectrometry to infer the peptide composition.  The sequence generated by the 
MASCOT software compared directly to the Avian HA-RBD v3.4 protein sequence and 
Swiss-prot protein database and was used to generate peptide scores. Based on the 
total ion current score results in Table 15, it was possible to identify one protein 
corresponding to the Avian HA-RDB v3.4 sequence. From the total protein sequence 
length in (Table 16), 45% of protein sequence coverage to the Avian HA RBD v3.4 was 
observed, strongly indicating the expression of this protein in the isolated band. In a 
separate Mass-Spectroscopic analysis, a second purification by size exclusion 
chromatography in addition to the DEAE Anion exchange recovery (Figure 21) 
reconfirmed (Table 17) the presence of peptides corresponding to the Avian HA-RBD 
V3.4 sequence.  However, this time there was only 29% protein sequence coverage 
when compared to the total protein length of the Avian HA-RBD 3.4 sequence   (Figure 
22).  
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Figure 20.  Expression analysis by SDS-PAGE of the Avian HA-RBD V3.4 Clone 
1.1 from 48 h methanol-induced supernatants before (A) and after DEAE Anion 
Exchange chromatography purification (B). In A), Lane M and 1, Blueye protein 
standard; lane 2, mock induced culture with X-33 clones integrated with pPicZalphaA 
plasmid; lane 3-4, clone 1.1 integrated with Avian RDB V3.4 in pPicZalphaA,  the 
orange box corresponds to a 75-100 KDa putative Avian HA-RBD V3.4 protein, 
intended for MASS-Spectroscopic analysis. In B, elution fractions in 300mM Tris-HCl pH 
7.72 buffer, with the putative Avian HA-RBD V3.4; lane M and 1, Blueye protein 
standard, lane 2, second fraction collected and loaded in 300 mM Tris-HCl pH7.72  
buffer; lane 3,4,5, correspond to the first, third and fourth, fractions collected at 300 mM 
Tris-HCl pH7.72  buffer. Second, third and fourth fractions were gel sliced and analysed 
by Mass-Spectroscopy. 
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Table 17. Calculated peptide sequences positively identified by Mass-Spectroscopy from the Avian HA-RBD V3.4 
Clone 1.1.  Highlighted in yellow, the calculated peptide sequences with a combination of a high score values and lowest 
expect value indicating more confidence in the match.  
Query Start – End Observed Mr(expt) Mr(calc) ppm M Score Expect Peptide 
5163 39 – 58 1202.5061 2402.9977 2402.9961 0.65 0 22 0.0083 K.DNPSNDLCYPGNFDNYEELK.H 
5164 39 – 58 1202.5066 2402.9986 2402.9961 1.06 0 45 0.000062 K.DNPSNDLCYPGNFDNYEELK.H 
3352 59 – 69 448.2039 1341.5899 1341.5918 -1.37 0 2 1.5 K.HLMSSTNHMER.I 
3353 59 – 69 448.2039 1341.5899 1341.5918 -1.37 0 13 0.11 K.HLMSSTNHMER.I 
609 102 – 108 436.2718 870.529 870.5327 -4.24 0 10 1.1 R.NVVWLIK.K 
610 102 – 108 436.273 870.5315 870.5327 -1.37 0 7 2.4 R.NVVWLIK.K 
611 102 – 108 436.2731 870.5317 870.5327 -1.22 0 10 0.83 R.NVVWLIK.K 
612 102 – 108 436.2733 870.532 870.5327 -0.87 0 41 0.035 R.NVVWLIK.K 
613 102 – 108 871.5402 870.5329 870.5327 0.26 0 27 0.21 R.NVVWLIK.K 
614 102 – 108 436.2739 870.5332 870.5327 0.53 0 19 1.4 R.NVVWLIK.K 
615 102 – 108 871.5406 870.5333 870.5327 0.69 0 23 0.24 R.NVVWLIK.K 
616 102 – 108 436.274 870.5334 870.5327 0.81 0 43 0.019 R.NVVWLIK.K 
1456 102 – 109 500.3205 998.6264 998.6277 -1.3 1 24 0.61 R.NVVWLIKK.N 
1457 102 – 109 500.3207 998.6269 998.6277 -0.75 1 27 0.12 R.NVVWLIKK.N 
1458 102 – 109 500.3208 998.6271 998.6277 -0.56 1 14 0.66 R.NVVWLIKK.N 
1459 102 – 109 500.3213 998.6281 998.6277 0.47 1 23 0.85 R.NVVWLIKK.N 
4991 146 – 164 1086.0581 2170.1017 2170.1018 -0.084 0 107 9.9E-09 K.LYQNLNTYVSVGTSTLNQR.S 
4992 146 – 164 1086.0596 2170.1046 2170.1018 1.27 0 62 0.0000096 K.LYQNLNTYVSVGTSTLNQR.S 
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4993 146 – 164 1086.0599 2170.1053 2170.1018 1.61 0 102 4.3E-09 K.LYQNLNTYVSVGTSTLNQR.S 
4994 146 – 164 1086.0604 2170.1063 2170.1018 2.05 0 81 0.0000002 K.LYQNLNTYVSVGTSTLNQR.S 
4995 146 – 164 1086.5507 2171.0868 2170.1018 454 0 9 0.51 K.LYQNLNTYVSVGTSTLNQR.S 
4996 146 – 164 1086.5509 2171.0873 2170.1018 454 0 31 0.0068 K.LYQNLNTYVSVGTSTLNQR.S 
4997 146 – 164 1086.551 2171.0875 2170.1018 454 0 18 0.061 K.LYQNLNTYVSVGTSTLNQR.S 
4998 146 – 164 1086.5516 2171.0887 2170.1018 455 0 40 0.0014 K.LYQNLNTYVSVGTSTLNQR.S 
4194 165 – 179 542.628 1624.8621 1624.8645 -1.46 0 11 1.3 R.STPTIATRPQVNGQR.G 
3614 180 – 190 714.3796 1426.7447 1426.7431 1.13 1 24 0.035 R.GRMEFFWTILK.S 
3680 180 – 190 481.9203 1442.7392 1442.738 0.82 1 8 2.5 R.GRMEFFWTILK.S + Oxidation (M) 
3681 180 – 190 722.3779 1442.7412 1442.738 2.18 1 10 0.52 R.GRMEFFWTILK.S + Oxidation (M) 
5161 191 – 211 1200.5576 2399.1007 2399.0957 2.06 0 52 0.00018 K.SNDSIFFESTGNFIAPEYAYK.I 
5162 191 – 211 1200.5582 2399.1019 2399.0957 2.57 0 39 0.00045 K.SNDSIFFESTGNFIAPEYAYK.I 
3157 223 – 238 650.8461 1299.6777 1299.6783 -0.46 0 67 0.000017 K.SGGGGSGGGGSPLILK.D 
3159 223 – 238 650.8465 1299.6784 1299.6783 0.11 0 106 0.000000011 K.SGGGGSGGGGSPLILK.D 
3160 223 – 238 650.8466 1299.6786 1299.6783 0.2 0 91 0.000000094 K.SGGGGSGGGGSPLILK.D 
3161 223 – 238 650.8467 1299.6789 1299.6783 0.48 0 54 0.00017 K.SGGGGSGGGGSPLILK.D 
3162 223 – 238 650.8478 1299.681 1299.6783 2.08 0 18 0.21 K.SGGGGSGGGGSPLILK.D 
3275 288 – 298 442.2183 1323.633 1323.6353 -1.74 0 5 1.1 K.HLMSSTNHLER.I 
3276 288 – 298 442.2184 1323.6334 1323.6353 -1.46 0 16 0.1 K.HLMSSTNHLER.I 
3277 288 – 298 442.2184 1323.6335 1323.6353 -1.39 0 21 0.36 K.HLMSSTNHLER.I 
5395 305 – 330 954.4016 2860.1828 2859.1943 346 0 8 0.18 R.NSWPNHDSSSGVSSACPFNGESSFFR.N 
5396 305 – 330 954.4019 2860.1839 2859.1943 346 0 25 0.01 R.NSWPNHDSSSGVSSACPFNGESSFFR.N 
93 
 
4236 394 – 408 819.4578 1636.9011 1636.9009 0.12 0 2 1.1 R.SIPTIATRPQVNGQR.G 
4238 394 – 408 546.6412 1636.9017 1636.9009 0.49 0 19 0.55 R.SIPTIATRPQVNGQR.G 
4252 394 – 408 546.9699 1637.8879 1636.9009 603 0 9 1.2 R.SIPTIATRPQVNGQR.G 
2038 487 – 495 546.2895 1090.5645 1090.5659 -1.2 0 36 0.012 K.FDADLIIER.R 
2039 487 – 495 546.2903 1090.5661 1090.5659 0.25 0 65 0.00014 K.FDADLIIER.R 
2040 487 – 495 546.2906 1090.5666 1090.5659 0.7 0 53 0.0023 K.FDADLIIER.R 
2885 487 – 496 416.563 1246.667 1246.667 0.065 1 16 0.85 K.FDADLIIERR.E 
2888 487 – 496 624.3413 1246.6681 1246.667 0.88 1 11 0.68 K.FDADLIIERR.E 
2889 487 – 496 624.342 1246.6695 1246.667 2.06 1 5 1.3 K.FDADLIIERR.E 
5087 496 – 514 565.2687 2257.0456 2257.0433 1.01 2 15 0.15 R.REGTDVCYPGKFTNEESLR.Q 
5088 496 – 514 753.356 2257.046 2257.0433 1.2 2 16 0.057 R.REGTDVCYPGKFTNEESLR.Q 
2229 497 – 506 563.2469 1124.4792 1124.4808 -1.43 0 10 0.31 R.EGTDVCYPGK.F 
2230 497 – 506 563.2476 1124.4807 1124.4808 -0.13 0 0 1.4 R.EGTDVCYPGK.F 
4912 497 – 514 701.3212 2100.9417 2100.9422 -0.27 1 9 0.14 R.EGTDVCYPGKFTNEESLR.Q 
4913 497 – 514 701.3213 2100.942 2100.9422 -0.094 1 22 0.015 R.EGTDVCYPGKFTNEESLR.Q 
4914 497 – 514 701.3218 2100.9437 2100.9422 0.69 1 37 0.00038 R.EGTDVCYPGKFTNEESLR.Q 
4915 497 – 514 1051.4796 2100.9447 2100.9422 1.16 1 25 0.041 R.EGTDVCYPGKFTNEESLR.Q 
4921 497 – 514 1051.9803 2101.9461 2100.9422 478 1 11 0.29 R.EGTDVCYPGKFTNEESLR.Q 
1436 507 – 514 498.2425 994.4704 994.472 -1.59 0 8 2.1 K.FTNEESLR.Q 
1437 507 – 514 498.2429 994.4712 994.472 -0.79 0 30 0.042 K.FTNEESLR.Q 
1438 507 – 514 498.2434 994.4722 994.472 0.25 0 20 0.82 K.FTNEESLR.Q 
2758 515 – 525 613.3594 1224.7042 1224.6939 8.44 2 1 4.1 R.QILRRSGGIDK.E + Gln->pyro-Glu (N-term Q) 
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4819 519 – 536 654.3232 1959.9477 1959.9472 0.24 2 48 0.00024 R.RSGGIDKESMGFTYSGIR.T 
4833 519 – 536 659.6543 1975.9411 1975.9422 -0.56 2 8 1.5 R.RSGGIDKESMGFTYSGIR.T + Oxidation (M) 
4835 519 – 536 659.6545 1975.9418 1975.9422 -0.19 2 29 0.012 R.RSGGIDKESMGFTYSGIR.T + Oxidation (M) 
4839 519 – 536 659.6553 1975.944 1975.9422 0.92 2 59 0.000014 R.RSGGIDKESMGFTYSGIR.T + Oxidation (M) 
4612 520 – 536 902.9308 1803.847 1803.8461 0.49 1 24 0.0066 R.SGGIDKESMGFTYSGIR.T 
4613 520 – 536 602.2899 1803.8479 1803.8461 0.99 1 40 0.00053 R.SGGIDKESMGFTYSGIR.T 
4629 520 – 536 607.6207 1819.8404 1819.8411 -0.39 1 42 0.0016 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4630 520 – 536 910.9279 1819.8412 1819.8411 0.055 1 16 0.15 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4631 520 – 536 607.6212 1819.8418 1819.8411 0.41 1 5 3.4 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4632 520 – 536 607.6213 1819.842 1819.8411 0.52 1 13 0.12 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4633 520 – 536 910.9283 1819.842 1819.8411 0.52 1 24 0.051 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4634 520 – 536 910.9288 1819.843 1819.8411 1.06 1 49 0.00005 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
4635 520 – 536 607.6219 1819.8438 1819.8411 1.52 1 49 0.000093 R.SGGIDKESMGFTYSGIR.T + Oxidation (M) 
2882 526 – 536 624.2897 1246.5648 1246.5652 -0.34 0 29 0.049 K.ESMGFTYSGIR.T 
2977 526 – 536 632.2868 1262.5591 1262.5601 -0.86 0 22 0.016 K.ESMGFTYSGIR.T + Oxidation (M) 
2978 526 – 536 632.2871 1262.5597 1262.5601 -0.37 0 23 0.0065 K.ESMGFTYSGIR.T + Oxidation (M) 
3299 546 – 556 665.3163 1328.618 1328.6183 -0.2 1 42 0.0018 R.RSNPSFYAEMK.W 
3300 546 – 556 665.3163 1328.6181 1328.6183 -0.11 1 16 0.17 R.RSNPSFYAEMK.W 
3301 546 – 556 665.3167 1328.6189 1328.6183 0.44 1 48 0.0014 R.RSNPSFYAEMK.W 
3374 546 – 556 449.2111 1344.6115 1344.6132 -1.24 1 11 0.34 R.RSNPSFYAEMK.W + Oxidation (M) 
3375 546 – 556 673.313 1344.6115 1344.6132 -1.24 1 3 1 R.RSNPSFYAEMK.W + Oxidation (M) 
3376 546 – 556 673.3137 1344.6129 1344.6132 -0.24 1 20 0.4 R.RSNPSFYAEMK.W + Oxidation (M) 
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2509 547 – 556 587.2653 1172.5161 1172.5172 -0.94 0 16 0.11 R.SNPSFYAEMK.W 
2510 547 – 556 587.2656 1172.5167 1172.5172 -0.42 0 50 0.00016 R.SNPSFYAEMK.W 
2511 547 – 556 1173.5244 1172.5171 1172.5172 -0.04 0 15 0.27 R.SNPSFYAEMK.W 
2512 547 – 556 587.2661 1172.5176 1172.5172 0.32 0 55 0.00012 R.SNPSFYAEMK.W 
2513 547 – 556 1173.525 1172.5177 1172.5172 0.48 0 15 0.4 R.SNPSFYAEMK.W 
2514 547 – 556 587.2667 1172.5188 1172.5172 1.36 0 17 0.054 R.SNPSFYAEMK.W 
2580 547 – 556 595.2623 1188.5101 1188.5121 -1.68 0 31 0.0063 R.SNPSFYAEMK.W + Oxidation (M) 
2581 547 – 556 595.2629 1188.5113 1188.5121 -0.65 0 51 0.00032 R.SNPSFYAEMK.W + Oxidation (M) 
2583 547 – 556 595.263 1188.5114 1188.5121 -0.55 0 4 0.94 R.SNPSFYAEMK.W + Oxidation (M) 
2584 547 – 556 595.2632 1188.5119 1188.5121 -0.14 0 11 1.2 R.SNPSFYAEMK.W + Oxidation (M) 
5091 579 – 599 566.296 2261.1547 2261.1553 -0.24 0 17 0.48 R.NKPALITWGVHHSGSATEQTK.L 
5092 579 – 599 566.296 2261.155 2261.1553 -0.13 0 27 0.017 R.NKPALITWGVHHSGSATEQTK.L 
3931 600 – 614 508.9466 1523.8179 1523.8195 -1.09 1 12 0.23 K.LYGSGDKLITVGSSK.Y 
3932 600 – 614 762.9166 1523.8186 1523.8195 -0.62 1 35 0.011 K.LYGSGDKLITVGSSK.Y 
3934 600 – 614 508.947 1523.8191 1523.8195 -0.3 1 14 0.34 K.LYGSGDKLITVGSSK.Y 
3935 600 – 614 762.917 1523.8194 1523.8195 -0.056 1 9 0.22 K.LYGSGDKLITVGSSK.Y 
3936 600 – 614 508.9471 1523.8196 1523.8195 0.056 1 32 0.0078 K.LYGSGDKLITVGSSK.Y 
3937 600 – 614 508.9472 1523.8197 1523.8195 0.11 1 54 0.00056 K.LYGSGDKLITVGSSK.Y 
3939 600 – 614 762.9177 1523.8209 1523.8195 0.9 1 82 0.00000085 K.LYGSGDKLITVGSSK.Y 
5078 615 – 635 749.7138 2246.1196 2246.1192 0.16 0 5 1.2 K.YLQSFTPSPGARPQVNGQSGR.I 
5081 615 – 635 750.0419 2247.1038 2246.1192 438 0 10 0.77 K.YLQSFTPSPGARPQVNGQSGR.I 
5083 615 – 635 750.0428 2247.1067 2246.1192 440 0 7 1.1 K.YLQSFTPSPGARPQVNGQSGR.I 
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3530 663 – 675 699.854 1397.6935 1397.6939 -0.34 1 28 0.019 R.ASFFRGESIGIQS.- 
3531 663 – 675 699.8549 1397.6952 1397.6939 0.89 1 31 0.0075 R.ASFFRGESIGIQS.- 
3532 663 – 675 699.8553 1397.6961 1397.6939 1.59 1 62 0.000019 
R.ASFFRGESIGIQS.- 
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Table 18. Details of Avian HA-RBD V3.4 Peptides Matched to Observed Spectra.  
In red are shown the calculated peptides from (Table 14) which comprised a partial 
coverage of 45% from the total Avian HA-RBD V3.4 protein sequence.  
 
1 SVKGGFILKD CSVAGWLLGN PMCDEFLTAP EWSYIVEKDN PSNDLCYPGN 
51 FDNYEELKHL MSSTNHMERI QIFPRNSWTN HNASAGVSSA CPFNGGSSFF 
101 RNVVWLIKKN DVYRTLKRNY TNTNVEDLLI IWGVHHPNDA TEQTKLYQNL 
151 NTYVSVGTST LNQRSTPTIA TRPQVNGQRG RMEFFWTILK SNDSIFFEST 
201 GNFIAPEYAY KIVKKGKSTV MKSGGGGSGG GGSPLILKDC SVAGWLLGNP 
251 MCDEFLNVQE WSYIVEKDNP SNDLCYPGNF DNYEELKHLM SSTNHLERIQ 
301 IFPRNSWPNH DSSSGVSSAC PFNGESSFFR NVVWLIKKND VYRTLKRNYT 
351 NTNVEDLLII WGVHHPNDAT VQTKLYQNLN TYVSVGTSTL NQRSIPTIAT 
401 RPQVNGQRGR VEFFWTILES NDSIFFESTG NFIAPEYAYK VTKKGKSAVM 
451 KSGGGGSGGG GSPTDLGQCG LLGTLIGPPQ CDQFLKFDAD LIIERREGTD 
501 VCYPGKFTNE ESLRQILRRS GGIDKESMGF TYSGIRTNGT TSACRRSNPS 
551 FYAEMKWLLS NSDNATFPQM TKSYRNPRNK PALITWGVHH SGSATEQTKL 
601 YGSGDKLITV GSSKYLQSFT PSPGARPQVN GQSGRIDFHW LLLDPNDTVT 
651 FTFNGAFIAP DRASFFRGES IGIQS   
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Figure 21. Protein purification of Avian HA-RBD V3.4 by size exclusion chromatography. The characterization of 
the eluted fractions following separation on DEAE Anion exchange chromatography.  The sample fractions were pooled 
and concentrated to 1.6 ml using a 30 MWCO ultrafiltration device (Centricon) and then loaded by injection onto an AKTA 
system fitted with a Superdex 75 pq Hi Load 16-200 (10,000-600,000 MW) size exclusion column.  Fractions were eluted 
using PBS, pH 7.4 as the isocratic mobile phase and buffer exchange solution. Arrow in A) indicates the protein peak 
fractions selected  (A8,A9,A10) for Mass-Spec Analysis and N-terminal sequencing as observed in B), after SDS-PAGE 
analysis (orange box).  
 
135 KDa 
100 KDa 
75    KDa 
A8 A9 A10 A11 
A B 
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Table 19. Calculated peptide sequences positively identified by Mass-Spectroscopic analysis from the Avian HA 
RBD V3.4 Clone 1.1. As in Table 15, the calculated peptide sequences were determined using a combination of the high 
score values and the lowest expect value to indicate more confidence in the match analysis. The sample was purified by 
DEAE Anion Exchange chromatography followed by Size exclusion chromatography and SDS-PAGE and the protein gel 
slice isolated and characterized by mass spectroscopy. 
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Figure 22. Details of Avian HA-RBD V3.4 Peptides Matched to Observed Spectra.  
In A), Highlighted in bold, are shown the calculated peptides from the MASCOT spectra 
analysis observed in B), and from Table 16, which comprised 29% of partial coverage 
from the total Avian HA RBD V3.4 protein sequence.  The arrow indicates the spectra 
result in a major peak for which it was not possible to identify the type of chemistry by 
the method applied for that particular signal. 
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101 RNVVWLIKKN DVYRTLKRNY TNTNVEDLLI IWGVHHPNDA TEQTKLYQNL 
151 NTYVSVGTST LNQRSTPTIA TRPQVNGQRG RMEFFWTILK SNDSIFFEST 
201 GNFIAPEYAY KIVKKGKSTV MKSGGGGSGG GGSPLILKDC SVAGWLLGNP 
251 MCDEFLNVQE WSYIVEKDNP SNDLCYPGNF DNYEELKHLM SSTNHLERIQ 
301 IFPRNSWPNH DSSSGVSSAC PFNGESSFFR NVVWLIKKND VYRTLKRNYT 
351 NTNVEDLLII WGVHHPNDAT VQTKLYQNLN TYVSVGTSTL NQRSIPTIAT 
401 RPQVNGQRGR VEFFWTILES NDSIFFESTG NFIAPEYAYK VTKKGKSAVM 
451 KSGGGGSGGG GSPTDLGQCG LLGTLIGPPQ CDQFLKFDAD LIIERREGTD 
501 VCYPGKFTNE ESLRQILRRS GGIDKESMGF TYSGIRTNGT TSACRRSNPS 
551 FYAEMKWLLS NSDNATFPQM TKSYRNPRNK PALITWGVHH SGSATEQTKL 
601 YGSGDKLITV GSSKYLQSFT PSPGARPQVN GQSGRIDFHW LLLDPNDTVT 
651 FTFNGAFIAP DRASFFRGES IGIQS   
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101 
 
3.5. Immunoblot and N-terminal sequencing analysis fail to identify Avian HA 
RBD HA3.4 from positive MASS-Spectroscopy samples isolated by Anion 
exchange and Size exclusion chromatography. 
  
Immunodetection analysis using ferret polyclonals raised against AIV H7N2, AIV 
H5N1 failed to detect the purified protein at the expected molecular size (~72KDa-
100KDa). A positive signal was observed for the sample purified by Anion 
Chromatography between 180 KDa and 245 KDa of the molecular standard, suggesting 
a reactive band at a higher molecular weight under denaturing and reducing conditions 
(Figure 24, A Lane 6 and B Lane 6). On the other hand, the N-terminal analysis of the 
putative Avian RBD HA V3.4 protein identified derivatized amino acids with the 
sequence N-(E/A)-Y-V-P-Q-(E-I)-P (Table 18) that was in contrast with the expected 
sequence S-V-K-G-G-F-I-L. Single and clear peaks were not observed in the 
chromatogram results (Figure 21), as was expected from the sequence of the purified 
protein. 
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Table 20. N-Terminal sequencing analysis for the putative band identified by 
Mass-Spectroscopy as the Avian HA-RBD V3.3 derived from Clone 1.1. The 
analysis resulted in an derivatized N-Terminal Sequence: (E/A)-Y-V-P-Q-(E-I)-P which 
was not found in the expected protein sequence residues (SVKGGFIL).  
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Figure 23. N- Terminal Analysis of the putative Avian HA-RBD V3.4. Chromatograms of the Derivatized amino group 
obtained from Edman-degradation of the N-terminal peptide. These chromatograms did not result in clear derivatized 
peaks, indicating a mixed population of proteins (which complement the Mass Spectroscopy-Results) or multiple 
proteolyzed peptides. 
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Figure 24. Western Blot analysis of the putative Avian HA RBD V3.4 protein from multiple purification steps using 
in ferret polyclonal Antisera (1:7500 dilution) (anti-H5N2, anti-H7N3 strains) to Avian Influenza A virus. Lane 1, 
Blueye Protein Ladder; Lane 2, HA3.4 PBS 7.2 (AEX, Size Exclusion purified), Lane3, #1 AEX Elution fraction 150 mM 
(Amicon >10Kda) retentate; Lane 4, #4 AEX Elution fraction 150+200 mM (Amicon >10Kda) retentate; Lane 5, #5 AEX 
Elution fraction 150 mM (Amicon >10Kda) retentate; Lane 6, HA 3.4 PBS 7.2 (First Mass-Spec Sample); Lane 7, BSA (3 
ug); Lane 8 , Trivalent Sanofi Pasteur 2013 Vaccine; Lane 9, Blueye Ladder.  In B) Western Blot analysis of HA3.4 protein 
from purification steps using ferret pAbs Antisera (1:7500 dilution) (H5N2, H7N3 strains) to Avian Influenza A virus. Lane 
B1, Blueye Protein Ladder; Lane B2, HA3.4 PBS 7.2 (AEX, Size Exclusion purify), LaneB3, #1 AEX Elution fraction 150 
mM (Amicon >10Kda) retentate; Lane B4, #4 AEX Elution fraction 150+200 mM (Amicon >10Kda) retentate; Lane B5, #5 
AEX Elution fraction 150 mM (Amicon >10Kda) retentate; LaneB 6, HA 3.4 PBS 7.2 (First Mass-Spec Sample); Lane B7, 
BSA (3 ug); Lane B8 , Trivalent Sanofi Pasteur 2013 Vaccine.  Samples were run in a SDS-PAGE 4%-7%  Semi-dry 
transferred to a PVDF membrane (25 V x 15 minutes). Secondary antibody Goat anti Ferret-HRP (1:10,000) as the 
detection reagent and Ultra-1-step-TMB solution as substrate. Black arrows indicate the position of the putative Avian HA 
RBD V3.4 protein in the membrane, blue arrows indicate reactive signals as in A2, A5, A6,A8, B6 and B8. 
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3.6. PCR mutagenesis and cloning of Influenza HA-RBD versions in the 
extracellular expression plasmid pPicZalpha-A and in the intracellular 
expression plasmid pPicZ-B, restore the open reading frame for c-Myc and  
6-HIS tags. 
 Cloned PCR mutated versions were generated for the Avian HA-RBD mut-E-
V3.4, and Avian HA-RBD mut-E-V3.6 versions (Figure 25),. Human HA-RBD mut-E-
V3.3 was cloned in the extracelullar expression vector pPicZalpha-A only. The 
enzymatic ligation of each of the PCR XhoI /XbaI digested product was re-confirmed 
following restriction of the plasmid preparations obtained from transformed individual E. 
coli clone cultures with the same enzymes (Figure 26, Figure 27). Only Avian HA-RBD 
mut-E-V3.4 and Avian HA-RBD mut-E-V3.6 were fully sequenced and the results 
confirmed the correct removal of the premature Stop codon, and that the open-reading 
frame extended to include the C-Myc and 6-Histitdine tags contained in the pPicZalpha-
A plasmid. The expected nucleotide sequences corresponding to the codon optimized 
multimeric avian genes were also confirmed (Figure 28). The consensus result 
represented the alignment of three plasmid preparation clones that were individually 
assembled from their sequencing results.  
On the other hand, the PCR mutated version for only the Avian HA-RBD mut-I-
V3.4, Avian HA-RBD mut-I-V3.6 and Human HA-RBD mut-I-V3.3 (Figure 26, Figure 
27) were amplified, enzymatic digested and cloned in the intracellular (I) expression 
vector pPicZ-B. The incorporation fo the  PCR XhoI /XbaI digested product into the 
plasmids were re-confirmed by applying enzymatic restriction of the plasmid 
preparations obtained from individual E. coli clones cultures with the same enzymes. 
Only pPicZB- Avian HA-RBD mut-I-V3.4 and pPicZB-Avian HA-RBD mut-I-V3.6 were 
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fully sequenced. The results confirmed the correct removal of the premature Stop codon 
at the 3’ end of the gene and that the open-reading frame extended to include the C-
Myc and 6-Histitdine tags contained in the pPicZ-B plasmid. The expected nucleotide 
sequences corresponding tof the codon optimized multimeric avian genes and the 
correct addition of the Kozak consensus sequences for translation initiation were also 
confirmed (Figure 29). 
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Figure 25. General cloning strategy for 6-His Tagged Avian and Human HA RBD 
mutated version. 1) A plasmid template pPicZalphaA-containing the Avian or 
Human HA-RBD version is used for PCR amplification. The PCR products and 
empty expression vector ((extracellular goes 2a), (intracellular goes 2b)) are restricted 
with specific endonucleases and their product ligated. In 3a) or 3b) Plasmid preps from 
transformed E coli cells are analyzed for the correct insertion then sequencing using 
specific primers to corroborate the mutated HA RBD versions. Plasmid from positives 
clones were amplified and used for transformation in Pichia pastoris X-33 
electrocompetent cells.  
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Figure 26. Restriction analysis of Avian HA-RBD mutV3.4 (A) and Avian HA-RBD 
mutV3.6 (B)  and Avian HA-RBD mutV3.7 (C) using XhoI and XbaI endonucleases. 
In A, lanes (2-6) and lanes (8-12) show individual plasmid preparations (Top10 E coli 
clones) confirming that the genes were ligated into the plasmid backbone and 
transformed into E. coli.  The ligation product of pPicZalpha and the Avian HA-RBD 
mut3.4 PCR XhoI/XbaI digested product and the product of pPicZB and the Avian HA-
RBD mutHA3.4 PCR Xho/Xba digested product, were analyzed, respectively. In B,  the 
same analysis was performed for the HA 3.6 (2.1 kB) gene (four clones, Lane 2-5) 
ligated into pPicZalphaA (3.3 kB) vector and the HA 3.6 (2.1Kb) gene (four clones, 
lanes 8 -11), ligated into the vector pPicZB (3.0 kb). All clones were positive for the HA 
RBD fragments. In C, restriction analysis was used to confirm the ligation of the Avian 
HA-RBD mutV3.7 into the intracellular expression plasmid pPicZB , one plasmid prep 
(Lane 1-3)  from three clones was positive for the analysis. 
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Figure 27. Restriction analysis of the gene Human HA-RBD mutV3.3 using XhoI 
and XbaI endonucleases (A), and its PCR amplification from the Human HA RBD 
V3.3 unmodified version integrated  in Pichia pastoris genome (B). In A, Three 
(Lane 3-5) of four individual plasmids preps (Top10 E coli clones) confirming the gene 
ligation that were transformed with the ligation reaction of pPicZalpha + Avian HA-RBD 
mut3.3 PCR XhoI/XbaI digested product and in (lanes 7-9) one of three clones was 
positive for the ligation reaction pPicZB + Avian HA-RBD mutHA3.3 PCR Xho/Xba 
digested product, respectively. In B, Lane 2-4, PCR amplification (A) of the gene Human 
HA-RBD mutV3.3 (2.1 Kb),  from the Pichia genome tranformed with the unmodified 
version of the gene (clone D7)  for extracellular expression using specific primers and 
with two genomic DNA extraction methods applied, lanes 6-8. DNA Ladder standard are 
observed in lanes A1, A6, B1 and B5.  
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Figure 28. Sequencing result for the extracellular Avian HA-RBD mutV3.4 cloned 
in pPicZalphaA, showing the added features. There was no observed premature 
Stop codon which allowed the Avian HA-RBD mutV3.4 to be expressed in-frame with 
the c-myc and 6-His tags as indicated by the arrows which differed from the original 
Avian version. Identical sequencing results were obtained for the three different E. coli 
clones harboring the enzymatically confirmed multimeric gene. Below, there is a 
diagram showing the ORF features.  Similar results applied to the Avian Extracellular 
and Intracellular HA-RBD mutV3.6 gene. 
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Figure 29. Sequencing result for the Avian HA-RBD mutV3.4 cloned into pPicZB, 
showing the added features. The sequence shows the Kozak consensus sequences, 
followed by the ATG start codon, and the 5’ portion of the multimeric Avian gene. 
Sequencing results of the plasmids purified from three different E. coli clones harboring 
the enzymatic confirmed gene showed identical results. Similar results applied for the 
Avian Intracellular HA-RBD mutV3.6 gene. 
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3.7. Pichia pastoris transformed with the Human and Avian His-Tagged HA 
RBD extracellular versions, express highly and heterogenous N-
glycosylated polypeptides recognized by ferret anti-sera to influenza, but 
lack of fuctional hemagglutination.  
  
The mutated versions of the Avian and Human RBD generated by PCR and 
integrated into pPicZalphaA (Avian HA RBD mutV3.4, Avian HA RBD mutV3.6, Human 
HA RBD mutV3.3) and pPicZB (Avian HA RBD mutV3.4, Avian HA RBD mutV3.6 and 
Human HA RBD mutV3.3) were transformed in Pichia pastoris X-33. Zeocin 
hyperresistant clones for all the versions were selected. Methanol-induced protein 
expression by the Zeocin hyperresistance clones was performed for the extracellular 
secreted versions pPicZalphaA-Avian HA RBD mutV3.4,  pPicZalphaA-Avian HA RBD 
mutV3.6, and pPicZalphaA-Human HA RBD mutV3.3; and for the pPicZB-Avian HA 
RBD mutV3.4 intracellular version. Only the three extracellular versions were able to 
generate detectable levels of protein expression in the supernatant of cultures treated 
with methanol for 48 h when recovered by Ni-NTA agarose chromatography (Figure 
30). The recovered molecules were detected using a mouse anti-6Histidine-HRP 
monoclonal antibody in immunoblot analysis (Figure 31). The protein yield range from 
140 µg/L for the Human HA RBD mutV3.3, 22µg/L for the Avian HA RBD mutV3.4, and 
67.2 µg/L for the Avian HA RBD mutV3.6  transformed yeast (Figure 30D). 
Coomasie blue staining of SDS-PAGE, under reducing conditions (Figure 29), 
and anti-Histidine monoclonal antibody immunoblot analysis for the two Avian versions, 
HA RBD mutV3.4,  and HA RBD mutV3.6, detected a high molecular weight protein 
band  between 135-235KDa. These observed bands differ from the expected (~79 KDa) 
calculated sequences. Furthermore, enzymatic deglycosylation assays performed on 
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these two avian version, demonstrate that the recovered proteins are highly N-
glycosylated.  Deglycosylation produces de-glycosylated protein bands in the range of 
77KDa and 16KDa as detected by Anti-His antibody.  Based on extrapolation of  their 
relative mobility values (Figure 32, Table 19), structural models were generated based 
on the de-glycosylated results (Figure 34) that suggest a full-size glycosylated Avian 
HA RBD mutV3.4  and Avian HA RBD mutV3.6 (V3.4 core)(Figure 35)  
In the case of the Human HA RBD mutV3.3 immunoblot analysis using Anti-6 
histidine monoclonal antibodies, detected a protein smear on SDS-PAGE analysis 
(Figure 31). Enzymatic deglycosylation using the EndoHf enzyme followed by Anti-His 
monoclonal immonoblot detection for this protein, produced mostly a low molecular ~35 
KDa peptide (Figure 231) (Table 19) suggesting a heterogeneous N-glycosylated and 
mostly truncated Human HA RBD V.3.3 protein form (Figure 36) based on cleavage 
site analysis. 
Contrary to the extracellular strategy, no protein expression was detected for the 
intracellular Avian HA RDB mutV3.4 strategy tested to date. 
Antibody characterization using ferret antisera to the influenza virus resulted in 
the detection of the Avian HA-RBD mutV3.4 by the ferret immunized antisera: H5 
subtyping (FR-229), H5 subtyping (FR-231:ferret anti-sera to Influenza 
A/Duck/Hunan/795/2002(H5N1)) and H7 subtyping (FR-1088: ferret anti-sera to 
Influenza A/Turkey/Virginia/2002 (H7N2)/PR8/BCDC-5 (Figure 33A). Avian HA-RBD 
mutV3.6 samples was recognized by H5 subtyping (FR-231:ferret anti-sera to influenza 
A/Duck/Hunan/795/2002(H5N1, slightly recognized by H7 subtyping (FR-1088 :ferret 
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anti-sera to Influenza A/Turkey/Virginia/2002 (H7N2) /PR8/BCDC-5) (Figure 33B). The 
Human HA-RBD mutV3.3 was recognized by influenza B subtyping FR-1080 (ferret 
anti-sera to B influenza virus B/Texas/06/2011) but was not recognized by H1 subtyping 
(FR-359: ferret anti-sera to influenza A virus A/Cal/07/2009 H1N1 pdm09) or H3 
subtyping (FR-1000 (WHO Supplemental Antiserum, influenza A(H3N2)v reference 
ferret antiserum) (Figure 33C) adding evidence to protein truncation and only detection 
to the B type subunit. 
 
Hemmaglutination assays fail to detect functional activity for the HA-RBD 
mutV3.3, HA-RBD mutV3.4, HA-RBD mutV3.6 proteins, but were positive to 
hemmaglutination, the samples Trivalent Vaccine Fluviral (2015-2016), Hemagglutnin 
Inhibition HA positive control, used to validate the assay. 
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Figure 30. SDS-PAGE analysis for expression of the Avian and Human HA-RBD 
versions. After 48 h of methanol induction for protein expression under the control 0f 
the promoter AOX1, cultures were harvested and purified using Ni-NTA agarose beads. 
In A, in lanes 2-5, elution profile (first to fourth in Elution Buffer (250 mM imidazole in 
phosphate Buffer, pH 8.0) of clone E1 for Avian HA-RBD mutV3.4; lanes 6-9 elution 
profile (first to fourth elution in Elution Buffer) of clone E2 for the Avian HA-RBD 
mutV3.4. In B, in lanes 2-4, elution profile (first to third elution in Elution Buffer) of clone 
E1 for the Avian HA-RBD mutV3.6; lanes 5-7 elution profile (first to third elution in 
Elution Buffer) of clone E2 for the Avian HA-RBD mutV3.6; lanes 8-10, elution profile 
(first to third elution in Elution Buffer) of clone E3 for the Avian HA-RBD mutV3.6. In C, 
Human Versions HA RBD mutV3.3 for three clones E1 (lane2-4), E2 (lane 5-7), E3 
(lane 8-10), with their three elution samples, respectively. Clones E2 from Avian HA-
RBD mutV3.4, clone E2 from Avian HA-RBD mutV3.6, and Clone E3 from Human HA-
RBD mutV3.3, were selected for further protein analysis. In D, RBD-HA mutV3.3, RBD-
HA mutV3.6, RBD-HA mutV3.7 quantified after Ni-NTA protein recovery and determined 
by the BCA method for after IMAC purification, ultrafiltration, desalted and corrected for 
final volumen in PBS, pH 7.4.   
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Figure 31. Immunodetection of the selected clones for the Avian and Human His-
Tag HA-RBD mutVersions. Samples were purified by IMAC and immune-detected with 
mouse Anti-6His-HRP monoclonal antibody. In lane 2, Human HA RBD mutV3.3 
produced a highly heterogeneous molecular size smear, in lane 3, Avian HA RBD 
mutV3.4 and lane 4,Avian HA RBD mutV3.6 are immunodetected as high molecular 
size recovered proteins between 135 KDa and 245 KDa. In lane 5, Vhh nanobody as a 
positive control for 6-Histidine tag detection. 
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Figure 32. Deglycosylation enzymatic assays on Avian and Human RBD 
mutVersions. Avian HA-RBD mutV3.4 and Avian HA-RBD mutV3.6 were treated with 
EndoHf  or EndoH glycosidase generating a discrete and sharp band with a molecular 
size ~75 KDa, which is close to the expected ~80 KDa molecular weight of their protein 
sequences, thus indicating a highly N-Glycosylated Avian glycoproteins (HA3.4(-) and 
HA3.6(-)). The Human HA RBD mutV3.3 is highly N-glycosylated, with heterogeneous 
glycoforms reduced to mostly a single discrete, sharp, and truncated ~35KDa molecular 
weight band after Endoglycosidase treatment, as calculated in Table 18.  
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Table 21. Molecular weight determination by SDS-PAGE for the Avian and Human 
Glycosylated and Deglycosylated forms. In A, Blueye protein standard for Molecular 
weight determination from Relative mobility (Rf). In B, Calculated Molecular weight for 
the discrete band observed in the Figure 30. (*) Indicates the most conspicuous 
immunodetected band after deglycosylation treatment. 
 
 Total distance (mm) 54         
 
Protein  Standard,  
Blueye Ladder (KDa)  
log 
MW Rf      
 245 2  2.3892 0.03704      
 180 3.5  2.2553 0.06481      
 135 5.5  2.1303 0.10185      
 100 9  2 0.16667      
 75 13  1.8751 0.24074      
 63 17.5  1.7993 0.32407      
 48 23.5  1.6812 0.43519      
 35 32.5  1.5441 0.60185      
 25 42.5  1.3979 0.78704      
 20 47  1.301 0.87037      
 
17 51.5  1.2304 0.9537      
  
D 
(mm)   Rf  y Linear Regression 10(Y)=MW 
Y linear 
regression M.W (KDa) 
  HA3.3 endoHf 11.5   0.21296  2.012191 102.8468513 1.943376 87.776043 
  HA3.3 endoHf 22   0.40741  1.792629 62.03388777 1.751502 56.428954 
  HA3.3 endoHf 33.5   0.62037  1.552155 35.65783738 1.541353 34.781876* 
  HA3.4 endoHf 15   0.27778  1.939003 86.89664319 1.879418 75.756168* 
  HA3.4 endoHf 22   0.40741  1.792629 62.03388777 1.751502 56.428954 
  HA3.4 endoHf 26.5   0.49074  1.69853 49.94936828 1.669269 46.694852 
  HA3.4 endoHf 34.5   0.63889  1.531244 33.98161381 1.523079 33.348707 
  HA3.4 endoHf 35   0.64815  1.520789 33.17332473 1.513942 32.654422 
  HA3.4 endoHf 38.5   0.71296  1.447601 28.02857381 1.449983 28.182726 
  HA3.4 endoHf 51   0.94444  1.186217 15.35383963 1.221561 16.655628 
  HA3.6 endoHf 14.5   0.26852  1.949459 89.01413994 1.888554 77.366687* 
  HA3.6 endoHf 21.5   0.39815  1.803084 63.54538276 1.760638 57.628591 
  HA3.6 endoHf 26   0.48148  1.708986 51.16653411 1.678407 47.687768 
  HA3.6 endoHf 34   0.62963  1.541699 34.80959737 1.532215 34.057675 
  HA3.6 endoHf 34.5   0.63889  1.531244 33.98161381 1.523079 33.348707 
  HA3.6 endoHf 38   0.7037  1.458056 28.71150778 1.45912 28.781936 
  HA3.6 endoHf 50.5   0.93519  1.196672 15.72794566 1.230698 17.009753 
  
HA3.4 Negative 
EndoHf 4   0.07407  2.169022 147.578129 2.08043 120.34554* 
  
A 
B 
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Figure 33. WES analysis for ferret anti-influenza polyclonal characterization of the 
glycosylated Avian and Human HA-RBD multimeric genes, purified by IMAC. In A, 
Avian HA-RBD mutV3.4 transformed yeast expressed protein with high molecular sizes 
of ~230 KDa which were weakly recognized by the antisera directed against FR-229 
(H5 subtype). The FR-231 (Ferret anti-sera to Influenza A/Duck/Hunan/795/2002 
(H5N1)) antisera recognized two bands of 230KDa and ~116KDa. The FR-1088 (Ferret 
anti-sera to Influenza A/Turkey/Virginia/2002 (H7N2)/PR8/BCDC-5) reacted strongly 
with a 165KDa band. In B, Avian HA-RBD mutV3.6 samples were not detected by the 
FR-229 (H5 subtype) antisera, but were recognized by the FR-231 (ferret anti-sera to 
influenza A/Duck/Hunan/795/2002(H5N1)) antisera, with one high molecular size band 
at 230 KDa,  and were weakly recognized by the FR-1088 (ferret anti-sera to influenza 
A/Turkey/Virginia/2002 (H7N2) /PR8/BCDC-5) antisera. In C, the Human HA-RBD 
mutV3.3 expressed proteins were recognized by FR-1080 (ferret anti-sera to B 
Influenza virus  B/Texas/06/2011) antisera with a molecular size of 239 KDa, but was 
not recognized by the FR-359 (ferret anti-sera to Influenza A virus  A/Cal/07/2009 H1N1 
pdm09) or FR-1000 (WHO Supplemental Antiserum, Influenza A(H3N2)v Reference 
Ferret Antiserum) antisera. All samples were compared to a non-immune FR-282 (ferret 
negative Control sera) antiserum in A, B and C analysis. 
 
 
122 
 
 
 
Figure 34. Structural model of the Avian HA-RBD mutV3.4. The PDB file for this 
multimeric protein sequence was generated by the Phyre2 server  (72). RBD1 subunit 
fail  to generate a folded structure for the whole multimeric model, therefore, the two 
remaining regions RBD2 and RBD3 were superimposed to the determined crystal 
structure maps of the Hemagglutinin H5 (in green) of the virus 
A/duck/Egypt/10185SS/2010 (H5N1) (PDB file 5E2Y) (79) and the Hemmaglutinin H7 of 
the virus  A/Anhui/1/2013 (PDB file 4R8W) (80). The graphs were generated using 
Chimera UCSF software, crystal structure PDB file retrieved from the RCSB Protein 
Data Bank website.  In A, Avian HA RBD V2.4 (top view). In B, same as A (lateral view). 
In C (top view) and D (lateral view), Avian HA-RBD V3.4 model superimposed to crystal 
structure 5E2Y(H5 hemagglutinin)  and 4R8W (H7 hemagglutinin). 
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Figure 35. In silico N-glycosylation modelling for the Avian HA-RBD mutV3.4. The 
Avian HA-RBD mutV3.4 PDF file obtained from Phyre2 server  (72) were modelled in 
the GlyProt server to calculate the geometric permitted N-Glycosylation sites. A total of 
7 potential and geometrically permitted glycosylation motifs were detected and in-silico 
constructed under a “very large carbohydrate branch” assumption. 
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Figure 36. In silico N-glycosylation modelling for the truncated Human HA-RBD 
mutV3.3 showing different levels of N-glycosylation synthesis and its effect on 
protein heterogeneity. N-Glycosylation profile were generated with GlyProt Server, 
using the PDB files generated by Phyre2 server (72). In A, basic N-Glycosylation 
modelling profile showing the complete RBD3 subunit comprising the Influenza B RBD 
region, and also showing the human RBD2 subunit partially proteolysis. In B, low 
mannose N-glycosylation model, corresponding a moderate glycosylated form as seen 
in sequence in D. In C, a very large N-glycosylated protein form that correspond to its 
highly glycosylated protein in figure D. In D, protein heterogeinty of N-glycosylated 
forms, in lane 1, blueye protein ladder; lane 2, Human HA RBD mutV3.3, showing 
discrete forms of glycosylations; lane 3, Avian HA RBD mutV3.4 showing its higly 
glycosylated form, corresponding to the hypothetical glcyo-form in C. In E, Avian HA-
RBD sequences used for the structural model, and the five N-glycosylation sites 
geometrically permitted for the in-silico modelling. 
A B C 
D E 
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Figure 37.  Hemagglination assays in RBC guinea pig erythrocytes with the HA-RBD recombinant proteins. Red 
blood cells where incubated for 30 min. with serial dilutions of HA RBD proteins and their hemagglutination were 
evaluated qualitatively, observing a lack of functional (round botton in the well) hemagglutination propierties. Positive 
control (diffused cells across the well forming a homogenous sieve) comprising the Inlfuenza vaccine Fluviral and 
Influenza A control antigen FR-187, were used to compare results.
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3.8. Human HA-RBD mutV3.3 peptide truncation is explained by a predicted 
internal pro-peptide cleavage site. 
 
One internal protease cleavage signal for Human HA RBD mutV3.3 is predicted 
by ProP v1.0 software (Table 21), and is expected to result in a peptide with a similar 
calculated molecular weight of ~36KDa (Table 22) when compared to the observed 
deglycosylated peptide  with a molecular weight of ~35 Kda. On the other hand, no 
predicted internal protease signal is observed within the peptide sequence of the Avian 
HA RBD mutated V3.7 (Table 23).    
 The effect of amino acid substitution within the predicted sequence was 
determined using ProP v1.0 (Table 24). Substitutions present in nine of twelve 
sequences scored numbers below the predicted threshold value of the wildtype 
sequence. Four of these nine sequences, Mut6 (K/A), Mut7 (R/A), Mut10 (K/R), Mut12 
(K/R)/(R/K) scored the lowest values with the dibasic Kex2 cleavage site (KR) involved. 
When alanine-scanning mutagenesis is used, the lowest values correspond to Mut6 
(K/A)(0.063) and Mut7 (R/A)(0.059). Alternatively, basic substitution in Mut10 
(K/R)(0.140), or the double basic mutant Mut12 (K/R)/(R/K)(0.100) are predicted to have 
an negative effect in cleavage site recognition. 
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Table 22. Protease-cleavage site predicted for the Human HA-RBD mutV3.3. The peptide sequence was analyzed 
using the propeptide cleavage site software tool ProP 1.0 server. Two predicted sites were detected above the threshold, 
the first (in green) correspond to to the signal peptide (Kex2) sequence endogenous to the post-translational processing 
signals designed in the Pichia pastoris expression system, and the second site (highlighted in red) corresponded to an 
internal signal peptide at the position (410) above the threshold value of the amino acid input sequence that is consistent 
with the experimental result for the de-glycosylation assays observed for the truncated HA RBD mutV3.3 (MW ~35KDa) 
peptide (Figure 32).  
ProP v.1.0b ProPeptide Cleavage Site Prediction  
General PC cleavage site prediction (Arginine/Lysine residues)  
 
  Human HA RBD mutV3.3 Sequence     
TIASIAAKEEGVSLEKRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSDNGTCYPGDFIDYEELREQLSSVS      80 
SFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQ     160 
SLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISD     240 
GGGGSGGGGSGEICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTL     320 
EFNNESFNWTGVTQNGTSSACIRRSNNSFFSRLNWLHRLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTDKEQIFLYAQS     400 
SGRITVSTKRSQQAVIPNIGSRPRIRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGGGG     480 
SGGGGSGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYENIRL     560 
STQNVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVWGFHSDNKTQ     640 
MKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRS     720 
KVIKGLEQKLISEEDLNHHHHHH                                                              800 
................P...............................................................      80 
................................................................................     160 
................................................................................     240 
................................................................................     320 
................................................................................     400 
.........P......................................................................     480 
................................................................................     560 
................................................................................     640 
................................................................................     720 
.......................                                                              800 
  
Propeptide cleavage sites predicted: Arg(R)/Lys(K): 2 
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Name           Pos    Context     Score  Pred 
____________________________v_________________ 
Sequence         8    IASIAAK|EE  0.071    . 
Sequence        16    EGVSLEK|RG  0.087    . 
Sequence        17    GVSLEKR|GV  0.952 *ProP* 
Sequence        26    APLHLGK|CN  0.074    . 
Sequence        73    IDYEELR|EQ  0.044    . 
Sequence        84    SVSSFER|FE  0.215    . 
Sequence        90    RFEIFPK|TS  0.097    . 
Sequence       101    PNHDSNK|GV  0.092    . 
Sequence       113    CPHAGAK|SF  0.080    . 
Sequence       117    GAKSFYK|NL  0.093    . 
Sequence       124    NLIWLVK|KG  0.075    . 
Sequence       125    LIWLVKK|GN  0.138    . 
Sequence       131    KGNSYPK|LS  0.078    . 
Sequence       134    SYPKLSK|SY  0.066    . 
Sequence       140    KSYINDK|GK  0.058    . 
Sequence       142    YINDKGK|EV  0.064    . 
Sequence       176    VFVGSSR|YS  0.074    . 
Sequence       179    GSSRYSK|KF  0.048    . 
Sequence       180    SSRYSKK|FK  0.271    . 
Sequence       182    RYSKKFK|PE  0.061    . 
Sequence       188    KPEIAIR|PK  0.034    . 
Sequence       190    EIAIRPK|VR  0.084    . 
Sequence       192    AIRPKVR|DQ  0.125    . 
Sequence       197    VRDQEGR|MN  0.060    . 
Sequence       210    LVEPGDK|IT  0.065    . 
Sequence       223    GNLVVPR|YA  0.048    . 
Sequence       230    YAFAMER|NA  0.083    . 
Sequence       284    CDGFQNK|KW  0.071    . 
Sequence       285    DGFQNKK|WD  0.048    . 
Sequence       292    WDLFVER|SK  0.199    . 
Sequence       294    LFVERSK|AY  0.101    . 
Sequence       311    PDYASLR|SL  0.033    . 
Sequence       343    TSSACIR|RS  0.036    . 
Sequence       344    SSACIRR|SN  0.370    . 
Sequence       352    NNSFFSR|LN  0.040    . 
Sequence       358    RLNWLHR|LN  0.048    . 
Sequence       362    LHRLNFK|YP  0.084    . 
Sequence       378    NNEQFDK|LY  0.071    . 
Sequence       391    HHPGTDK|EQ  0.089    . 
Sequence       403    YAQSSGR|IT  0.278    . 
Sequence       409    RITVSTK|RS  0.066    . 
Sequence       410    ITVSTKR|SQ  0.527 *ProP* 
Sequence       422    IPNIGSR|PR  0.035    . 
Sequence       424    NIGSRPR|IR  0.066    . 
Sequence       426    GSRPRIR|NI  0.262    . 
Sequence       431    IRNIPSR|IS  0.053    . 
Sequence       440    IYWTIVK|PG  0.064    . 
Sequence       457    GNLIAPR|GY  0.049    . 
Sequence       461    APRGYFK|IR  0.069    . 
Sequence       463    RGYFKIR|SG  0.031    . 
Sequence       466    FKIRSGK|SS  0.049    . 
Sequence       471    GKSSIMR|SD  0.110    . 
Sequence       489    GGGSGTR|TR  0.269    . 
Sequence       491    GSGTRTR|GK  0.176    . 
Sequence       493    GTRTRGK|LC  0.080    . 
Sequence       510    LDVALGR|PM  0.033    . 
Sequence       521    GTTPSAK|AS  0.055    . 
Sequence       529    SILHEVR|PV  0.035    . 
Sequence       542    FPIMHDR|TK  0.032    . 
Sequence       544    IMHDRTK|IR  0.100    . 
Sequence       546    HDRTKIR|QL  0.040    . 
Sequence       553    QLPNLLR|GY  0.041    . 
Sequence       559    RGYENIR|LS  0.041    . 
Sequence       570    NVIDAEK|AP  0.110    . 
Sequence       577    APGGPYR|LG  0.049    . 
Sequence       590    CPNATSK|IG  0.072    . 
Sequence       603    MAWAVPK|DN  0.075    . 
Sequence       607    VPKDNYK|NA  0.094    . 
Sequence       638    GFHSDNK|TQ  0.143    . 
Sequence       642    DNKTQMK|SL  0.088    . 
Sequence       652    GDSNPQK|FT  0.074    . 
Sequence       685    GLPQSGR|IV  0.142    . 
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Sequence       694    VDYMMQK|PG  0.080    . 
Sequence       697    MMQKPGK|TG  0.074    . 
Sequence       705    GTIVYQR|GV  0.035    . 
Sequence       712    GVLLPQK|VW  0.113    . 
Sequence       719    VWCASGR|SK  0.038    . 
Sequence       721    CASGRSK|VI  0.081    . 
Sequence       724    GRSKVIK|GL  0.069    . 
Sequence       729    IKGLEQK|LI  0.149    . 
____________________________^_________________ 
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Table 23. The predicted truncated peptide derived from Human HA-RBD mutV3.3 after an hypothetical cleavage 
site cut. The molecular weight of the predicted peptide (36.172 KDa) is highly similar to that observed after IMAC 
purification and deglycosylation assays performed over the expressed Human HA RBD mutV3.3 (~35KDa) protein in 
Pichia pastoris. Parameter was calculated using the Bioinformatic tool ExpasyCompute pI/MWserver.   
Compute pI/Mw 
Theoretical pI/Mw (average) for the user-entered sequence: 
        10         20         30         40         50         60  
SQQAVIPNIG SRPRIRNIPS RISIYWTIVK PGDILLINST GNLIAPRGYF KIRSGKSSIM  
 
        70         80         90        100        110        120  
RSDAPIGGGG SGGGGSGTRT RGKLCPDCLN CTDLDVALGR PMCVGTTPSA KASILHEVRP  
 
       130        140        150        160        170        180  
VTSGCFPIMH DRTKIRQLPN LLRGYENIRL STQNVIDAEK APGGPYRLGT SGSCPNATSK  
 
       190        200        210        220        230        240  
IGFFATMAWA VPKDNYKNAT NPLTVEVPYI CTEGEDQITV WGFHSDNKTQ MKSLYGDSNP  
 
       250        260        270        280        290        300  
QKFTSSANGV TTHYVSQIGD FPDQTEDGGL PQSGRIVVDY MMQKPGKTGT IVYQRGVLLP  
 
       310        320        330  
QKVWCASGRS KVIKGLEQKL ISEEDLNHHH HHH  
Theoretical pI/: 9.36 Mw /: 36172.18  
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Table 24. The protease cleavage site as calculated for the Avian HA-RBD mutV3.7 obtained from the ProP 1.0 
server. For comparison with the Human HA RBD mutV3.3, only the Pichia pastoris endogeneous Kex2 cleavage site 
(highlighted in green) is correctly predicted with a high probability value (0.975) within the Avian Ha RBD 3.7 peptide 
sequence. In the graph it is observed that there is a lack of additional internal cleavage sites above the threshold line for 
any of the calculated propeptide cleavage sites (PC, blue bars) beside the Kex2 signal peptide encoded by Pichia pastoris 
pPicZalphaA vector (In green). 
 
ProP v.1.0b ProPeptide Cleavage Site Prediction  
General PC cleavage site prediction (Arginine/Lysine residues) 
 
  Avian HA RBD mutV3.7 Sequence     
TIASIAAKEEGVSLEKRSVKGGFILKDCSVAGWLLGNPMCDEFLTAPEWSYIVEKDNPSNDLCYPGNFDNYEELKHLMSS      80 
TNHMERIQIFPRNSWTNHNASAGVSSACPFNGGSSFFRNVVWLIKKNDVYRTLKRNYTNTNVEDLLIIWGVHHPNDATEQ     160 
TKLYQNLNTYVSVGTSTLNQRSTPTIATRPQVNGQRGRMEFFWTILKSNDSIFFESTGNFIAPEYAYKIVKKGKSTVMKS     240 
GGGGSGGGGSPLILKDCSVAGWLLGNPMCDEFLNVQEWSYIVEKDNPSNDLCYPGNFDNYEELKHLMSSTNHLERIQIFP     320 
RNSWPNHDSSSGVSSACPFNGESSFFRNVVWLIKKNDVYRTLKRNYTNTNVEDLLIIWGVHHPNDATVQTKLYQNLNTYV     400 
SVGTSTLNQRSIPTIATRPQVNGQRGRVEFFWTIL ESNDSIFFESTGNFIAPEYAYKVTKKGKSAVMKSGGGGSGGGGSP     480 
TDLGQCGLLGTLIGPPQCDQFLKFDADLIIERREGTDVCYPGKFTNEESLRQILRRSGGIDKESMGFTYSGIRTNGTTSA     560 
CRRSNPSFYAEMKWLLSNSDNATFPQMTKSYRNPRNKPALITWGVHHSGSATEQTKLYGSGDKLITVGSSKYLQSFTPSP     640 
GARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESIGIQSKWCECRKKRRQRRRSLEQKLISEEDLNH     720 
HHHHH                                                                                800 
................P...............................................................      80 
................................................................................     160 
................................................................................     240 
................................................................................     320 
................................................................................     400 
................................................................................     480 
................................................................................     560 
................................................................................     640 
................................................................................     720 
.....                                                                                800 
  
Propeptide cleavage sites predicted: Arg(R)/Lys(K): 1 
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Name           Pos    Context     Score  Pred 
____________________________v_________________ 
Sequence         8    IASIAAK|EE  0.071    . 
Sequence        16    EGVSLEK|RS  0.081    . 
Sequence        17    GVSLEKR|SV  0.975 *ProP* 
Sequence        20    LEKRSVK|GG  0.082    . 
Sequence        26    KGGFILK|DC  0.096    . 
Sequence        55    WSYIVEK|DN  0.081    . 
Sequence        75    DNYEELK|HL  0.061    . 
Sequence        86    STNHMER|IQ  0.188    . 
Sequence        92    RIQIFPR|NS  0.030    . 
Sequence       118    GGSSFFR|NV  0.159    . 
Sequence       125    NVVWLIK|KN  0.066    . 
Sequence       126    VVWLIKK|ND  0.118    . 
Sequence       131    KKNDVYR|TL  0.064    . 
Sequence       134    DVYRTLK|RN  0.043    . 
Sequence       135    VYRTLKR|NY  0.048    . 
Sequence       162    DATEQTK|LY  0.068    . 
Sequence       181    TSTLNQR|ST  0.311    . 
Sequence       189    TPTIATR|PQ  0.034    . 
Sequence       196    PQVNGQR|GR  0.082    . 
Sequence       198    VNGQRGR|ME  0.066    . 
Sequence       207    FFWTILK|SN  0.143    . 
Sequence       228    APEYAYK|IV  0.064    . 
Sequence       231    YAYKIVK|KG  0.068    . 
Sequence       232    AYKIVKK|GK  0.073    . 
Sequence       234    KIVKKGK|ST  0.063    . 
Sequence       239    GKSTVMK|SG  0.062    . 
Sequence       255    GSPLILK|DC  0.092    . 
Sequence       284    WSYIVEK|DN  0.081    . 
Sequence       304    DNYEELK|HL  0.061    . 
Sequence       315    STNHLER|IQ  0.155    . 
Sequence       321    RIQIFPR|NS  0.033    . 
Sequence       347    GESSFFR|NV  0.124    . 
Sequence       354    NVVWLIK|KN  0.066    . 
Sequence       355    VVWLIKK|ND  0.118    . 
Sequence       360    KKNDVYR|TL  0.064    . 
Sequence       363    DVYRTLK|RN  0.043    . 
Sequence       364    VYRTLKR|NY  0.048    . 
Sequence       391    DATVQTK|LY  0.065    . 
Sequence       410    TSTLNQR|SI  0.297    . 
Sequence       418    IPTIATR|PQ  0.033    . 
Sequence       425    PQVNGQR|GR  0.091    . 
Sequence       427    VNGQRGR|VE  0.082    . 
Sequence       457    APEYAYK|VT  0.079    . 
Sequence       460    YAYKVTK|KG  0.060    . 
Sequence       461    AYKVTKK|GK  0.082    . 
Sequence       463    KVTKKGK|SA  0.064    . 
Sequence       468    GKSAVMK|SG  0.057    . 
Sequence       503    QCDQFLK|FD  0.061    . 
Sequence       512    ADLIIER|RE  0.066    . 
Sequence       513    DLIIERR|EG  0.047    . 
Sequence       523    DVCYPGK|FT  0.117    . 
Sequence       531    TNEESLR|QI  0.113    . 
Sequence       535    SLRQILR|RS  0.034    . 
Sequence       536    LRQILRR|SG  0.153    . 
Sequence       542    RSGGIDK|ES  0.073    . 
Sequence       553    FTYSGIR|TN  0.050    . 
Sequence       562    GTTSACR|RS  0.042    . 
Sequence       563    TTSACRR|SN  0.198    . 
Sequence       573    SFYAEMK|WL  0.059    . 
Sequence       589    TFPQMTK|SY  0.080    . 
Sequence       592    QMTKSYR|NP  0.044    . 
Sequence       595    KSYRNPR|NK  0.078    . 
Sequence       597    YRNPRNK|PA  0.069    . 
Sequence       616    SATEQTK|LY  0.089    . 
Sequence       623    LYGSGDK|LI  0.086    . 
Sequence       631    ITVGSSK|YL  0.105    . 
Sequence       643    TPSPGAR|PQ  0.054    . 
Sequence       652    VNGQSGR|ID  0.044    . 
Sequence       679    AFIAPDR|AS  0.033    . 
Sequence       684    DRASFFR|GE  0.055    . 
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Sequence       693    SIGIQSK|WC  0.082    . 
Sequence       698    SKWCECR|KK  0.035    . 
Sequence       699    KWCECRK|KR  0.073    . 
Sequence       700    WCECRKK|RR  0.060    . 
Sequence       701    CECRKKR|RQ  0.101    . 
Sequence       702    ECRKKRR|QR  0.056    . 
Sequence       704    RKKRRQR|RR  0.053    . 
Sequence       705    KKRRQRR|RS  0.105    . 
Sequence       706    KRRQRRR|SL  0.086    . 
Sequence       711    RRSLEQK|LI  0.107    . 
____________________________^_________________ 
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Table 25. Amino acids mutagenesis on the predicted pre-sequence and cleavage  
sites (context) and its possible outcome. The betterbest predicted substitutions are 
those located within the pre-sequence (in bold, X4X3X2X1, where X is any amino acid 
residue  which is necessary within the cleavage context, and the cleavage site (B1B2, 
where B is a basic residue) of the Kex2 region. The underlined residue(s) in the 
predicted sequences represent the mutated site. 
 
 
Mutagenesis 
substitution predictor 
Position Context 
(X4X3X2X1/B1B2) 
Score Prediction 
Wt 25 ITVSTKR|SQ   0.527 *ProP* 
Mut1 (I/A) 25 ATVSTKR|SQ   0.461     . 
Mut2 (T/A) 25 IAVSTKR|SQ   0.758 *ProP* 
Mut3 (V/A) 25 ITASTKR|SQ   0.682  *ProP* 
Mut4 (S/A) 25 ITVATKR|SQ   0.256     . 
Mut5 (T/A) 25 ITVSAKR|SQ 0.417     . 
Mut6 (K/A) 25 ITVSTAR|SQ   0.063     . 
Mut7 (R/A) 24 RITVSTK|AS   0.059     . 
Mut8 (S/A) 25 ITVSTKR|AQ   0.670 *ProP* 
Mut9 (Q/A) 25 ITVSTKR|SA   0.463     . 
Mut10 (K/R) 25 ITVSTRR|SQ   0.140     . 
Mut11 (R/K) 25 ITVSTKK|SQ   0.312     . 
Mut12 (K/R)/(R/K) 25 ITVSTRK|SQ   0.100   . 
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4.0. DISCUSSION  
The results of the first attempt to induce the expression of  HA-RBD multimers 
lacking additional tagging sequences in  Pichia pastoris expression system, indicated 
that our protein of interest, specifically, the Avian HA RBD V3.4 was detected in the 
samples analyzed by MASS-Spectroscopy and isolated by SDS-PAGE, anion-exchange 
chromatography, and size exclusion chromatography. Nevertheless, Mass-
Spectroscopy results for this molecule identified additional proteins, of Yeast origin, as 
potential contaminants leading to miss-identification of the selected band 
(chromatography Figure 20). This suggests the co-isolation of more than one Pichia 
pastoris protein during purification of the recombinant protein (Appendix Table A1). 
The mass spectroscopy also indicates possible proteins of human origin (indicating 
cross contamination during sample preparation) and proteins from the media source in 
addition to our expected HA-RBD V3.4 peptides, indicating co-purification of peptides 
isolated by the chromatography methods. Additionally, the N-terminal sequencing 
chromatograms of the derivatized residues did not show a single, clear signaling peak 
as expected for an absolute sequence determination suggesting the presence of 
multiples sequences (82). Since subsequent analysis has identified heterogeneous and 
highly glycosylated His-Tag versions of the expressed protein, it is possible that the first 
attempt at purification isolated heterogeneous forms from Avian HA RBD V3.4 
glycosylated antigen that may be co-purified in the analysed sample (Figure 20, Figure 
21).  Ferret anti-H5N1 polyclonal immunodetection of the 200 mM NaCl anion exchange 
chromoatography eluent (Figure 24) of the Avian HA-RBD V3.4 samples identified a 
high molecular size region.  This indicated that the expressed Avian HA-RBD V3.4 
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could be present at a higher molecular weight than was expected (72-78 KDa).  This 
was corroborated later in the expression strategy using the His-Tag versions (Figure 
32).   
 At the level of quantified protein expression, the extracellular soluble protein 
recovered following IMAC-dependent purification of the Human HA-RBD mutV3.3 
transformed yeast (105 g/mL) had a higher yield than Avian HA-RBD mutV3.4 (63 
g/ml)  and the Avian HA-RBD mutV3.6 (22 g/mL) yeast (Figure 30). Extracelullar 
expression analysis of the Avian HA-RBD mutV3.7 proteins remains to be done.  
 The Human HA-RBD mutV3.3 is expressed primarily as an heterogeneous 
hyper-glycosylated and proteolyzed form (~36KDa)(Figure 32) after 48 h of methanol 
induction.  This makes this contruct currently unsuitable to initiate a study to measure 
responses to Human trivalent RBD immunization.  However, there is an enzymatically 
de-glycosylated form of the protein band, in the range of ~87 KDa, that could represent 
a partially de-glycosylated form, or alternatively this same protein band may be a full-
length HA RBD mutV3.3 polypeptide. Staining for carbohydrate side chains would help 
distinguish these possibilities. If the latter assumption is correct, it could be possible to 
adjust the conditions used for protein induction to increase the protein yield of the non-
cleaved HA-RBD mutV3.3 peptide For example, the alkalinity of the protein expression 
media could be increased to pH 8.0, the time of expression couild be decreased from 
48h to 24 h, or a Protease deficient Pinchia pastoris strain (Pink Strain) could be used 
to express the transformed gene, as possible solutions. On the other hand, the Avian 
HA-RBD mutV3.4 and Avian HA RBD mutV3.6 transformed yeast expressed full length,  
non-truncated forms as assessed by the de-glycosylation assays.  However, these 
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recombinant proteins were expressed at lower yields compared to the Human version 
mutV3.3 as detected in immunoblot analysis using the anti-his monoclonal antibody. 
Optimization of the conditions to increase expression of the recombinant protein, like re-
transformation of the yeast with the expression DNA vector to increase copy number, 
fermentation scale-up, optimization of the media composition, increasing the final 
density in the media at the time of induction (O.D=4 instead of O.D=1), increasing the 
pH of the media, decreasing the final temperature of induction to 25oC from 30oC, 
increasing the final methanol percentage in the media (from 0.5 % to  2% vol/vol), to 
mention a few possibilities, could improve the protein yield.  
 
 In terms of protein characterization, sequencing results of both the Avian and 
Human versions did not show base modifications during the cloning process.  The 
expression products of these transformed plasmids were recognized by a specific anti-
6-His Tag monoclonal antibody suggesting that the group of peptides are in frame with 
the 6Histidine tag present in the Pichia pastoris vector used to express the Avian HA-
RBD mutV3.4 and the Avian HA-RBD mutV3.6. The Human HA-RBD mutV3.3 and 
Avian HA-RBD mutV3.7 constructs remains to be sequenced, since additional primers 
are required for complete gene sequencing. ,  
 Additional characterization using ferret specific polyclonal anti-influenza virus 
antibodies  that were created to recognize H7 and H5 subtype epitopes are also able to 
detect immunoreactive proteins in the non-de-glycosylated Avian HA RBD mutV3.4  and 
Avian HA-RBD mutV3.6 samples.  This suggests there is an interaction between the 
polyclonal antibodies and the linear Avian HA-RBD epitopes (the samples were reduced 
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in DTT before being loaded on the SDS-PAGE gel to further disrupt tertiary structure). 
Based on the dissimilarities in molecular size observed between the different proteins 
that are identified, depending on the type of anti-sera used (ie H5 or H7 subtype 
directed antibodies), it is likely that the high molecular size  265 KDa protein that is 
detected with with the FR-231 antiserum (H5 subtyping) may represent a highly 
glycosylated molecule that includes the RBD1 and RBD2 regions (H5 subtype).  
However, this protein was not recognized by the FR-1088 antiserum (H7 subtype), 
although a smaller 165 kDa protein was detect with this antibody and could represent a 
glycosylation-free form of the RBD3 (H7 subtype) region in the multimeric HA-RBD 
protein. 
 In the case of the Human HA-RBD mutV3.3, only the specific ferret polyclonal 
antibodies raised against Influenza B virus (Yamagata Lineage) were able to recognize 
the purified protein.  The ferret polyclonal antibodies raised against the influenza 
A/H1N1/07/California 2009 pandemic virus did not recognize the protein.  This indicates 
that the protein had been proteolytically cleaved to generate the N-terminal RBD1 in 
frame with the His6 purification tag that did not contain the remaining RBD domains. , 
derived from the H1 subtype and part of the RBD2 derived from the H3 subtype of the 
mutV3.3 version.  
 Further experiments are required to confirm that the mass spectroscopy and N-
terminal sequencing of the Avian and Human HA-RBD construct fully demonstrate their 
identity. These experiments will give valuable information that is required in order to 
proceed with animal immunization studies. N-Glycosylation, assessed by Endo H 
glycosidase, appears to be the main type of carbohydrate added by the Pichia pastoris 
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expression system for all ofsd the HA-RBD versions evaluated (mutV3.3, mutV3.4, 
mutV3.6). The characteristic N-linked consensus sequence was used to calculate the 
potential N-glycosylated forms that might be occurring in the expressed proteins 
(mutV3.3, mutV3.4 and applies for mutV3.6, as well).  This analysis might also 
demonstrate which residues to modify in order to eliminate endogenous glycosylation of 
the recombinant proteins (Figure 35, Figure 36). 
 The experiments that examined intracellular expression of the HA-RBDs by the 
Pinchia pastoris transformants did not generate a confirmed candidate.  The yeast were 
transformed with HA-RBD DNA constructs that contained a HisT tag sequence but 
preliminary results did not show any of the recovered proteins were positive in 
immunoblots with Anti-6-Histidine antibodies. Nevertheless, to discard the possibility of 
using intracellular expression and protein recovery conditions is premature.  These 
conditions should be modified since these protein products may be useful since they 
represent low-glycosylated forms not targeted to the secretory pathway and therefore 
have the potential to induce a broader immune responses as observed in  de-
glycosylated hemagglutinin molecules evaluated by other influenza research groups 
(61,63,65,83–91).  
 
His-Tagged Human HA-RBD mutV3.3 and its post-translational process. A tale for 
Avian versions, as well. 
 The truncation of the human HA-RBD mutV3.3, likely by proteolysis, might also 
be minimized in an intracellular expression system.  Most of the Kex2 activity, which 
likely mediates this cleavage, is found in the endoplasmic reticulum where the 
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recombinant protein is exposed during translocation of the exported protein  (92–94).  
Intracellular expressed proteins would not encounter the Kex2 protease.  
In Pichia pastoris, Kex2 is a highly abundant subtilisin/kexin‐like proprotein 
convertase (PC) member of the proteolytic enzyme family that is responsible for post-
translational processing and translocation through the secretory pathway.  Kex2 
processes the signal peptide of the transported proteins and is localized to the 
transmembrane Golgi network (92) and endocytic compartment (95). Based on the 
expression pattern and the truncation of the Human HA-RBD mutV3.3 and the results of 
the protein analysis that detected an internal PC signal, the results are consistent with 
the identification of the de-glycosylated ~37 KDa Human HA-RBD mutV3.3 truncated 
peptide (Figure 32) as resulting from the presence of an internal sequence of the 
Influenza virus H3 subtype HA-RBD subunit 2 (Table 20, Table 21)  Furthermore, the 
predicted data for the Avian HA-RBD versions (Table 22) are consistent with the lack of 
observed major proteolysis degradation as determined by SDS-PAGE for the IMAC-
purified and de-glycosylated protein (Figure 32).  Results compared the observed and 
predicted data (Table 21) indicate that is possible to correct the truncated peptide within 
the Human HA-RBD ITVSTKR|SQ (0.527) cleavage sequence to generate a mutated 
sequence that avoids cleavage by the Kex2 protease. The predicted substitution 
analysis suggest that in order to avoid post-translation processing of the internal 
predicted Kex2 cleavage site, the human H3 HA RBD subunit may require the use of 
alanine-scanning mutagenesis (96,97).  In particular, mutation of the Mut7 (R/A)(0.059) 
and Mut6 (K/A)(0.063) sequences might be  best first options to evaluate in developing 
new experimental Human HA RBD mutV3.3 mutants. Two additional mutants with 
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basic/basic amino-acids substitution sequences, the double basic mutant Mut12 
(K/R)/(R/K)(0.100) and the Mut10 (K/R)(0.140), represent the next alternative mutations 
to evaluate the effect on truncation repair  and full-size expression of  Human HA RBD 
sequences.  However, even though the positive/positive charge substitution required in 
these mutations may seem not to be of big concern, some previous structure-modelled 
analysis has shown these changes could be pertinent since the amino acid charges in 
the antigenic sites have been correlated with changes in the antigenic cluster in 
influenza virus (98). Whether thees substitutions could impact the antigenic recognition 
sites for the well characterized  Influenza H3 region (98–100), needs to be evaluated 
experimentally. Undoubtedly, the experimental analysis of these new Human HA RBD 
mutants could help us to shape a better design for Human HA RBDs molecules.  This  
ultimately could impact  their evaluation as immunogenic molecules at least, when the 
use of Human H3 subtype RBD’s are used as potential vaccine candidates in a Pichia 
pastoris expression platform.  
 There is some evidence from studies using mutational analysis, removal of 
carbohydrates, or carbohydrate shielding that glycosylation of vaccinating influenza 
hemagglulin proteins may enhance the production of functional antibodies (83–
86,88,89,101).  However, further experimental evidence is required to test the potential 
effect of N-glycosylation on vaccine design, proper immune system recognition, and 
production of neutralizing antibodies. Site-directed mutagenesis substitution at residues 
within the glycosylation motif N-X-S/T, with the preference to substitute the asparagine 
residue position with aspartate or to substitute lysine at the serine residue position of 
the motif (83) can be performed.  These studies should reveal the effect of substituting 
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for any of the seven structural permitted N-glycosylation motifs in the Avian HA-RBD 
mutV3.4 and mutV3.6 versions or any of the nine consensus N-glycosylation domains in 
the full length Human HA-RBD mutV3.3 or any of the five consensus domains contained 
in the truncated Human HA-RBD mutV3.3 (Figure 35, Figure 36E).  Similar studies 
have shown that changes in glycosylation can effect the Receptor Binding Domain 
derived from MERS-CoV  (65,102).  
 Even more, this study demonstrates that Pichia pastoris could provide an 
excellent expression system for work related to the expression of HA-RBD designs 
where the presence rather than absence of glycosylation may be important for biological 
function For example, HA-RBD can be designed  an selected by directed-evolution in 
order to have the highest binding affinities for sialic acid moieties. The generated 
molecules could then be serving as competitive inhibitors for the binding of wild type 
hemagglutinins required for virus recognition, attachment and infection in the respiratory 
epithelium.  Therefore, hyper-glycosylated and functionally-active forms of HA-RBD 
expressed in Pichia pastoris could serve as a shielding strategy against the activation of 
the immune response without compromising the biological intended function.  
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FUTURE DIRECTIONS: 
1. Site-directed mutagenesis for removal of N-Glycosylation sites are necessary to 
determine if these point mutation can generate homogeneous polypeptides 
rather than t the multiple variations that carbohydrate heterogeneity may be 
present after protein isolation and immunoblot analysis  of the HA-RBD 
multimeric genes. 
 
2. Site-directed mutagenesis of the Human HA-RBD version (H3 subtype) to alter 
the putative internal peptidase cleavage site should facilitate recovery of the full-
size recombinant protein  and will demonstrate the suitability of human HA-RBD 
version for use as a vaccine. This version was shown to have a higher yield 
which is the main purpose for using Pichia pastoris as a heterologous expression 
system. 
 
 
3. Optimization of the process for expressing and purifying the intracellular HA-RBD 
versions could overcome issues with protein cleavage and glyosylation that result 
in the heterogeneous expression of the hyperglycosylated HA-RBD version 
evaluated to date. 
 
4. Tests of functional activity and immunogenicity of the N-glycosylated forms, 
deglycosylated forms, and mut Deglycosylated forms will be required in order to 
confirm that the HA-RBD are properly folded, that they can interact with cellular 
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surface receptors, and that they can induce appropriate neutralizing  antibody 
production in vaccinated animal experiments. The utility of the Human and Avian 
HA-RBD versions could be applied to different platforms of generating immunity  
(for example, DNA vaccines)that could be demonstrated if all the aforementioned 
experiments were shown to be an effective and could indicate a strategy to 
generate novel Influenza vaccines.   
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Appendix Table 1. Full- set of peptides predicted for the MASS-Spec Results.   
 
 
DB Accession Score Mass Matches Pep(sig) Sequences Seq(sig) emPAI Description 
Client_Sequences 1::CUSTOM_HA3.4 1080 75823 109 53 28 18 2.46 CUSTOM jaguilaryanez_amric.ca HA3.4 
SwissProt 3::HEMA_I71A2 40 62829 8 5 3 3 0.26 Hemagglutinin OS=Influenza A virus (strain A/Turkey/Oregon/1971 H7N3) GN=HA PE=3 SV=2 
SwissProt 3::VIME_HUMAN 1037 53676 116 51 42 24 7.56 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 
contaminants_custom 2::P04264 557 66149 33 20 19 10 0.73 SWISS-PROT:P04264 Tax_Id=9606 Gene_Symbol=KRT1 Keratin, type II cytoskeletal 1 
SwissProt 3::K22E_HUMAN 179 65678 15 9 11 8 0.55 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 
contaminants_custom 2::P13647 103 62568 5 4 5 4 0.26 SWISS-PROT:P13647 Tax_Id=9606 Gene_Symbol=KRT5 Keratin, type II cytoskeletal 5 
SwissProt 3::ACTB_BOVIN 289 42052 45 13 19 9 1.35 Actin, cytoplasmic 1 OS=Bos taurus GN=ACTB PE=1 SV=1 
SwissProt 3::ACTBL_HUMAN 133 42318 14 4 6 2 0.19 Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 
SwissProt 3::LMNA_HUMAN 274 74380 22 12 17 9 0.63 Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 
SwissProt 3::K1C10_HUMAN 271 59020 19 12 13 9 0.73 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 
SwissProt 3::ALBU_BOVIN 254 71244 35 16 19 12 0.93 Serum albumin OS=Bos taurus GN=ALB PE=1 SV=4 
SwissProt 3::HS90A_BOVIN 162 85077 15 10 9 5 0.29 Heat shock protein HSP 90-alpha OS=Bos taurus GN=HSP90AA1 PE=2 SV=3 
SwissProt 3::HSP90_CANAL 160 80773 13 8 5 4 0.2 Heat shock protein 90 homolog OS=Candida albicans (strain SC5314 / ATCC MYA-2876) GN=HSP90 PE=1 SV=1 
SwissProt 3::HS90B_HORSE 143 83527 19 11 12 6 0.36 Heat shock protein HSP 90-beta OS=Equus caballus GN=HSP90AB1 PE=2 SV=3 
SwissProt 3::HSP83_DROAV 111 81994 8 5 4 3 0.14 Heat shock protein 83 OS=Drosophila auraria GN=Hsp83 PE=3 SV=1 
SwissProt 3::HSC82_YEAST 103 80850 16 5 7 3 0.14 ATP-dependent molecular chaperone HSC82 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GN=HSC82 PE=1 SV=4 
SwissProt 3::ENPL_BOVIN 58 92654 6 3 5 3 0.12 Endoplasmin OS=Bos taurus GN=HSP90B1 PE=2 SV=1 
contaminants_custom 2::GST26_SCHJA 208 25710 10 6 2 1 0.15 Glutathione S-transferase class-mu 26 kDa isozyme OS=Schistosoma japonicum PE=1 SV=3 
SwissProt 3::GRP78_HUMAN 160 72402 20 11 15 10 0.65 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 
SwissProt 3::HSP71_CANAL 78 70452 8 2 6 2 0.11 Heat shock protein SSA1 OS=Candida albicans (strain SC5314 / ATCC MYA-2876) GN=SSA1 PE=1 SV=2 
SwissProt 3::HSP70_PLACB 35 75069 4 2 3 2 0.1 Heat shock 70 kDa protein OS=Plasmodium cynomolgi (strain Berok) PE=2 SV=1 
SwissProt 3::TRYP_PIG 143 25078 24 8 4 3 0.76 Trypsin OS=Sus scrofa PE=1 SV=1 
SwissProt 3::K1C9_HUMAN 127 62255 12 4 8 4 0.26 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 
SwissProt 3::FINC_HUMAN 101 266052 10 6 10 6 0.09 Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 
SwissProt 3::GELS_BOVIN 101 80966 5 3 3 2 0.09 Gelsolin OS=Bos taurus GN=GSN PE=2 SV=1 
SwissProt 3::INV2_YEAST 97 60715 17 6 9 6 0.43 Invertase 2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GN=SUC2 PE=1 SV=1 
SwissProt 3::IFM1_HUMAN 93 14126 2 2 1 1 0.28 Interferon-induced transmembrane protein 1 OS=Homo sapiens GN=IFITM1 PE=1 SV=3 
SwissProt 3::CKAP4_HUMAN 91 66097 11 4 11 4 0.24 Cytoskeleton-associated protein 4 OS=Homo sapiens GN=CKAP4 PE=1 SV=2 
SwissProt 3::K1C14_HUMAN 90 51872 9 4 7 4 0.32 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 
SwissProt 3::ANXA2_CANFA 84 38915 9 4 8 4 0.44 Annexin A2 OS=Canis familiaris GN=ANXA2 PE=1 SV=1 
SwissProt 3::H2A1B_HUMAN 83 14127 7 4 3 2 0.63 Histone H2A type 1-B/E OS=Homo sapiens GN=HIST1H2AB PE=1 SV=2 
SwissProt 3::LEG1_HUMAN 83 15048 6 2 4 2 0.58 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 
SwissProt 3::H4_MASBA 77 11903 15 4 7 3 1.37 Histone H4 OS=Mastigamoeba balamuthi PE=3 SV=3 
SwissProt 3::TRUD_SHEON 76 41443 44 8 1 1 0.09 tRNA pseudouridine synthase D OS=Shewanella oneidensis (strain MR-1) GN=truD PE=3 SV=1 
SwissProt 3::BCHL_CHLCH 70 29883 45 5 1 1 0.13 Light-independent protochlorophyllide reductase iron-sulfur ATP-binding protein OS=Chlorobium chlorochromatii (strain CaD3) GN=bchL PE=3  
SwissProt 3::SERPH_HUMAN 62 46525 4 2 4 2 0.17 Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2 
SwissProt 3::KPYM_HUMAN 61 58470 7 4 5 3 0.2 Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 
SwissProt 3::FAA22_MYCMM 61 75818 39 5 2 1 0.05 p-hydroxybenzoic acid--AMP ligase FadD22 OS=Mycobacterium marinum (strain ATCC BAA-535 / M) GN=fadD22 PE=1 SV=1 
SwissProt 3::TBA_TORMA 60 50820 2 2 2 2 0.15 Tubulin alpha chain OS=Torpedo marmorata PE=2 SV=1 
SwissProt 3::CALD1_HUMAN 59 93232 9 2 6 2 0.08 Caldesmon OS=Homo sapiens GN=CALD1 PE=1 SV=3 
SwissProt 3::PDIA1_HUMAN 57 57480 3 1 3 1 0.06 Protein disulfide-isomerase OS=Homo sapiens GN=P4HB PE=1 SV=3 
SwissProt 3::TBB5_BOVIN 50 50095 7 3 5 3 0.24 Tubulin beta-5 chain OS=Bos taurus GN=TUBB5 PE=2 SV=1 
SwissProt 3::H2B1B_HUMAN 51 13942 10 2 4 1 0.28 Histone H2B type 1-B OS=Homo sapiens GN=HIST1H2BB PE=1 SV=2 
SwissProt 3::MUC1_BOVIN 50 58284 1 1 1 1 0.06 Mucin-1 OS=Bos taurus GN=MUC1 PE=1 SV=1 
SwissProt 3::GLU2B_HUMAN 49 60357 3 1 2 1 0.06 Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH PE=1 SV=2 
SwissProt 3::ENOA_HUMAN 48 47481 3 1 3 1 0.08 Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 
SwissProt 3::PDIA3_CHLAE 46 57143 9 3 9 3 0.21 Protein disulfide-isomerase A3 OS=Chlorocebus aethiops GN=PDIA3 PE=2 SV=1 
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SwissProt 3::ACON_CANAL 45 84625 1 1 1 1 0.04 Aconitate hydratase, mitochondrial OS=Candida albicans (strain SC5314 / ATCC MYA-2876) GN=ACO1 PE=1 SV=2 
SwissProt 3::PLOD2_HUMAN 45 85373 2 2 2 2 0.09 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 OS=Homo sapiens GN=PLOD2 PE=1 SV=2 
SwissProt 3::TBA_ENTDO 44 50846 1 1 1 1 0.07 Tubulin alpha chain OS=Enteroctopus dofleini PE=2 SV=1 
SwissProt 3::ATPB_NOVAD 44 51107 1 1 1 1 0.07 ATP synthase subunit beta OS=Novosphingobium aromaticivorans (strain DSM 12444) GN=atpD PE=3 SV=1 
SwissProt 3::CALX_CANFA 42 68017 3 1 3 1 0.05 Calnexin OS=Canis familiaris GN=CANX PE=1 SV=3 
SwissProt 3::ACTN1_CHICK 41 103610 3 1 3 1 0.04 Alpha-actinin-1 OS=Gallus gallus GN=ACTN1 PE=1 SV=3 
SwissProt 3::COFC_ARCPA 41 24138 2 1 1 1 0.16 2-phospho-L-lactate guanylyltransferase OS=Archaeoglobus profundus (strain DSM 5631 / JCM 9629 / NBRC 100127 / Av18) GN=cofC PE=3 SV  
SwissProt 3::OSB5_DICDI 41 42649 2 1 1 1 0.09 Oxysterol-binding protein 5 OS=Dictyostelium discoideum GN=osbE PE=3 SV=1 
SwissProt 3::GFAP_DANRE 40 51275 3 1 2 1 0.07 Glial fibrillary acidic protein OS=Danio rerio GN=gfap PE=1 SV=2 
SwissProt 3::DNAK_NOVAD 39 68071 2 1 2 1 0.05 Chaperone protein DnaK OS=Novosphingobium aromaticivorans (strain DSM 12444) GN=dnaK PE=3 SV=1 
SwissProt 3::EF1A0_XENLA 38 50524 5 1 4 1 0.07 Elongation factor 1-alpha, somatic form OS=Xenopus laevis GN=eef1as PE=2 SV=1 
SwissProt 3::NHA1_RHORH 37 22991 3 1 2 1 0.17 High-molecular weight cobalt-containing nitrile hydratase subunit alpha OS=Rhodococcus rhodochrous GN=nhhA PE=1 SV=3 
SwissProt 3::CH60_NOVAD 37 57622 4 2 4 2 0.13 60 kDa chaperonin OS=Novosphingobium aromaticivorans (strain DSM 12444) GN=groL PE=3 SV=1 
SwissProt 3::HLAH_HUMAN 35 41094 1 1 1 1 0.09 Putative HLA class I histocompatibility antigen, alpha chain H OS=Homo sapiens GN=HLA-H PE=5 SV=3 
SwissProt 3::TRY1_BOVIN 35 26453 1 1 1 1 0.14 Cationic trypsin OS=Bos taurus PE=1 SV=3 
SwissProt 3::APAF_HUMAN 34 144087 9 1 1 1 0.03 Apoptotic protease-activating factor 1 OS=Homo sapiens GN=APAF1 PE=1 SV=2 
SwissProt 3::G3P_HUMAN 34 36201 2 2 2 2 0.22 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 
SwissProt 3::ANXA5_BOVIN 33 36124 1 1 1 1 0.1 Annexin A5 OS=Bos taurus GN=ANXA5 PE=1 SV=3 
SwissProt 3::DDX17_HUMAN 33 80906 2 1 2 1 0.05 Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17 PE=1 SV=2 
SwissProt 3::APE2_CANAL 31 104873 2 1 2 1 0.04 Aminopeptidase 2 OS=Candida albicans (strain SC5314 / ATCC MYA-2876) GN=APE2 PE=1 SV=2 
SwissProt 3::RS10_NOVAD 31 11638 1 1 1 1 0.34 30S ribosomal protein S10 OS=Novosphingobium aromaticivorans (strain DSM 12444) GN=rpsJ PE=3 SV=1 
SwissProt 3::5NTD_HUMAN 31 63898 1 1 1 1 0.06 5'-nucleotidase OS=Homo sapiens GN=NT5E PE=1 SV=1 
SwissProt 3::P4HA2_CHICK 31 61796 1 1 1 1 0.06 Prolyl 4-hydroxylase subunit alpha-2 OS=Gallus gallus GN=P4HA2 PE=2 SV=1 
SwissProt 3::PDIA3_PAPHA 30 4084 1 1 1 1 1.1 Protein disulfide-isomerase A3 (Fragments) OS=Papio hamadryas GN=PDIA3 PE=1 SV=1 
SwissProt 3::PDIA6_HUMAN 29 48490 1 1 1 1 0.08 Protein disulfide-isomerase A6 OS=Homo sapiens GN=PDIA6 PE=1 SV=1 
SwissProt 3::RPOA_EAVBU 28 351434 1 1 1 1 0.01 Replicase polyprotein 1ab OS=Equine arteritis virus (strain Bucyrus) GN=rep PE=1 SV=3 
SwissProt 3::CD44_HUMAN 28 82001 4 1 2 1 0.05 CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=3 
SwissProt 3::OMPA_CITFR 27 25762 1 1 1 1 0.15 Outer membrane protein A (Fragment) OS=Citrobacter freundii GN=ompA PE=3 SV=1 
SwissProt 3::SAV_STRAV 27 18822 1 1 1 1 0.2 Streptavidin OS=Streptomyces avidinii PE=1 SV=1 
SwissProt 3::P4HA1_BOVIN 27 61257 1 1 1 1 0.06 Prolyl 4-hydroxylase subunit alpha-1 OS=Bos taurus GN=P4HA1 PE=1 SV=1 
SwissProt 3::METE_CANAL 27 85763 3 1 2 1 0.04 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase OS=Candida albicans (strain SC5314 / ATCC MYA-2876) GN=MET6 P   
SwissProt 3::PTRF_HUMAN 25 43450 6 2 6 2 0.18 Polymerase I and transcript release factor OS=Homo sapiens GN=PTRF PE=1 SV=1 
SwissProt 3::HNRPC_RAT 25 18122 1 1 1 1 0.21 Heterogeneous nuclear ribonucleoprotein C (Fragment) OS=Rattus norvegicus GN=Hnrnpc PE=2 SV=1 
SwissProt 3::OTC_ARCFU 24 35062 1 1 1 1 0.11 Ornithine carbamoyltransferase OS=Archaeoglobus fulgidus (strain ATCC 49558 / VC-16 / DSM 4304 / JCM 9628 / NBRC 100126) GN=argF PE=   
SwissProt 3::ACON_DEIRA 22 98169 4 1 1 1 0.04 
Aconitate hydratase OS=Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1      
SV=1 
SwissProt 3::MNMG_SULNB 22 69602 1 1 1 1 0.05 tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG OS=Sulfurovum sp. (strain NBC37-1) GN=mnmG PE=3 SV=1 
SwissProt 3::YQOA_CAEEL 20 81822 1 1 1 1 0.05 Putative RNA-binding protein EEED8.10 OS=Caenorhabditis elegans GN=EEED8.10 PE=4 SV=3 
SwissProt 3::PBPB_BUCBP 17 85913 1 1 1 1 0.04 Penicillin-binding protein 1B OS=Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) GN=mrcB PE=3 SV=1 
SwissProt 3::EST1C_RAT 16 60479 1 1 1 1 0.06 Carboxylesterase 1C OS=Rattus norvegicus GN=Ces1c PE=1 SV=3 
 
 
